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Abstract
Chronic constriction injury (CCI) of the rat sciatic nerve, produces an animal
model of peripheral neuropathy exhibiting abnormal pain states similar to those seen
in man, including behavioural signs of spontaneous pain, hyperalgesia and allodynia.
Many components ofneuropathic pain are resistant to classical opioid analgesics, and
anaesthetic nerve blocks or surgical sympathectomies often provide only temporary
relief. Since the expression of Vasoactive Intestinal Polypeptide (VIP) and Pituitary
Adenylate Cyclase-Activating Polypeptide (PACAP) is markedly up-regulated in
dorsal root ganglia following peripheral nerve injury, we investigated whether
VIP/PACAP receptors are important regulators of the amplified sensory responses
which develop following neuropathy.
This study addressed the role of VIP,, VIP2 and PACAP receptors with regard
to the responses of dorsal horn neurones in normal compared to CCI animals, using
novel selective agonists and antagonists. In electrophysiological experiments on
anaesthetised rats, the effects of ionophoretic application of VIP,, VIP2 and PACAP
receptor antagonists were investigated on neuronal activity induced by innocuous
brushing or cold stimulation of the cutaneous receptive field, or following peripheral
application of the chemical algogen mustard oil. In normal rats, VIP, and PACAP
receptor antagonists appeared to exert a general modification of dorsal horn neurone
responses, inhibiting both brush- and mustard oil-induced activity to similar extents.
In contrast, a novel VIP2 receptor antagonist selectively inhibited mustard oil-evoked
activity, whilst showing negligible effects on brush-evoked activity.
The effects of the VIP/PACAP receptor antagonists changed markedly in CCI
animals so that antagonists for all three receptor subtypes showed negligible effects
on brush-induced activity of dorsal horn neurones. In contrast, VIP,/PACAP
receptor antagonists significantly inhibited cold-induced activity, while a VIP2
receptor antagonist had little effect. However, mustard oil-induced activity was
significantly inhibited by all three receptor antagonists in CCI animals.
The activity of single, multireceptive dorsal horn neurones was markedly
increased following ionophoretic administration of selective VIP,, VIP2 and PACAP
receptor agonists both in normal and CCI rats. Following nerve injury however, two
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main differences were apparent, and these may reflect changes in receptor
expression: the number of dorsal horn neurones activated by the VIP2 receptor
agonist doubled (these neurones also showed a greater extent of cell activation than
those excited in normal animals), while the percentage of neurones activated by the
VIP, receptor agonist was seen to decrease. The proportion of cells activated by the
PACAP receptor agonist remained unchanged.
In addition, in situ hybridisation histochemistry (ISHH) detection ofmRNA
for the three receptor subtypes, was employed to monitor any changes in receptor
expression following nerve injury. This study revealed that CCI of the rat sciatic
nerve produced a significant increase in the expression of VIP2 receptor mRNA in
laminae III/IV of the spinal dorsal horn. In contrast, VIP, receptor mRNA was seen
to markedly decrease, while the expression of mRNA for the PACAP receptor
appeared to be unchanged.
In conclusion, these results provide evidence that VIP/PACAP receptors may
be important mediators/modulators of the transmission of sensory information at the
spinal cord level, underlining the potential for VIP/PACAP receptor antagonists as
new analgesics, particularly for use in currently intractable neuropathic pain states.
These data demonstrate the involvement of the VIP2 receptor in the transmission of
nociceptive (C-fibre-mediated) information, both in normal and neuropathic animals.
Although VIP, and PACAP receptor antagonists are rather non-selective inhibitors of
sensory inputs in normal states, they may represent useful analgesics for certain
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pain - the range of unpleasant bodily sensations produced by illness or
harmful bodily contact. The Concise Oxford Dictionary.
1.1 General Introduction
Pain is a normal consequence of acute and chronic damage or illness.
Chronic pain due to nerve injury often persists long after the initial injury has healed,
and the abnormal pain sensations which remain are thought to be indicative of a
dysfunctional nervous system. Despite the prevalence of these symptoms,
neuropathic pain remains a chronic condition that, as yet, has no clear physiological
explanation nor a satisfactory treatment. The discovery ofpain-modulatory systems
within the central nervous system, and of the neurotransmitters that mediate their
action, has contributed to our understanding of the complex pathways involved in the
transmission ofnociceptive information. Identifying the specific neurochemical
alterations that arise in neuropathic conditions may provide important new insights
into targets for the development of new and effective analgesic therapies.
1.2 Anatomy of the Spinal Cord
The spinal cord, located in the spinal canal of the vertebral column, begins as
a continuation of the medulla oblongata, the inferior part of the brain stem.
Somatosensory information is relayed from peripheral receptors to the spinal cord (or
in certain cases the brain stem), via primary afferent fibres, and then on to the brain.
So the processing ofnociceptive information at the spinal cord level represents the
first stage of effective control over its access to higher regions of the central nervous
system (CNS).
1.2.1 Laminar Organisation of the Dorsal Horn
The grey matter of the spinal cord, which consists primarily of nerve cell
bodies, fibres (both axons and dendrites) and associated non-neuronal cells, presents
the general shape of an H within the white matter. This characteristic H shape, in
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transverse section, can be subdivided into two main regions; the anterior or ventral
horns and the posterior or dorsal horns.
The grey matter has a distinct architecture with a nomenclature which
originated from the work of Rexed (1952), who divided the entire grey matter of the
cat spinal cord and classified the laminae according to their cytoarchitectonic
characteristics. Further anatomical studies have demonstrated a similar
cytoarchitectonic scheme in the rat (Molander et al. 1984)(See Figure 1.1). In this
scheme, the dorsal hom is divided into six layers or laminae:-
(a) Lamina I (The Marginal Zone): Lamina I is the thinnest and most
superficial layer of the dorsal horn (Molander et al. 1984), characterised by the
presence of the horizontally arranged, large marginal cells of Waldeyer (1888). Both
unmyelinated C-fibres and myelinated AS fibres terminate in lamina I (but the
myelinated AS primary afferent input is thought to predominate), and these afferents
project to the thalamus, midbrain, or to other parts of the spinal cord (Willis and
Coggeshall, 1991). There is no evidence that collaterals from large diameter primary
afferent fibres enter lamina I (Brown, 1981). A number of early reports have
suggested that lamina I contains primarily noci-specific neurones, which receive their
projections from cutaneous, high-threshold AS mechanoreceptors and C-fibre
thermal nociceptors (Cervero et al. 1976; 1979; Christensen, Perl, 1970; Light and
Perl, 1979; Rethelyi et al. 1983), while more recent studies have revealed a large
proportion of rat lamina I cells to be multireceptive (McMahon and Wall, 1983;
Menetrey and Besson, 1981). So overall, the vast majority of dorsal horn neurones
have the ability to respond to nociceptive stimuli, and this highlights the potential
importance of lamina I in the transmission of noxious sensory information.
(b) Lamina II (the Substantia Gelatinosa): Lamina II is located directly
beneath lamina I and also curves around the lateral edge of the dorsal horn. This
lamina has a gelatinous appearance due to the large numbers of small cells and
unmyelinated afferent fibres which it accommodates, hence the name 'substantia
gelatinosa' (Willis and Coggeshall, 1991). Lamina II is concerned predominantly
with the processing of sensory information from the skin and receives very little
input from the non-cutaneous structures (muscle and viscera). This area displays an
extensive unmyelinated primary afferent input, with perhaps some small, myelinated
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afferents terminating here, while large myelinated afferents appear to be largely
excluded (Willis and Coggeshall, 1991). The most superficial part of lamina II
displays an extensively dense accumulation of very fine primary afferent fibres (C-
fibres), and is filled with small, densely packed neurones, while the lower portion
also has many small cells, which are much less densely packed (Light and Perl,
1979).
(c) Lamina III-IV (The Nucleus Proprius): Lamina III forms a broad band
across the dorsal hom which is distinguished from lamina II by its slightly larger and
more widely spaced cells (Light and Perl, 1979; Rexed, 1952). Intracellular
injections and retrograde filling studies have demonstrated that significant
populations of lamina III neurones project to the Spinocervical nucleus and into the
dorsal columns (Brown, 1981; Brown et al. 1977). Lamina IV is a relatively thick
layer which also extends across the dorsal hom, and is distinguished from lamina III
by the heterogeneity of neurone size (ranging from very small, to quite large cells),
and by the prominent presence of some very large cells (Molander et al. 1984). It is
predominantly the intermediate to thick diameter A-fibres which innervate these
deeper dorsal hom laminae, including non-nociceptive A8 fibres, originating from D-
type hair follicles, and the large diameter A(5 axons of sensory, cutaneous
mechanoreceptors (Brown and Iggo, 1967; Light and Perl, 1979). In addition, many
of the lamina IV neurones also receive a direct primary afferent input from their
dorsal dendrites which project superficially into laminae I-III (Willis and Coggeshall,
1991).
(d) Lamina V-VI: Lamina V extends as a thick band across the narrowest
part of the dorsal hom and contains many bundles of myelinated fibres as well as a
large number of large diameter cells (Molander et al. 1984). Lamina VI only exists
in the cervical and lumbosacral enlargements of the spinal cord where it represents
the transitional layer between the primary afferent-dominated dorsal hom and the
ventral hom. Very few primary afferents terminate here and this lamina is dominated
by a large number of small neurones (Willis and Coggeshall, 1991).
The remaining laminae, laminae VII to X, represent the ventral hom and are
beyond the scope of this study. Despite the obvious lamination pattern shown in
Figure 1.1, there are no precise cytoarchitectonic borderlines within the spinal cord.
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Laminae are recognised as zones of concentrations ofparticular cell types and tend to
have intermingled edges. In addition, the borders between the various laminae differ
slightly between different segmental sections (Molander et al. 1984).
1.2.2 Classification of Dorsal Horn Neurones
The spinal dorsal horn represents the first synaptic relay of the majority of
afferents from skin, muscle and viscera. It is therefore an important site for the initial
processing of signals from the periphery to the CNS with regards the transmission
and modulation of pain. The dorsal horn is characterised by a wide range of cells of
different sizes and morphological appearances (See Figure 1.2). This study will refer
to three different types of dorsal horn neurone, found throughout the dorsal horn,
which can be classified according to their response properties to cutaneous sensory
stimuli:
(a) Non-nociceptive neurones (Class I): These cells are innervated by low-
threshold mechanosensitive A-fibres, which respond only to innocuous mechanical
stimulation of the cutaneous receptive field (Dubner and Bennett, 1983).
(b) Multireceptive neurones (Class II): Multireceptive, or wide-dynamic
range (WDR) neurones (Mendell, 1966), have convergent inputs from both
peripheral nociceptors and mechanoreceptors, enabling them to respond to both
innocuous and noxious mechanical stimulation of the cutaneous receptive field
and/or noxious thermal stimulation (Price et al. 1976; 1978). Electrical stimulation,
either of the cutaneous nerve or transcutaneously, has revealed that quite often, the
whole spectrum ofprimary afferents can activate multireceptive neurones, from large
myelinated A(3 fibres to unmyelinated C-fibres (Besson and Chaouch, 1987; Willis
and Coggeshall, 1991). Multireceptive neurones are most frequently found in
laminae IV-VI of the dorsal horn, particularly in lamina V (Besson and Chaouch
1987). However they have also been recorded in the superficial laminae as well
(Iggo, 1974; Menetrey and Besson, 1981; McMahon and Wall, 1983; Woolf and
Fitzgerald, 1983).
(c) Nocispecific neurones (Class III): Nocispecific neurones are a well-
defined population of neurones which appear to receive substantial inputs only from
myelinated and unmyelinated nociceptive afferents (A5- and C-fibres) and therefore
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respond only to high-threshold, noxious stimuli (Cervero et al. 1976). They have
small cutaneous receptive fields and display little or no spontaneous activity (Perl,
1984). A relatively high proportion ofnocispecific neurones has been reported in
lamina I, including cells which project to thalamic and brain stem regions (Cervero et
al. 1976; 1979; Christensen and Perl, 1970; Light and Perl, 1979). They are
exclusively activated by noxious cutaneous stimulation, although some nocispecific
neurones can also be driven by non-cutaneous inputs originating in the muscle or
viscera (Cervero, 1983; Craig and Kniffki, 1983).
The transmission of nociceptive information will clearly be influenced then
by differences in the distribution of these different types of neurone throughout the
dorsal horn. In addition, the projection pattern of the different primary afferent fibre
types will influence the type of response made by these dorsal horn neurones in
different laminae, in particular the multireceptive neurones. Multireceptive dorsal
horn neurones within the superficial layers of the dorsal horn are likely to be
predominantly involved in mediating nociceptive information, as cutaneous A8
nociceptors terminate primarily in lamina I, and C-fibres (mechanical, nociceptive
and thermal) predominantly innervate lamina II. In contrast, Ap fibres project into
the deeper dorsal horn (laminae III-IV) (Willis and Coggeshall, 1991) where they
have the ability to exert segmental control on the responses of spinal cord neurones
(see Section 1.3.1). So the Ap fibres may also directly influence the responses of
both multireceptive and non-nociceptive neurones to cutaneous sensory stimuli.
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Figure 1.1
Schematic diagram of the cytoarchitectonic organisation of segments L1-L6 of
the rat spinal cord
Representation of the laminar divisions ofRexed (1952) as demonstrated in the
lumbar (L) segments of the rat spinal cord.
Abbreviations
I - X - spinal cord laminae; CC - column of Clarke; IL - intermedio-lateral nucleus;
IM - intermedio-medial nucleus; LSN - lateral spinal nucleus; Liss - Lissauer's
tract; LG - lateral group of large cells in the dorso-lateral part of the ventral horn;
LM - latero-medial nucleus; MG - medial group of large neurones in the
intermediate zone; Pyr - pyramidal tract; VM - ventro-medial nucleus.
Note that LG, LM and VM are parts of lamina IX.




Schematic diagram of the cutaneous afferent input to, and neuronal
organisation of the spinal dorsal horn
A hypothetical cross section of the spinal dorsal horn, illustrating the afferent fibres
and neuronal elements present in the first four laminae. The laminar divisions of
Rexed (1952) are indicated on the right. Afferent fibre types are listed to the left of
the diagram, shown projecting onto neuronal types typical of laminae I-IV. The
neurones illustrated are (from top to bottom): a marginal cell, an SG limiting cell,
two SG central cells and two neurones of the nucleus proprius, the more superficial
of which has dendrites penetrating lamina II.
(Taken from Cervero and Iggo, 1980)
High-threshold A5 mechanoreceptors, with thin myelinated fibres, terminate
predominantly in lamina I and II of the dorsal hom, as shown here, however they
may also have scattered endings which terminate in lamina V of the deeper dorsal
hom (Light and Perl, 1979). Similarly, the majority of C-fibre nociceptive afferents
terminate in the superficial dorsal hom, particularly lamina II (as shown), but again
may project their branches deep down into lamina V (Light and Perl, 1979).
In contrast, non-nociceptive A5 axons from D-Type hair follicles, and large diameter
A(3 myelinated afferent fibres (which innervate sensory cutaneous mechanoreceptors)
distribute their axons in the deeper dorsal hom , laminae III-VI (Brown and Iggo,
1967; Perl, 1984), with some endings projecting to the inner portion of lamina II
(Brown, 1981; Light and Perl, 1979).
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Outer Inner III IV
1.2.3 Fibre Composition of Cutaneous Nerves
Peripheral nerves are composed of axons of sensory neurones and somatic
and motor neurones. Primary afferent neurones and their associated fibres, represent
the first step in the processing of sensory information from the periphery to the CNS.
The large majority ofperipheral nerve fibres terminate in the dorsal hom of the
spinal cord. These afferent fibres can be divided into two main groups on the basis
of their size, conduction velocity and whether or not they are myelinated.
The largest group ofnerve fibres in cutaneous nerves is the myelinated A-
fibre class. The rat sciatic nerve contains approximately twice as many of these
myelinated, sensory axons compared to unmyelinated fibres (Schmalbruch, 1986).
This group can be further subdivided according to their size and conduction velocity.
The small diameter A5 fibres conduct at 4-30m/s and supply hair follicle receptors or
mechanical nociceptors. The large Ap fibres have the fastest conduction velocities
(30-100 m/s) and are mostly non-nociceptive, innervating corpuscular endings or hair
follicle receptors (Willis and Coggeshall, 1991). The unmyelinated C-fibres have the
smallest diameter and the slowest conduction velocities (< 2.5 m/s) (Gasser, 1950),
and the majority of these fibres are nociceptive.
1.2.4. Classification of Afferent Fibre Receptors
The terminal regions of the primary afferent fibres, found in the peripheral
tissue, constitute the receptive or dendritic part of the neurone, which have contact
with well defined areas of skin from which the afferent fibres can be excited
(receptive field). The cutaneous receptors transmit information about changes in the
external and internal environment of the animal, and they are specialised to respond
to specific stimuli (e.g. heat, pressure, chemicals). So clearly distinguishable classes
of specialised nociceptors and mechanoreceptors exist in the periphery (Lynn, 1994),
and these can be identified by experimentally applying a series of test stimuli to the
receptive field area of the skin.
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(a) Non-nociceptive Mechanoreceptors
Cutaneous mechanoreceptors are the most sensitive receptors, responding
most readily to mechanical pressure stimuli of various intensity. They can be further
subdivided according to their other characteristics:
Hair follicle receptors. These receptors, as their name suggests, are found in
hairy skin and are activated by hair movement. They are the predominant class of
units with myelinated A5 axons within rat peripheral nerves (Lynn and Carpenter,
1982), and can be classified according to the type ofhair which they innervate
(Brown and Iggo, 1967). D-hair units tend to have relatively slowly conducting
axons with large receptive fields, and respond well to slow movement of the fine
down hairs, while G-hair units with their larger axons have relatively small receptive
fields and tend only to be activated by fast movement of the guard hairs (Lynn and
Carpenter, 1982). In addition T-hair units also exist, but are the least numerous, and
these units can be excited by movement of the large tylotrich hairs.
Field receptors, rapidly adapting (RA) cutaneous receptors and Pacinian
Corpuscles. These receptors also respond to light pressure, stroking or vibration of
the receptive field area on the skin, but are not activated by hair movement. They are
predominantly associated with the large A(3 fibres and generally transmit only non-
nociceptive information.
Field receptors can only be activated by the brushing of large numbers of
hairs along with direct stimulation of the underlying skin. RA receptors are found in
glabrous skin. They signal the rate at which the skin is displaced (stimulus velocity),
and are typically associated with Meissner's corpuscles. Pacinian corpuscles are
subcutaneous receptors which respond to deformation of the cutaneous receptive
field caused by firm pressure (Willis and Coggeshall, 1991)
Slowly adapting (SA type I or II) mechanoreceptors. These receptors are
again associated primarily with large Ap fibres, but tend not to innervate hair
follicles. They detect both the displacement and velocity ofmechanical stimuli, and
tend to fire to maintained skin or joint displacements (Lynn and Carpenter, 1991).
SA I mechanoreceptors are low threshold receptors associated with Merkel cell
11
complexes in the basal layer of the epidermis. SAII mechanoreceptors are identified
with Ruffini endings located in the dermis and so respond to small displacements of
the skin usually as a result of the skin stretching (Willis and Coggeshall, 1991).
C-mechanoreceptors. These sensitive mechanoreceptors with unmyelinated
afferent fibres, are a distinct group of C-fibres with a high sensitivity to mechanical
stimulation (Bessou and Perl, 1969). They constitute approximately 12-15% of all
C-fibres within the saphenous nerve (Lynn and Carpenter, 1982), but have a slightly
higher occurrence in the rat sural nerve (approximately 33%) (Leem et al. 1993), and
tend to respond to slow brushing of the cutaneous receptive field, or to stretching of
the surrounding skin. The receptive fields are generally small single points (Bessou
et al. 1971) and are primarily found on hairy skin. These receptors rarely respond to
warm thermal stimuli, although a large proportion have been reported to respond to
cold stimuli (Bessou and Perl, 1969; Leem et al.1993; Lynn and Carpenter, 1982).
The majority of these receptors are rapidly adapting, such that repeated forceful
stimulation (for example probing or pinching the cutaneous receptive field) will
result in "inactivation" of this group of fibres (Bessou and Perl, 1969).
(b) Non-nociceptive Thermoreceptors
Thermoreceptors signal innocuous changes in temperature, and respond
poorly if at all to mechanical stimuli. They can generally be classified into two
types:
(i) Cold thermoreceptors. Innocuous cool sensations and cold pain are
mediated by different populations ofprimary afferent fibre. Cool sensations are
signalled by activity in cold specific A8-fibres (and to a lesser degree cold-specific
C-fibres) (Iggo, 1959; 1969), with specific cutaneous receptors in both the hairy and
glabrous skin (Iggo, 1969). Cold thermoreceptors are characterised by their high
sensitivity to small falls in skin temperature (as little as 0.1 deg.), and the most
commonly studied in the rat are facial and scrotal thermoreceptors. The majority of
these receptors have a relatively restricted range of innocuous cold temperatures
(approximately 20 to 30°C) over which they give dynamic responses to small
reductions in skin temperature (Heinz et al. 1990; Iggo, 1969).
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(ii) Warm thermoreceptors respond to slight warming of the skin and are
generally thought to be unmyelinated (Iggo, 1959). They are active at normal skin
temperature (approximately 30°C) and are silenced by noxious levels of heat
(48°C +).
(c) Nociceptors
Nociceptors were first described by Sherrington (1900) as sensory endings
that respond to stimuli that threaten or actually damage tissue. There are two main
groups of cutaneous nociceptors, the A8 mechanical nociceptor and the C polymodal
nociceptor.
(i) A8 mechanoreceptors. These nociceptors are associated with A5 fibres,
exist in both glabrous and hairy skin, and are only excited by high-threshold, noxious
mechanical stimulation. They are not normally activated by thermal stimuli (Besson
and Chaouch, 1987; Burgess and Perl, 1967), but they may become sensitised upon
repeated or long-lasting heat stimulation, after which they subsequently respond to
future heat challenges (Burgess and Perl, 1973; Fitzgerald and Lynn, 1977; Perl,
1984). Approximately 20% of all A-fibre units within the rat saphenous nerve are
high threshold mechanoreceptors, which display a wide range of conduction
velocities and generally have small receptive fields (Lynn and Carpenter, 1982). The
thresholds vary with the lowest thresholds found within the innocuous range.
Electrophysiological recordings in conjunction with the use of neuronal tracing
techniques based on the axoplasmic transport of marker substances (such as horse
radish peroxidase (HRP) and the plant lectin Phaseolus vulgaris leukagglutinin
(PHA-L)) have revealed that A8 nociceptive primary afferents, originating from high
threshold mechanoreceptors, terminate predominantly in Rexed laminae I, IV and V,
with a few fibres branching in to lamina II and X (Cervero et al.1976; Light and Perl
1979; Perl 1984, Rethelyi et al.1983) (See Figure 1.2).
(ii) C polymodal nociceptor units are the most common form of primary C-
afferent unit found within peripheral nerves of the rat (Lynn and Carpenter, 1982;
Schmalbruch, 1986). They respond to multiple stimulus modalities hence the term
polymodal, exist in both hairy and glabrous skin, and typically have small receptive
fields. Effective activating stimuli include noxious thermal heat (> 45°C) and more
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intense levels of mechanical pressure, as well as irritant chemicals (Perl, 1984). In
undamaged skin, they generally do not exhibit any spontaneous activity in the
absence of stimuli (Besson and Chaouch, 1987; Bessou and Perl, 1969). The vast
majority of cutaneous C-fibre polymodal nociceptors have been shown to terminate
in laminae I-II of the spinal dorsal horn (Cervero and Iggo, 1980; McMahon et al.
1984).
(iii) Cold nociceptors. Cold nociceptors may be associated with either A5-
or C-fibres, and are excited by noxious cold stimuli. Due to the vascular problems
incurred when attempting to stimulate the cutaneous receptive field or isolated nerve
fibres at noxious cold intensities, the full range of cold temperatures able to excite
cold nociceptors is not very clear. Saphenous nerve recordings in the rat have
revealed however, that the cold threshold for many of these nociceptors is below
12°C, with a large proportion of AS nociceptors only firing at temperatures below
0°C (Simone andKajander, 1996; 1997).
(iv) It has been reported that minor groups of nociceptors respond
preferentially to heat or chemical irritants, or may be completely inactive until
sensitised by the onset of inflammation or chemical irritants; the appropriately named
'silent' nociceptor (Bessou and Perl, 1969; Besson and Chaouch, 1987).
1.3 Central Mechanisms of Sensory Transmission
Melzack and Wall (1965) were the first to describe the existence of a specific
pain modulatory system within the CNS, with their "Gate Control Theory of Pain".
They proposed that messages transmitted from the peripheral nerves to the brain,
resulted from the convergence of more than one peripheral afferent impulse onto
spinal cord neurones, and that these signals could be influenced by impulses from the
brain which had the potential to exert a form of descending control. Many criticisms
have been made of this model, resulting in modifications of many of the details of the
gate control theory, but the hypothesis of a descending inhibitory control system,
mediated by activity in large afferent fibres, is still an important consideration when
investigating the transmission of nociceptive information at the spinal cord level.
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1.3.1 Descending Control of Nociceptive Transmission
In addition to receiving afferent inputs from the periphery, spinal cord
neurones also receive efferent influences from descending fibres. The effects of
descending pathways from the brain on dorsal horn neurones may be direct or
indirect, involving excitatory or inhibitory intemeurones at the spinal cord level.
These pathways are important in the maintenance of inhibitory control on dorsal hom
neurones.
(a) Tonic Descending Inhibition
Many areas of the brain exert a potent descending inhibitory influence on
spinal somatosensory mechanisms, in particular on nociceptive transmission in the
spinal dorsal horn. An experimental model used to demonstrate tonic descending
inhibition is reversible cold block, where the activity of a neurone, at a location
caudal to the area to be blocked, is examined before, during and after cold block of
the descending pathways (Brown, 1971). This technique has revealed that a number
of different dorsal horn neurones are under a tonic inhibitory control. In decerebrate
animals, cold block of the spinal cord at the thoracic level results in enhanced
responses of Spinocervical tract (SCT) cells to peripheral stimuli (Brown, 1971), due
to the blockade of descending inhibitory controls. Further studies have revealed that
tonic descending inhibitory controls affect nociceptive transmission in lamina I as
well as laminae IV-VI (Besson et al 1975; Brown, 1971; Duggan et al 1981), while
cells in lamina II appear to have no such inhibitory influence (Cervero et al. 1979).
The exact origin of tonic inhibition is unclear, but the lateral reticular nuclei and
nucleus paragigantocellularis lateralis in the brain stem appear to contribute, as
bilateral lesions in these areas appear to prevent such an inhibition (Foong and
Duggan 1986; Morton et al. 1983).
(b) Supraspinal Modulation
Descending pathways from the higher centres of the CNS can also modify
sensory or motor functions at the spinal level. A role for the brain stem in the
modulation ofpain is strongly supported by both behavioural and
electrophysiological studies. A number of groups have investigated the neuronal
effects induced by stimulating a variety of brain stem areas, and several areas have
been shown to provide analgesia when stimulated: including the periaqueductal grey
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(PAG) (Oliveras et al. 1974), the nucleus raphe magnus (NRM) (Guilbaud et al.
1977) and the reticular nuclei (Morton et al. 1983). Stimulation results primarily in
an inhibition of activity evoked by noxious, rather than non-noxious stimuli applied
to the periphery or the peripheral nerves (Duggan and Griersmith, 1979; Willis,
1977).
(c) Segmental Controls
The segmental controls are characteristically the inhibitory effects produced
by the large diameter (A(3) fibres on the responses of spinal neurones to nociceptive
stimulation (Besson and Chaouch, 1987), and these inhibitory influences can be
exerted on multireceptive and nocispecific dorsal horn neurones. A number of
pharmacological agents have been found to affect the activity of dorsal horn
interneurones. Excitatory amino acids (EAA) and neuropeptides have been proposed
as excitatory neurotransmitters or modulators and will be discussed in more detail in
Section 1.4. Inhibitory transmitters include the inhibitory amino acids y-
aminobutyric acid (GABA) and glycine and the endogenous opioids, which may be
released secondarily to the activation of spinal interneurones by primary afferent
fibres, or indirectly by the activation of pathways descending from the brain. In
addition, monoamines such as, serotonin and noradrenaline, may be directly released
by descending control systems to exert inhibitory effects (see Besson and Chaouch,
1987 for review).
GABA: GABA is an inhibitory neurotransmitter within the spinal cord,
where it is widely distributed. GABA is found in approximately one-third of laminae
I, II and III dorsal horn interneurones (Barber et al. 1982; Hunt et al. 1981; Todd and
McKenzie, 1989), as well as in neurones of the rostral ventral lateral medulla which
project to the spinal cord (Reichling and Basbaum, 1990). Ionophoresis of GABA
results in inhibition of dorsal horn neurone activity including those in the substantia
gelatinosa (Curtis et al. 1959;1977;Zieglgansberger and Sutor, 1983), implicating
this amino acid in the control of sensory processing at the spinal level. Other
evidence implicating a role for GABA in presynaptic inhibition is the blockage, at
least in part, ofprimary afferent depolarization by the GABA antagonists picrotoxin
and bicuculline (Besson et al. 1971; McLauchlin et al. 1975; Repkin et al. 1976).
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GABA is thought to exert its inhibitory effects by influencing the influx of cations
into the presynaptic cells (Robertson and Taylor, 1986).
Glycine: Glycine is also an important neurotransmitter with widespread
distribution throughout the spinal cord. The highest concentrations of this amino
acid appear to be found more ventrally in the spinal cord (Graham et al. 1967), but
glycine-containing neurones and synaptic terminals are also found in the superficial
layers of the dorsal hom (Todd, 1990). Electrophysiological experiments have
revealed that ionophoresis of glycine into the spinal cord can inhibit the responses of
dorsal horn neurones (Curtis et al. 1967a; 1967b; Werman et al. 1968;
Zieglgansberger and Sutor, 1983). However it is now commonly understood that
glycine can have two opposing functions in nociceptive processing: an excitatory
action via the glycine co-agonist binding site on the NMDA (N-methyl-D-aspartate)
receptor (GlyNMDA)> or an inhibitory action via the strychnine-sensitive glycine
receptor. Glycine is thought to be an important modulator of SP-evoked responses,
as it has been shown to be released following microdialysis of SP in to the spinal
cord in vivo (Smullin et al. 1990) and following bath application in vitro (Maehara et
al. 1993). In addition, intrathecal glycine inhibits substance P (SP) evoked biting and
scratching behaviours (Beyer et al. 1989), while intrathecal application of the glycine
antagonist strychnine facilitates the nociceptive flexor reflex (Sivilotti and Woolf,
1994). The modulatory influences of glycine are therefore quite complicated, and
can be exerted through several different pathways. The possible interactions between
glycine and the NMDA and SP receptors will be discussed in more detail in section
1.4.
Endogenous Opioids: The functional importance of the spinal opioid
system is well supported by the powerful and long-lasting analgesic effects seen in
animals following the intrathecal-administration of morphine (Yaksh, 1981). These
clinical effects clearly demonstrate the potential role for spinal opioid receptors in the
inhibitory modulation of nociceptive messages. Several opioid peptides are known
to be present within the intemeurones and synaptic terminals of the spinal dorsal
hom (Cruz and Basbaum, 1985; Glazer and Basbaum, 1981; Willis and Coggeshall,
1991), including enkephalin and dynorphin. Opiate receptors have been identified on
primary afferent terminals, and p-, 5- and k- receptors have all been found in the
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spinal cord (Atweh and Kuhar, 1977), particularly in the superficial dorsal horn,
using specific radioligand binding assays. Ionophoresis of opioids in the substantia
gelatinosa strongly inhibits the responses of dorsal horn neurones to noxious
stimulation (Duggan and North, 1984; Fleetwood-Walker et al. 1988), this inhibitory
action may be presynaptic or may be an indirect action following the activation of
neighbouring interneurones.
1.3,2 Ascending Somatosensory Pathways
In addition to receiving inputs from descending controls, many dorsal horn
neurones are projection neurones which relay sensory information to higher regions
of the CNS, through tracts in the white matter. The main ascending tracts implicated
in the transmission of nociceptive information in the rat are:
(a) Spinothalamic tract (STT): The STT transmits information from the
spinal dorsal horn to the thalamic nuclei via the ventrolateral quadrant of the spinal
cord. Anatomical studies based on the retrograde transport of HRP have revealed
that the majority of STT neurones, projecting to the lateral part of the thalamus, are
found in laminae I, III and IV of the rat spinal dorsal horn (Giesler et al. 1979).
Willis et al. (1983) characterised the neurones of the STT in the monkey on the basis
of their responses to peripheral stimulation to reveal that a high proportion of STT
neurones respond to noxious stimulation (55% were multireceptive, while 32% were
nocispecific). In the rat, STT cells usually respond to noxious mechanical
stimulation of the cutaneous receptive field, but they can also respond to innocuous
mechanical stimulation (Giesler et al, 1976), and so the STT is not solely involved in
the transmission of nociception and pain. However, STT cells can be inhibited by
stimulation of a number of different areas of the brain, including the NRM (Willis,
1977), PAG and the adjacent midbrain reticular formation (Gerhart et al. 1984;
Hayes et al. 1979), and the periventricular grey (Ammons et al. 1986). The resulting
inhibition following stimulation of these areas of the brain, is predominantly
inhibition of the noxious responses of nocispecific and multireceptive neurones,
therefore implicating the STT in the modulation and processing of nociceptive
information, although responses to innocuous stimuli were also occasionally
affected.
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(b) Spinoreticular tract (SRT): The SRT projects from the dorsal horn to
the brainstem reticular formation, again via the ventrolateral quadrant of the spinal
cord. IIRP mapping has demonstrated that the majority of SRT cells are
concentrated in laminae VII and VIII in the rat ventral horn (Chaouch et al. 1983),
with very few cells found in the more superficial layers of the dorsal hom.
Activation of SRT neurones via stimulation of the reticular formation (Menetrey et
al. 1980) revealed that the majority of these cells could be activated by noxious
sensory stimuli, with a large proportion being multireceptive neurones.
(c) Spinomesencephalic tract (SMT): The SMT projects to the
mesencephalic reticular formation and lateral part of the PAG as well as to other sites
in the midbrain (Mehler et al. 1960). SMT cells are predominantly found in lamina I
as revealed by HRP tracing (Menetrey et al. 1982), as well as lamina V.
Electrophysiological evidence has revealed a high proportion of the SMT neurones
which originate in the marginal zone, to be nociceptive neurones (Menetrey et al.
1980), implicating the involvement of the SMT in the control of nociception and
pain. However, there are also SMT cells which respond only to innocuous
mechanical stimulation (Menetrey et al.1980).
(d) Postsynaptic dorsal column (PSDC): The PSDC originates primarily
from neurones in lamina III of the rat spinal cord (Giesler et al. 1984), and contains
ascending branches ofprimary afferent fibres which project through the dorsal
funiculus to the nucleus gracilis and nucleus cuneatus (Giesler et al.1984). PSDC
neurones may respond to either innocuous or to both innocuous and noxious
stimulation of the cutaneous receptive field (Brown et al. 1983), however a few
nocispecific neurones have also been reported (Angaut-Petit, 1975).
1.4 Neurotransmitters of the Primary Afferent Nociceptor
Primary afferent nociceptors consist of a cell body (located in the dorsal root
ganglia (DRG)) and adjacent nerve fibres which project both centrally and
peripherally (Willis and Coggeshall, 1991). Activation of primary afferent
nociceptors requires an intense mechanical, thermal or chemical stimulus at the
peripheral terminal, resulting in the release of chemical substances from the nerve
endings or 'synapses', which ultimately mediate the transmission of nociceptive
19
information centrally, as well as at the periphery. A greater knowledge of the
identities and properties of these chemical transmitters released in the dorsal horn of
the spinal cord and in the brain, would therefore be of great interest in the
understanding of the processing of sensory information. Selective manipulation of
those transmitters involved predominantly in the transmission of noxious
information, being the prime targets for new analgesics.
A number of criteria have been proposed for the identification of
neurotransmitters (Salt and Hill, 1983) summarised as follows:
1. the transmitter and the mechanism for its production should be present in the
presynaptic neurone/terminal
2. the transmitter should be released upon physiological stimulation of the
presynaptic neurone/terminal
3. exogenously applied transmitter candidates and the release of the endogenous
transmitter should have the same effect on the postsynaptic neurone, and these
effects should be attenuated following application of the appropriate
pharmacological antagonist
4. an inactivation or removal mechanism for the putative transmitter should exist
A large number ofpharmacological agents have been found to affect the
responses of dorsal horn neurones (Willis and Coggeshall, 1991). Some of these,
including the excitatory amino acids (EAAs) and several peptides, have been
implicated in synaptic transmission via primary afferent fibres, and several
neuroactive substances have been shown to co-exist within both primary afferents
and sensory neurones (Ju et al. 1987; Smith et al. 1993). This highlights the potential
for co-transmission of many substances, such that primary afferent fibres may affect
various populations of dorsal horn neurones by releasing several different
transmitters at the same time. In addition, a variety of transmitters acting at different
receptors on the same postsynaptic neurone might have synergistic effects or may
differentially modulate the threshold for neuronal firing. The dorsal hom is a
primary receiving area for somatosensory input and contains high concentrations of a
large variety of receptors for a number of different neurotransmitters, some of the
principal ones are listed below:-
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1.4.1 Glutamate
Glutamate is an extensively studied EAA which has been shown to be a
neurotransmitter eliciting fast excitatory responses within the CNS (Watkins and
Evans, 1981) and is believed to be involved in the transmission of nociceptive
information. Curtis and colleagues first demonstrated the potential excitatory role for
glutamate following its ionophoretic application onto spinal neurones (Curtis et al.
1959). Since then other studies have implicated this EAA as an important
neurotransmitter. Electrical stimulation of dorsal column primary afferents has
induced the release of glutamate in vivo (Roberts, 1974), while immunohistochemical
and radiological studies have revealed the presence of glutamate in primary afferent
fibres of the spinal dorsal horn (De Biasi and Rustioni, 1988), dorsal root ganglia
(DRG) (Salt and Hill, 1983) and dorsal roots (Duggan and Johnston, 1970).
There are several receptor subtypes through which glutamate can mediate its
cellular actions. The ionotropic group, which are receptor linked ion channels and
comprise of the a-amino-3-hydroxy-5-isoxazole-4-propionate (AMPA), kainate
(KA) and NMDA receptors, and also the metabotropic glutamate receptors (mGluR)
which are coupled to various second messenger systems through GTP-binding
proteins (Willis and Coggeshall, 1991).
NMDA receptors have been shown to be located throughout the brain and
spinal cord (particularly in the superficial dorsal horn) (Greenamyre et al. 1984;
Monaghan and Cotman, 1985), and there is compelling evidence to suggest that they
play a role in excitability changes such as long term potentiation (LTP) (Collingridge
et al. 1983; Morris et al. 1986) as well as in the generation of hyperalgesia
(Dougherty et al. 1992b; Zhou et al. 1996). Intrathecal administration ofNMDA has
been shown to produce thermal hyperalgesia in the rat (Kolhekar et al. 1994), while
NMDA receptor antagonists inhibit the responses of dorsal horn neurones induced by
prolonged chemical nociception (Haley et al. 1990), joint inflammation (Neugebauer
et al. 1993) or repetitive C-fibre conditioning stimuli ('wind-up') (Davies and Lodge,
1987). So the activation ofNMDA receptors appears to contribute greatly to
prolonged states of nociception.
The abnormal pain-related behaviours induced by peripheral nerve injury,
such as hyperalgesia, allodynia and spontaneous pain, result from both increased
21
sensitivity ofprimary afferent fibres (peripheral sensitisation) (Campbell et al. 1988;
Kajander and Bennett, 1992; Wall and Devor, 1983) and an increase in the
excitability of spinal cord neurones (central sensitisation)(Coderre et al. 1993; Wall,
1991), and so the activation ofNMDA receptors by EAAs may also be an important
component in the development of neuropathic pain states. Indeed, in the chronic
constriction injury model, pre- and post-treatments with the NMDA antagonist MK-
801 have been reported to prevent or significantly reduce thermal and mechanical
hyperalgesia (Mao et al. 1992a; 1992b; Smith et al. 1994). However, a more recent
study has shown that although pre- and post-injury treatment with i.p. MK-801
suppressed the development of these pain states for a period ofup to 7 days, the
animals eventually became hyperalgesic by day 10-14 post injury (Kawamata and
Omote, 1996). This suggests that activation ofNMDA receptors appears to be
strongly involved in the induction and maintenance ofpain-related behaviours
following nerve injury, but that other factors may also contribute especially in the
longer term. Indeed, clinical trials in human patients have provided preliminary
evidence that NMDA receptors play an important role in neuropathy. Intravenous
infusions of the NMDA antagonist ketamine, reduced both allodynia and
hyperalgesia in a number ofpatients with chronic causalgic pain (Byas-Smith et al.
1993). However, the concentrations required to provide relief also produced
significant side effects, highlighting the need for the development ofmore effective
therapeutic agents.
A number of regulatory sites exist on the NMDA receptor, including the
glycine site (Kleckner et al. 1988), as mentioned earlier. Glycine has been termed a
co-agonist of the NMDA receptor and appears to be very important in regulating a
number ofNMDA receptor-mediated responses. The selective GlyNMDA site
antagonist 7-chlorokynurenate, has been shown to inhibit NMDA-induced thermal
hyperalgesia in the rat (Kolhekar et al. 1994), as revealed by an increased threshold
to noxious radiant heat. GlyNMDA site antagonists can also decrease the enhanced
responses of spinal neurones resulting from repetitive C-fibre stimulation (Dickenson
and Aydar, 1991). So occupation of the GlyNMDA site appears to be crucial for the
regulatory mechanisms and influences of the NMDA receptors expressed on dorsal
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horn neurones, and highlights the importance of interactive effects of the many
neuroactive substances found within the spinal cord.
The role of mGluRs within the CNS and their contribution to nociceptive
processing in the spinal cord is becoming increasingly clearer, and a number of
studies have provided evidence that mGluRs are involved in mediating noxious
inputs to the spinal cord. Electrophysiological studies revealed that the mGluRs are
important mediators in the sustained activation of dorsal horn neurones elicited by
topical, cutaneous application of the chemical irritant mustard oil (Young et al.
1994), which produces a sustained activation of dorsal horn neurones analogous to
'wind up'. Further experiments have since revealed that it is the mGluR5, and in
particular the mGluR! receptor subtypes which are particularly important in
mediating nociceptive transmission at the spinal cord level (Young et al, 1995a;
1995b; 1997).
So there are clearly a number of different pathways for glutamate to exert its
function as a neurotransmitter within the CNS. In addition, glutamate has been
shown to co-exist with SP in DRG neurones (Battaglia and Rustioni, 1988) and in
primary afferent terminals within the superficial laminae of the dorsal horn (DeBiasi
and Rustioni, 1988), and so it is highly likely that these compounds are co-released
following sustained stimulation of nociceptors. There is indeed a wide range of
evidence to implicate glutamate/SP interactions in the regulation of somatosensory
processing within the CNS. Electrophysiological studies revealed that ionophoretic
application of SP enhances the NMDA receptor-induced activity ofprimate STT
neurones (Dougherty and Willis, 1990; 1991), while ionophoresis of selective NKi
receptor agonists increase the NMDA receptor-mediated response of rat dorsal and
ventral horn neurones (Cumberbatch et al. 1995). More recently, Heppenstall and
Fleetwood-Walker revealed that this NIG receptor facilitation of the NMDA receptor
can be blocked by ionophoretic application of GlyNMDA site antagonists (Heppenstall
and Fleetwood-Walker, 1997a; 1997b), thereby implicating an important interactive
modulatory role for glycine, glutamate, SP and their receptors in the transmission of
nociceptive information.
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1.4.2 Substance P (SP)
SP was discovered by von Euler and Gaddam in 1931, and is the most
extensively studied primary afferent neuropeptide. Its role as a neurotransmitter was
first suggested by Lembeck (1953) who discovered, by means of a bioassay for the
peptide, that the dorsal roots of the spinal cord contained more SP than the ventral
homs. Gasparovic et al (1964), using a similar assay, went on to find that the levels
of SP became depleted in the dorsal roots following pre-treatment with capsaicin, a
neurotoxin which causes the destruction of the small diameter C-fibres the majority
ofwhich are nociceptors (Willis and Coggeshall, 1991). There is now a large body
of anatomical, behavioural and electrophysiological evidence implicating SP and its
receptors in sensory processing in the dorsal horn.
SP- immunoreactivity (-ir) and Preprotachykinin-A mRNA (the precursor
gene for SP) have been detected in a number of different areas of the CNS known to
be associated with the transmission of nociceptive information, including small
diameter primary afferent neurones, the spinal dorsal hom and small diameter DRG
cells (Gibson et al. 1981; Hokfelt et al. 1975;1977; 1980; 1993). SP is present in
approximately 20% of all DRG neurones (Ju et al. 1987), where it has been shown to
co-exist with a number of other substances including calcitonin gene-related peptide
(CGRP), somatostatin (SOM) and glutamate (Battaglia and Rustioni, 1988; Ju et al.
1987), thus highlighting the potential for co-release, and therefore possible
interactive roles, with other neuroactive substances. Within the spinal cord, the
highest concentrations of SP-ir are found within the superficial layers of the dorsal
hom (namely laminae I and II), but SP-ir has also been detected in laminae V-VII
and X (Gibson et al. 1981; Hokfelt et al. 1975;1977; 1980). SP mediates its effects
via the neurokinin] (NK]) receptor, dense concentrations ofwhich have been
demonstrated within the superficial layers of the spinal cord (Helke et al. 1986;
Nasstrom et al. 1992; Quirion et al. 1983; Yashpal et al. 1991a). In addition, at the
electron microscope level, NK] receptor-ir has been found in major dendrites of
dorsal hom neurones in laminae III, IV and to some extent V, dendrites which appear
to extend into lamina II and presumably act as targets for SP released in this area
(Brown et al. 1995; Nairn et al. 1997).
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Nerve section and dorsal rhizotomy largely, but not entirely reduce the
distribution of SP-ir, and so it seems likely that SP is derived from primary afferents,
intrinsic neurones and descending fibres (Jessell et al. 1979; Ogawa et al. 1985).
Further studies have revealed that capsaicin treatment causes the depletion of SP
from small primary afferents in the dorsal horn in conjunction with increasing
chemical and mechanical nociceptive thresholds (Hayes et al. 1981; Nagy et al. 1981;
Yaksh et al. 1979), further emphasising this fact. In fact it is now known that SP is
synthesised within the cell bodies of primary afferents then transported to peripheral
and central terminals of the sensory axon where it is released to exert its many
biological and physiological effects (Harmar and Keen, 1982).
There is now a large body ofboth behavioural and electrophysiological
evidence implicating a role for SP and NK] receptors in sensory processing in the
dorsal horn. Radioligand binding assays have shown that the expression ofNK]
receptors within the dorsal horn is altered by peripheral stimulation. Brief noxious
inputs decreased SP binding after 1 minute due to competition by the endogenous
ligand (Yashpal et al. 1994) whereas sustained forms ofnociception such as
inflammation or peripheral nerve injury raised levels of bound SP presumably as a
result of postsynaptic receptor upregulation (Aanonsen et al. 1992; Kar et al. 1994;
Yashpal et al. 1991a). In addition, the upregulation ofNK] receptors after
inflammation and nerve injury was seen with immunohistological techniques
(Abbadie et al. 1996), while in situ hybridisation studies have revealed that complete
Freund's adjuvant (CFA) or formalin-induced inflammation caused a considerable
upregulation ofNK] receptor mRNA throughout the superficial and deeper layers of
the spinal dorsal horn (McCarson and Krause, 1994; Schafer et al. 1993) which was
blocked by prior administration of opioid agonists (McCarson and Krause, 1995).
Together these results implicate the involvement of SP and its receptors as important
transmitters ofnociceptive information within the CNS.
Direct evidence of a neurotransmitter role for SP has been revealed in a
number ofbehavioural and electrophysiological studies. Behavioural studies have
shown that intrathecal SP evokes scratching and biting behaviours in mice and rats,
responses which are widely considered to reflect painful sensations (Hayes and
Tyers, 1979; Hylden and Wilcox, 1981; Yashpal et al. 1982). While ionophoretically
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applied SP has been shown to excite dorsal horn neurones (Henry, 1976;
Zieglgansberger and Tulloch, 1979) and selectively activate high threshold and
multireceptive laminae I and II neurones (Randic and Miletic, 1977). In addition, SP
enhanced the responses of multireceptive and nocispecific neurones to repetitive C-
fibre strength stimulation (Kellstein et al. 1990) which parallels the observed increase
in duration and magnitude of the flexor reflex evoked by C-fibre conditioning stimuli
(Wiesenfeld-Hallin, 1986). Furthermore, NK] receptor antagonists have been shown
to block both the SP-induced (Wiesenfeld-Hallin, 1986; Kellstein et al. 1990) and
electrically-conditioned elevated responses of the flexor reflex (De Koninck and
Henry, 1991; Laird et al. 1993; Xu et al. 1992a). However, NK! receptor antagonists
are generally not effective at reducing dorsal horn neurone responses to brief noxious
stimuli (Fleetwood-Walker et al. 1987;1990). Similarly, neuronal and behavioural
responses to more natural stimuli, such as brief noxious pinch and acute noxious
thermal stimulation of the tail or paw, are generally not affected by NKj receptor
antagonists (Couture et al. 1993; Garces et al. 1993; Malmberg and Yaksh, 1992;
Picard et al. 1993; Seguin et al. 1995; Yamamoto and Yaksh, 1992). These results
would suggest then, that SP and NKi receptors may have a more prominent role in
sustained noxious states.
Similarly, release studies strongly support a role for SP in sustained
nociception. SP is released from isolated rat spinal cord in vitro and from the cat
spinal cord in vivo, following electrical stimulation ofperipheral nerves at intensities
sufficient to activate small afferent fibres (A5 and C fibres) (Akagi et al. 1980; Klein
et al. 1992; Yaksh et al. 1980), implying that the main release of SP is from
nociceptive afferents. Microdialysis techniques revealed that noxious mechanical
and severe thermal stimuli specifically evoked SP release (Kuraishi et al. 1989) and
that greater increments in SP levels were recorded following stimuli which caused
damage to the peripheral tissues. In addition, antibody microprobe techniques
showed a release of SP within the superficial dorsal horn following noxious heat
(52°C +), noxious mechanical or chemical stimuli (Duggan et al. 1987; 1988). So
the main role for SP and NK, receptors in sensory processing therefore appears to be
modulators of sustained nociception, due to inflammation.
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1.4.3 Other Possible Neurotransmitters
It is apparent then that a number of different neurotransmitters and their
receptors are important in the regulation ofnoxious sensory transmission within the
CNS, and that different neuroactive substances may have synergistic or counter¬
active inhibitory effects on one another.
CGRP is yet another main constituent ofprimary afferent fibres, found in
approximately 30% of all primary afferent axons (Levine et al. 1993). CGRP-
containing fibres are largely unmyelinated (C) fibres or small diameter (A6) fibres,
and have been shown to terminate predominantly in laminae I, II and V of the spinal
cord (Carlton et al. 1988). In addition, the antibody microprobe technique revealed
that noxious thermal, mechanical or electrical stimulation evokes the release of
CGRP in the superficial dorsal horn (Morton et al. 1990), implicating this peptide as
another important mediator ofnociceptive transmission. A high proportion
(approximately 80%) of SP-expressing DRG also contain CGRP (Battaglia and
Rustioni, 1988; Ju et al. 1987), and so these two peptides will be predominantly co-
released. CGRP exerts limited effects by itself but can dramatically potentiate the
effects of SP. Ionophoresis of CGRP produces a slow-onset, long-lasting excitation
of nociceptive dorsal horn neurones in vivo (Miletic and Tan, 1988). However,
concentrations which have little or no consistent effect alone, synergistically increase
the effect of SP on rat dorsal horn neurones (Biella et al. 1991), as well as enhancing
the release of SP from spinal cord slices (Oku et al. 1987). In addition, CGRP has
been found to inhibit the enzymatic degradation of SP (Le Greves et al. 1985);
another biological property which would enhance the function of SP. So CGRP
appears to be a neuromodulator rather than a neurotransmitter within the CNS, as it
exerts limited effects by itself but dramatically potentiates the effects of other
compounds (in particular SP).
Somatostatin (SOM) has also been implicated as a neurotransmitter within the
CNS, as high levels of this peptide are found in a population of small diameter
primary afferents, distinct from those which contain SP (Hokfelt et al. 1976; Nagy
and Hunt, 1982). In addition, SOM-ir is especially dense in lamina II of the dorsal
horn (Finley et al. 1981; Hokfelt et al. 1976). However, electrophysiological studies
on spinal neurones in vivo and in vitro have produced a variety of results,
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demonstrating both an inhibitory (Murase et al. 1982; Randic and Miletic, 1978) and
an excitatory (MacDonald and Nowak, 1981b; Salt et al. 1982) role for this peptide
within the CNS, so its functional role as a neurotransmitter is not very clear. It has
been suggested that SOM may effect the release of other transmitters (MacDonald
and Nowak, 1981a) which may explain the discrepancies in the electrophysiological
studies and would suggest that the primary role for this peptide may be as a
modulator rather than a transmitter.
Another two peptides which are thought to have an excitatory role within the
CNS are vasoactive intestinal polypeptide (VIP) and cholecystokinin (CCK). These
peptides also display properties which fit the criteria for a transmitter: They are both
found within the CNS of a number of different mammalian species (Yaksh et al.
1988). They are expressed primarily in small diameter DRG, as well as in peripheral
nerves, and the superficial layers of the spinal dorsal horn (Fuji et al. 1983;1985).
However, the levels of these peptides are relatively low in the spinal cord under
normal circumstances (Noguchi et al. 1993) and so it is possible that their transmitter
role becomes more important following nerve injury when their levels become
markedly up-regulated (Hokfelt et al. 1994; Noguchi et al. 1989). The role of VIP in
somatosensory transmission will be discussed in much more detail in the following
section (1.5).
So a vast number of different neurotransmitters appear to be able to mediate
the pain-modulatory systems within the CNS, and it seems likely that there is no one
sole mediator ofnociceptive pathways. Instead it seems much more likely that a
variety of neurotransmitters interact within the CNS to mediate/regulate the
transmission ofnociceptive (and non-nociceptive) information. A better
understanding of the complicated pathways involved in responses to noxious stimuli,
and the transmitters which are involved, would therefore provide new insights into




In 1970, work by Said and Mutt demonstrated the existence of a new
polypeptide, which they named Vasoactive Intestinal Polypeptide (VIP), due to its
potent vasodilatory activity. This peptide was isolated from porcine small intestine
based on its ability to increase peripheral blood flow and decrease arterial blood
pressure in dogs (Said and Mutt, 1970b). Further work revealed the peptide to
consist of 28 amino acid residues (Mutt and Said, 1974) having a distinct chemical
structure from the kinins; substance P, glucagon and secretin, despite showing some
sequence homology. Although originally considered as being a gut hormone (Said
and Mutt, 1970a; 1970b), radioimmunochemical and immunohistochemical studies
have revealed a widespread distribution ofVIP throughout the peripheral and central
nervous systems of a variety of species (Gibson et al. 1981; Larsson et al. 1976;
Yaksh et al. 1988), suggesting that it may also play an important role as a
neurotransmitter.
Pituitary Adenylate Cyclase-Activating Peptide (PACAP) is a basic 38 amino
acid neuropeptide originally isolated from ovine hypothalamus (Miyata et al. 1989),
based on its ability to cause adenylate cyclase activation in rat anterior pituitary cell
cultures. This peptide occurs as two variants, PACAP-38 (a 38 amino acid
polypeptide) and the C-terminally truncated form, PACAP-27 (with only 27
residues) (Miyata et al. 1990). PACAP-38 and PACAP-27 are derived from the same
precursor of 176 amino acids and have comparable biological activity (Miyata et al.
1990). PACAP is a member of the VIP/secretin/glucagon family of structurally
related peptides, as it shows 68% homology with VIP at its N-terminal (Arimura,
1992)(See Figure 1.3). It also has a widespread distribution throughout the
mammalian body and may also be an important neurotransmitter or modulator in the
peripheral and central nervous systems (Arimura, 1992; Arimura and Shioda, 1995;
Ghatei et al. 1993; Moller et al. 1993).
1.5.2 VIP/PACAP Receptor Subtypes
The sequence homology observed between VIP and PACAP means that they
share the same receptor binding sites (Harmar and Lutz, 1994). VIP and the two
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alternative processing forms ofPACAP are recognised by a family of three receptors,
namely the VIPi (Ishihara et al. 1992), VIP2 (Lutz et al. 1993) and PACAP (Hosoya
et al. 1993) receptors. All three receptors are G-protein-coupled receptors (Spengler
et al. 1993), with seven conserved transmembrane domains, and there is a
considerable degree of homology between the three receptor subtypes (Lutz et
al.1993) (See Figure 1.4). The most notable features of the VIP/PACAP receptors
are the relatively long amino-terminal extracellular tail, and the highly conserved
cysteine residues within the extracellular loops (Hashimoto et al. 1993; 1997).
Two specific forms of the VIP receptor have been identified so far, namely
the VIP! (Ishihara et al. 1992) and VIP2 (Lutz et al. 1993) receptors. They are both
positively-coupled to the a-subunit of the adenylate-cyclase-stimulating G-protein
(Gs), and so stimulate the activity of adenylate cyclase (See Figure 1.5) following
their activation (Ishihara et al. 1992; Lutz et al. 1993). Both receptors bind VIP and
PACAP with a similar high affinity, although they appear to be differentially
expressed throughout the CNS (Cauvin et al. 1991; Usdin et al. 1994). The VlPi
receptor was originally cloned from rat lung cDNA (Ishihara et al.1992) and is found
predominantly in the liver, intestine and certain areas of the brain (notably the cortex,
hippocampus and the olfactory bulb). The VIP2 receptor was isolated from rat
pituitary and olfactory bulb and is primarily expressed in the thalamus, hippocampus,
suprachiasmatic nucleus and the hypothalamus (Lutz et al. 1993).
The PACAP receptor displays a much greater affinity for the two forms of
PACAP (PACAP-27 and PACAP-38) than for VIP (Hashimoto et al. 1993; Shivers
et al. 1991), and also has a widespread distribution throughout the body, including
the CNS (Cauvin et al. 1991; Ghatei et al. 1993; Masuo et al. 1991). The PACAP
receptor is coupled to dual signalling cascades involving the Gs and Gq proteins (See
Figure 1.5), and so has the ability to stimulate both adenylate cyclase and
phospholipase C (PLC) second messenger pathways (Spengler et al. 1993). The
different second messenger pathways may be preferentially regulated by the two
forms of PACAP, as both PACAP-27 and PACAP-38 can stimulate adenylate
cyclase activity with similar EC50 values, but only PACAP-38 can stimulate PLC
with high potency (Spengler et al. 1993). In addition, five subtypes of the PACAP
receptor can be generated, by alternative splicing of the PACAP precursor, which
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vary in the amino acid sequence within the third intracellular loop. These splice
variants have a differential distribution within the peripheral and central nervous
systems and show altered patterns of adenylate cyclase and PLC activation (Spengler
et al. 1993). So variations in the expression of PACAP in its two amidated forms,
and of the different VIP/PACAP receptor subtypes, may potentially result in diverse
PACAP-mediated cellular activities within different areas of the body.
Comparison of the tissue distribution of the VIPi, VIP2 and PACAP receptors
by in situ hybridisation has revealed remarkable differences: PACAP receptor
mRNA is abundantly expressed in the brain but there is very little expression in
peripheral tissue (Arimura and Shioda, 1995), whereas VIP! receptor mRNA is
expressed in the lung, intestine and liver (Ishihara et al. 1992) while brain levels are
much lower than that of PACAP. In contrast, mRNA for the VIP2 receptor is found
predominantly in the thalamus, hippocampus and suprachiasmatic nucleus, as well as
in the stomach and testes (Harmar and Lutz, 1994; Usdin et al. 1994). This distinct
distribution of the VIP/PACAP receptors within the CNS suggests that these
receptors may have different physiological roles.
1.5.3 Anatomical Distribution of VIP/PACAP and their Receptors
VIP and PACAP are expressed widely in both the periphery and CNS of a
variety of species (Arimura and Shioda, 1995; Ghatei et al. 1993; Gibson et al. 1981;
LaMotte and de Lanerolle, 1986; Larsson et al. 1976; Vigh et al. 1991; Yaksh et al.
1988). Their distinct anatomical distribution within the CNS has led to the
suggestion that these peptides may serve as sensory transmitters, and so may play an
important role in the modulation of somatosensory processing.
Brain: Significant concentrations ofVIP have been reported in many areas of the
brain by a number of different laboratories, with the highest levels being found in the
cerebral cortex, hippocampus and the hypothalamus (Besson et al. 1986; Larsson et
al. 1976; Staun-Olsen et al. 1985). PACAP on the other hand, shows a much wider
distribution with high levels demonstrated in the rat hippocampus, hypothalamus and
anterior pituitary (Cauvin et al. 1991; Masuo et al. 1991; 1992). Within the rat brain,
the specific binding of radiolabeled PACAP was shown to be around 10 times greater
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than that of radiolabeled VIP, particularly at the level of the dorsal hippocampus
(Masuo et al. 1993), and this may reflect a dominant presence of the specific PACAP
receptor over the VIP] or VIP2 receptors. More recent studies have revealed a
distinct distribution of the VIP/PACAP receptor subtypes throughout the brain with
only a few areas of overlap, notably the thalamus, hippocampus and olfactory bulb
(See Figure 1.6), which may reflect the need for different biological functions in the
different areas. The VIP] receptor is found predominantly in the cerebral cortex,
hippocampus and the olfactory bulb of the brain, while the VIP2 receptor is found
primarily in the thalamus, hippocampus, hypothalamus, suprachiasmatic nucleus and
the olfactory bulb (Harmar and Lutz, 1994; Usdin et al. 1994; Vertongen et al. 1997).
So, the mRNAs encoding the VIP] and VIP2 receptors appear to have a
complimentary distribution within the CNS. Even in areas of the brain where they
are both present (for example the olfactory bulb and the cerebral cortex), they still
appear to have distinct distributions: VIP] receptor mRNA is found within the
external plexiform layer of the olfactory bulb while that of VIP2 is generally found in
the internal granular layer, similarly in the cortex, VIP] receptors are expressed in
layers III and V while VIP2 receptor expression appears to be exclusively in layer VI
(Usdin et al. 1994; Vertongen et al. 1997).
Spinal cord:
Segmental localisation. Radioimmunoassays have revealed the presence of
VIP and PACAP throughout all segments of the rat and cat spinal cord (Fuji et al.
1985; Moller et al. 1993; Mulder et al. 1994; Shehab and Atkinson, 1986a; 1986b;
Yaksh et al. 1982). The expression of these peptides is broadly distributed
throughout the full length of the spinal cord, but there is a clear rostro-caudal
gradient of the autoradiographic binding sites for VIP, with the greatest
concentrations generally found at lower lumbar to sacral levels (Gibson et al. 1981;
Yashpal et al. 1991b).
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Figure 1.3
Sequence Homology between VIP and the Two Amidated forms of PACAP
The aligned amino acid sequences of PACAP-38, PACAP-27 and ovine VIP, with
the amino acid residues common to all three polypeptides marked in bold, to
demonstrate the high degree of homology observed between the three peptides.














Sequence Homology Between the Rat VIPi, VIP2 and PACAP Receptors
Schematic model of the deduced amino acid sequence for the rat VIP2 receptor,
showing the areas ofhomology between the VIPi, VIP2 and PACAP receptors. All
three receptors are G protein-coupled and possess 7 transmembrane domains with
their associated intracellular and extracellular loops. Amino acids homologous to all
three receptors are marked in red, while those common to both VIP! and VIP2
receptors are coloured blue, VIP2 and PACAP receptors are yellow, and those found
in both VIP! and PACAP receptors are shown in green. The remaining, uncoloured
amino acids are found only in the VIP2 receptor. A similar degree of homology is
also seen between the human VIPi, VIP2 and PACAP receptors (Pisegna et al. 1996).
(Adapted from Lutz et al.1993)
Several domains appear to be important for the selectivity of the ligand binding and
subsequent receptor activation, including the amino-terminal extracellular domain,
the transmembrane domains (I and II), and the C-terminal region (Hashimoto et al.
1997; Wulff et al. 1997), while the third intracellular loop is the area of the receptor





VIP/PACAP Receptor Activation of Second Messenger Pathways
Schematic representation of the VIP/PACAP receptors and the second messenger
pathways associated with their activation. The VIP] and VIP2 receptors are both
positively-coupled to the a-subunit of the adenylate-cyclase-stimulating G-protein
(Gs) which activates adenylate cyclase (AC) following the agonist-induced exchange
of guanosine triphosphate (GTP) into guanosine diphosphate (GDP). Adenylate
cyclase subsequently converts adenosine triphosphate (ATP) into cyclic-adenosine
monophosphate (c-AMP), which in turn activates protein kinase A, to result in the
phosphorylation of a number of proteins and receptors within the cell. Both VIP and
PACAP can activate the VIP! and VIP2 receptors with similar binding affinity.
The PACAP receptor is coupled to dual signalling cascades involving the Gs protein,
which activates adenylate cyclase as above, and the Gq protein, which activates the
phospholipase C (PLC) second messenger pathway. Activation of the PLC pathway
converts phosphatidyl inositol 4,5-diphosphate (PIP2) into inositol 1,4,5- triphosphate
(IP3) which causes the intracellular release of calcium ions from the endoplasmic
reticulum (ER), and di-acyl glycerol (DAG) which induces phosphorylation of
intracellular proteins through activation of protein kinase C (PKC). Increases in the
intracellular levels of calcium ions have been linked with a number of physiological
effects including activation of immediate early genes and subsequently changes in
receptor and gene expression within the cell, as well as enhancing the effects of







Lamina localisation. VIP and PACAP immunoreactivity can be seen
throughout the spinal cord, but their highest levels are concentrated in the superficial
laminae of the dorsal horn, laminae I and II (Dun et al. 1996; Kar and Quirion, 1995;
Moller et al. 1993; Yashpal et al. 1991b). VIP-ir perikarya are found in the dorsal
horn, lamina X and the intermediolateral nucleus (Fuji et al. 1985; Knyihar-Csillik et
al. 1993; LaMotte and de Lanerolle, 1986; Yaksh et al. 1982), but the level of
expression is very low in normal animals. PACAP-ir has been detected in numerous
nerve fibres of laminae I and II of the dorsal horn (Dun et al. 1996; Moller et al.
1993), although some of these fibres also project into the deeper laminae of the
dorsal horn (laminae III, IV and V) of all spinal cord segments (Dun et al. 1996). In
the lower cervical, thoracic, lower lumbar and sacral segments, additional PACAP-ir
fibres were also detected in the intermediolateral cell column (Dun et al. 1996). The
mRNA for VIP, (Ishihara et al. 1992), VIP2 (Lutz et al. 1993) and the PACAP
receptors (Arimura and Shioda, 1995) is also expressed in spinal cord, particularly in
the superficial dorsal horn.
Primary afferents. VIP-ir nerve fibres have been shown to be distributed
within lamina I of the rat dorsal horn, with a few fibres projecting to lamina II (Fuji
et al. 1985; Gibson et al. 1981; LaMotte and de Lanerolle, 1986). Dorsal rhizotomy
produces an almost total depletion of VIP from the superficial laminae of the dorsal
horn (Shehab and Atkinson, 1986a; 1986b; Yaksh et al. 1982), suggesting that the
origin of VIP is attributed to fine primary afferent fibres. In addition, electrical
stimulation of the sciatic nerve at or above C/A5 fibre intensity, has been shown to
produce a significant increase in VIP levels within the spinal cord, while stimulation
at low threshold fibre intensity has no such effect (Yaksh et al. 1982). Suprisingly
however, intrathecal capsaicin has no effect on the spinal cord levels ofVIP (Yaksh
et al. 1982) suggesting that the origin of this peptide is not likely to be C-nociceptors.
Radioimmunological studies have revealed a dense accumulation of PACAP-ir nerve
fibres in the superficial layers of the spinal cord (Dun et al. 1996; Moller et al. 1993),
with a similar distribution to that of SP- and CGRP-ir fibres, but less numerous
fibres. Capsaicin treatment results in the release of PACAP-27 and PACAP-38 from
the rat spinal cord in vivo (Zhang YZ et al. 1997), as well as a significant decrease in
39
the number of PACAP-ir nerve fibres within the spinal cord (Moller et al. 1993)
indicating that PACAP is present in a population of nociceptive C-fibres.
Dorsal Root Ganglia (DRG)
The intrinsic levels of VIP appear to be very low, as very little expression of
mRNA for VIP can usually be seen in normal DRG (Noguchi et al. 1989; Yaksh et
al. 1982), significant levels can normally only be viewed following colchicine
treatment (Shehab and Atkinson, 1986a; Yaksh et al. 1982). Following axotomy
however, there is a marked upregulation in the expression of VIP, such that
approximately 40% of small to medium diameter DRG neurones now contain this
peptide (Shehab and Atkinson, 1986a; 1986b). Unilateral rhizotomy performed at
the same time as axotomy prevents this marked increase in VIP levels, and so the
injured nerve fibres are most likely the source of VIP seen following nerve section
(Shehab and Atkinson, 1986a; Shehab et al. 1986). PACAP mRNA on the other
hand, is normally present in about 10% of rat DRG neurones (Mulder et al. 1994),
and is predominantly expressed in small-medium diameter neurones (Dun et al.
1996; Moller et al. 1993; Mulder et al. 1994) suggesting that PACAP is a constituent
of primary afferent fibres. Immunohistochemical studies have revealed that PACAP
co-exists with CGRP and SP (Moller et al. 1993; Mulder et al. 1994), and so further
implies a role for this peptide as a neurotransmitter.
Peripheral Distribution: As stated previously, the distribution of VIP/PACAP
receptors is not solely confined to the CNS, a large number ofperipheral tissues and
organs also express these receptors, in particular the VIP) and VIP2 receptors
(Harmar and Lutz, 1994; Usdin et al. 1994). The VIP! receptor appears to have the
widest distribution within the periphery, and is found in the liver, lungs, small
intestine and the thymus (Ishihara et al. 1992; Usdin et al. 1994). In contrast, the
VIP2 receptor is present in a number of areas where VIP acts, but where VIPj
receptor mRNA is absent, or is present at very low levels, including the stomach and
the testes (Usdin et al. 1994). This again highlights the differential distribution of
these receptors and suggests that they each have different biological roles within the
body. On the other hand, there appears to be a very low level of expression of the
specific PACAP receptor within the periphery, despite the clear biological roles
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which PACAP has in a number of tissues and organs (Arimura, 1992; Hashimoto et
al. 1993). PACAP-ir fibres have been demonstrated in the stomach, liver, duodenum
and jejunum, but there appears to be no, or very little expression of the PACAP
receptors here (Arimura, 1992; Hashimoto et al. 1993; Hosoya et al. 1993). This
would suggest that any biological roles which PACAP has in these tissues are
mediated by either the VIP] or VIP2 receptors.
Thus, the wide distribution of VIP and PACAP within the CNS, in particular
in primary sensory neurones of the spinal dorsal horn, suggests a possible role for
these peptides in the transmission of somatosensory information. The majority of
VIP- and PACAP-ir fibres are found in the superficial layers of the rat spinal cord,
namely laminae I and II (Fuji et al. 1985; Moller et al. 1993; Yashpal et al. 1991b),
an area known to be important in the transmission of nociceptive information
(Cervero and Iggo, 1980).
However, the levels of these peptides, in particular ofVIP, are relatively low
under normal circumstances (Noguchi et al. 1993; Mulder et al. 1994), suggesting
perhaps that they are not primary transmitters within the normal spinal cord.
Following nerve injury however, the levels of these peptides are dramatically up-
regulated within the spinal dorsal horn (Knyihar-Csillik et al. 1993; Shehab and
Atkinson, 1986b; Zhang et al. 1996), as well as in small-medium diameter DRG
neurones (Hokfelt et al. 1994; Zhang et al. 1995a; Zhang et al. 1996) and so it may




Differential Expression of the VIP1? VIP2 and PACAP Receptors Within the Rat
Brain
Schematic representation of the rat brain showing the differential expression of VIP!
(blue), VIP2 (red) and PACAP (yellow) receptors, within the different brain areas.
All three receptors display a unique pattern of expression within the rat brain, with
only a few areas of complete overlap, namely the olfactory bulb and the
hippocampus. In the remaining areas there appears to be a preferential expression of
one receptor subtype above the others, which may reflect a need for different
physiological receptor properties within the different areas. The PACAP receptor is
widely expressed throughout the rat brain, with the most abundant expression in the
olfactory bulb, hippocampus, anterior pituitary and the cerebellum (where it is
expressed almost exclusively). It is also co-expressed with the VIP! receptor in the
dentate gyrus and the supraoptic nuclei of the hypothalamus. Relatively small
amounts of expression are noted in the thalamus, which is predominated by the VIP2
receptor, and the piriform layers of the cerebral cortex.
VIP2 receptor expression is most abundant in the thalamus, anterior pituitary,
olfactory bulb and the suprachiasmatic nucleus within the hypothalamus. It is also
co-expressed with VIP] in the cerebral cortex and hippocampus.
There appear to be no areas where the VIPi receptor is the sole receptor expressed. It
is found predominantly in the cerebral cortex, olfactory bulb and hippocampus, but
can also be expressed with the PACAP receptor in the supraoptic nuclei, dentate
gyrus and to a lesser degree within the cerebellum.
Based on information from (Harmar and Lutz, 1994; Hashimoto ct al. 1993; Ishihara
et al. 1992; Lutz et al. 1993; Spengler et al. 1993; Vertongen et al. 1997)
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PITUITARY
1.5.4 VIP/PACAP-mediated Spinal Somatosensory Transmission
The availability of synthetic VIP and PACAP, and their analogues, has led to
numerous in vivo and in vitro studies on the physiological properties of these two
peptides. In addition to their anatomical distribution within areas of the CNS known
to be associated with somatosensory processing (notably the superficial laminae of
the dorsal horn), functional studies have provided strong evidence for a regulatory
role of VIP and PACAP at the spinal cord level.
(a) Effects of VIP and PACAP on Behavioural Nociceptive Responses
Spinal reflexes have been extensively utilised in studies of pain mechanisms
in animals and man, to study the role of a number of different neuroactive substances
in modulating spinal cord excitability. The magnitude of the nocifensive hindpaw
flexor reflex to electrical stimulation or to physiological stimuli, has been positively
correlated to the activity of spinal dorsal horn neurones (Schouenborg and Sjolund,
1983), and is a graded response which is commonly used for both physiological and
pharmacological studies.
A number of studies have been performed using this technique to determine
the role of VIP at the spinal cord level, and to gain new insight into its proposed role
as a neurotransmitter/neuromodulator. A brief conditioning stimulus (CS) train,
applied to unmyelinated C-fibres has been shown to induce wind-up and facilitation
of the flexor reflex (Wall and Woolf, 1984). Although VIP facilitates spinal cord
reflex excitability in rats with intact peripheral nerves following its intrathecal
application (Weisenfeld-Hallin 1987; 1989; Xu and Weisenfeld-Hallin, 1991),
endogenous VIP does not appear to play a role in the C-fibre induced spinal
sensitisation under normal conditions, as intrathecal application of the VIP antagonist
(Ac-Tyr1, D-Phe2)-GRF(l-29)-NH2 had no effect on CS-induced reflex facilitation in
normal animals (Wiesenfeld-Hallin et al. 1990a; Xu and Wiesenfeld-Hallin, 1991).
However, within two weeks following sciatic nerve transection VIP becomes a major
excitatory mediator of spinal reflex hypersensitivity, as the VIP antagonist now
significantly inhibited C-fibre facilitation of the flexor reflex (Wiesenfeld-Hallin,
1989; Wiesenfeld-Hallin et al. 1990a), while the tachykinins (SP and CGRP)
appeared to lose their excitatory role (Wiesenfeld-Hallin et al. 1990a). These results
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suggest that there may be a switch in the role of excitatory neuropeptides following
peripheral nerve injury from SP to VIP, which would parallel the corresponding
changes in the expression of these peptides following axotomy.
The role of VIP in mediating nociceptive information at the spinal cord level
was then considered in more detail, revealing that VIP appeared to be involved
primarily in the transmission of thermal pain. Cridland and Henry revealed that
intrathecal VIP produced a dose-dependent decrease in the withdrawal latency of the
rat tail to noxious radiant heat, but showed no changes in the animal's withdrawal
threshold to innocuous mechanical stimulation of the tail (Cridland and Henry,
1988). In addition, the spinal cord excitability following intrathecal VIP was
considerably higher when the flexor reflex was evoked by noxious thermal
stimulation of the ipsilateral foot, compared to that seen following cutaneous noxious
mechanical pinch (Wiesenfeld-Hallin, 1987). These results are in contrast to those
seen for SP and CGRP, which appear to be important mediators of both mechanical
and thermal nociceptive information (Cridland and Henry, 1988), suggesting that
specific peptides may be involved in the transmission of different types of pain
modality.
The functional effects of PACAP are not quite as clear cut, and are currently
under debate. Some groups have demonstrated an antinociceptive effect of PACAP
at the spinal level, as intrathecal application of PACAP-27 was found to produce a
significant and long-lasting suppression of the C-fibre evoked flexor reflex over the
wide range of concentrations tested (Zhang et al. 1993). In addition, pre-treatment of
rats with intrathecal PACAP was shown to decrease the number of formalin-induced
instances of flinching behaviour, in a dose-dependent manner. However at the high
doses used (approximately 15.5nmol) there was evidence of some motor defects, as
tested using the placing/stepping reflex (Yamamoto and Tatsuno, 1995). However,
on repeating these studies at lower doses, which showed no motor impairment,
PACAP-27 was still found to depress both phases of the formalin responses, and
therefore still suggests an antinociceptive role for this peptide.
Weisenfeld-Hallin's group however, have suggested a nociceptive role for
PACAP. In decerebrate spinalised animals, they revealed that intrathecal PACAP,
delivered over a wide low dose range (lOng to 10pg) produced a dose-dependent
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facilitation of the flexor reflex, with no inhibitory effects observed at any of the doses
(Xu and Weisenfeld-Hallin; 1996). This data implies that PACAP has an excitatory
effect on the spinal cord function, similar to that seen for many other peptides
investigated in this model, including SP, CGRP, VIP and SOM (Cridland and Henry,
1988; Wiesenfeld-Hallin et al. 1990b; 1991; Xu et al. 1990). In agreement with these
findings, Narita et al.(1996) discovered that low doses of intrathecal PACAP (0.05-
0.5pg) produced a dose-dependent decrease in tail-flick latency to noxious heat in
mice, indicative of thermal hyperalgesia. Slightly higher doses (l-10pg) induced a
dose-dependent increase in biting and scratching behaviours, indicative of pain
behaviours (Narita et al. 1996), similar to those seen following intrathecal application
of SP (Hayes and Tyers, 1979; Hylden and Wilcox, 1981). These results strongly
support the idea that PACAP may be a sensory transmitter involved in nociceptive
processing within the mouse spinal cord, and suggests that it may well have several
distinct actions.
However, the different effects of PACAP observed in the results of the flexor
reflex studies may be due to differences in the experimental set up between the two
groups, including differences in the site ofnerve stimulation and recording, the
integrity of the spinal cord, and the presence or absence of anaesthesia, and so it is
therefore important to consider other physiological effects of PACAP when trying to
ascertain its role within the CNS.
(b) Effects of VIP and PACAP on Electrophysiological Responses
A number of electrophysiological studies have demonstrated the potential for
VIP to act as a neurotransmitter of a number of different cell types within the CNS.
Ionophoresis of synthetic VIP showed it to be a potent excitant ofboth nociceptive
and non-nociceptive neurones throughout the rat trigeminal nucleus caudalis (Salt
and Hill, 1981), while a similar non-selective excitatory effect was also observed on
the vast majority of spinal cord neurones (laminae I-VII) in both the mtact cat spinal
cord and the rat spinal cord slice preparation (Jeftinija et al. 1982), despite the fact
that the levels of VIP within the spinal cord appear to be lower than those seen in
many other regions of the CNS (Emson, 1979; Loren et al. 1979). This excitatory
role of VIP has also been demonstrated in different areas of the rat brain, including
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the hippocampus (Dodd et al. 1979) and cerebral cortex (Phillis et al. 1978). In an in
vitro slice preparation of the rat hippocampus, VIP was found to have an excitatory
role on CA1 pyramidal neurones following pressure ejection from micropipettes.
VIP application caused subsequent depolarisation of all the neurones tested, with an
increase in the rate of discharge. The membrane potential and excitability usually
returned to control resting levels within 60-180 sees of termination of VIP
application, although repeated application was seen to cause an apparent
desensitisation ofVIP receptors (Dodd et al. 1979). In an in vivo study on the rat
cerebral cortex, Phillis et al. recorded extracellularly from deep, spontaneously active
neurones, including identified pyramidal cells. They found that ionophoretically
applied VIP excited the vast majority of these cells, and that the membrane receptors
for VIP appeared to undergo an apparent desensitisation following repeated
application ofVIP. However, within the cat visual cortex, VIP appeared to have the
ability to increase or decrease both the spontaneous activity and the visual responses
of the majority of cortical neurones tested (Murphy et al. 1993), suggesting that VIP
may have dual modulatory roles within certain areas of the brain.
Extracellular patch-clamp recordings of cultured chick cortical neurones have
revealed a direct modulatory effect of PACAP-38 (Liu and Madsen, 1997). This
facilitatory effect appears to be independent of intracellular second messengers (such
as cAMP, calcium ions and inositol phosphate), and it has been proposed that
PACAP modulates this effect via the glycine co-agonist site(s) on the NMDA
receptor (Liu and Madsen, 1997). The direct modulation of NMDA receptors via the
glycine site has previously been suggested for the opioid peptides (Chen et al. 1995;
Rusin and Randic, 1991) as well as for the tachykinins (Rusin et al. 1992; 1993). A
similar facilitatory effect at the NMDA receptor has also been observed in patch-
clamp recordings of rat sympathetic preganglion neurones (SPN), although in these
experiments the effects of PACAP-38 were attenuated by pre-treatment of the cells
with cAMP inhibitors (Wu and Dun, 1997), suggesting that in these cells, PACAP
potentiates NMDA-receptor-mediated responses via second messenger systems (i.e.
cAMP), and so may be a facilitatory effect following activation of the VIP/PACAP
receptors (which are positively coupled to the adenylate cyclase pathway). PACAP
has also been shown to have an excitatory effect in other regions of the brain,
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including the magnocellular portion of the rat hypothalamic paraventricular nucleus.
In a brain slice preparation, perfusion ofPACAP-27 or PACAP-38 at low
concentration (< 1 pmol) produced prominent excitatory effects on a large proportion
of the spontaneously firing neurones tested (Uchimura et al. 1996).
So VIP and PACAP both appear to play an important role as
neurotransmitters/neuromodulators within the CNS. VIP appears to be a potent
excitant in at least three different areas of the CNS (the spinal cord, cerebral cortex
and hippocampus), and these effects are seen at low concentrations. Despite the
variability in PACAP effects in some of the behavioural studies, an overall review of
the current PACAP literature would suggest that its effect within the CNS is
predominantly excitatory, particularly within the brain.
1.5.5 Other Physiological Roles of VIP and PACAP
(a) General Biological Actions
Both PACAP and VIP possess a number ofphysiological roles within the
mammalian body. Although originally thought to be solely a gut hormone (Said and
Mutt, 1970a; 1970b), the discovery of the wide distribution of VIP throughout the
body has led to the revelation of numerous biological and physiological properties
for this peptide.
Investigations into the effects of VIP, have shown an unusually wide range of
biological activities for this peptide, including vasodilatory effects, increasing cardiac
output, as well as causing hypotension and hyperglycaemia (Said and Mutt, 1970a).
Within the systemic vascular system, VIP has been shown to have marked and
prolonged effects, increasing blood flow while decreasing systemic blood pressure
following intra-arterial infusion of the pure peptide (Said and Mutt, 1970b). In
addition, VIP is a highly potent stimulant of vasodilation in many different organs, as
well as playing a role in smooth muscle contraction (Piper et al. 1970) and so it
appears to be an important regulator of blood flow to the digestive organs as well as
being a mediator in various hypotensive states.
PACAP, as its name suggests, can stimulate the activation of adenylate
cyclase in anterior pituitary cells (Miyata et al. 1989), and despite its considerable
degree ofhomology with VIP (68% at its N-terminal), it can stimulate adenylate
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cyclase in certain tissues with many fold greater potency than VIP. A dense network
of PACAP containing fibres has been demonstrated in the gut wall of a number of
different species, including human, rat, chicken and cat (Arimura, 1992; Sundler et
al. 1992). These nerve fibres innervate longitudinal smooth muscle, blood vessels
and Brunnel's glands in the intestine which suggests that PACAP has important
regulatory actions within the gastrointestinal tract including motility, blood flow and
secretory activity of the glands.
(b) Immunoregulatory Role of VIP/PACAP
The delivery of various mediators to immune cells, is an important regulatory
aspect of the immune and inflammatory responses, and a substantial body of
evidence exists to suggest that VIP and PACAP can modulate immune responses. As
well as having the potential to exert an indirect influence on the immune response
through its vasodilatory role (causing vascular smooth muscle relaxation and
subsequently vasodilation at the site of injury/inflammation, thereby modulating
lymphocyte trafficking), VIP can also act directly on a number of different cells of
the immune system via specific receptors. Receptors for VIP and PACAP have been
found on a number of different cells, including lymphocytes, macrophages and
leukocytes (Goetzl et al. 1995; Gozes et al. 1991; Tatsuno et al. 1991; 1996; Xia et
al. 1996), thereby enabling VIP and PACAP to modulate the proliferative responses
of these immune cells and/or their release of various mediators. The expression of
VIPt and VIP2 receptors on human T and B lymphocytes (Gozes et al. 1991; Xia et
al. 1996) enables VIP to have potent and apparently distinctive effects on T cell
selection and T cell migration in the thymus, and so endogenous VIP may be one of
the factors which regulates the negative selection of T lymphocytes during an
immune response. In addition, VIP and PACAP can modulate the production of
various cytokines from immune cells (Gottschall et al. 1994; Xin et al. 1997) as well
as from epithelial cells in vitro, and so may indirectly influence immune and
inflammatory responses at the site of injury. Other regulatory roles include the
modulation of the growth rate of cultured lymphocytes, mediation of
immunoglobulin production and secretion, and the regulation of adherence molecule
expression which may ultimately effect immune cell migration (Goetzl et al. 1995;
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O'Dorisio et al. 1981). These various immunoregulatory roles implicate VIP and
PACAP in the modulation of a number of important biological processes within the
body. The neurotrophic properties of VIP and PACAP, which appear to be vitally
important in the regulation of immune and inflammatory responses, may therefore be
equally important in the degenerative and regenerative processes which ensue from
nerve injury.
(c) Neurotrophic Role of VIP and PACAP
There is a vast amount of evidence to suggest that VIP and PACAP may be
important neurotrophic factors within the nervous system. VIP and/or PACAP have
been shown to exhibit a number of distinct actions on the cell proliferation, survival
and phenotypic expression of a number of well-characterised cell culture systems,
including neural cells. These actions may be directly on the cells themselves or a
result of the indirect activation ofneighbouring cells.
VIP and PACAP appear to play an important role in the sympathetic nervous
system, and have been shown to exert a number of effects on cultures of superior
cervical ganglion (SCG) cells including increasing neurite outgrowth, promotion of
cell survival and increasing cell proliferation (Colbert et al. 1994; Deutsch and Sun,
1992; Hernandez et al. 1995; Klimaschewski et al. 1995; Pincus et al. 1994). In
addition, VIP and PACAP are also capable of inducing NPY gene expression in
PC 12 cell cultures (Colbert et al. 1994), and so their function in the sympathetic
nervous system is not purely trophic. PACAP in particular, appears to play an
important role preventing neuronal apoptotic death. This property was observed
within physiological concentrations (10~10to 10"sM)and was considerably more
pronounced than the effects ofVIP (which was only effective in increasing cell
survival at unphysiologically high concentrations (10~6)) (Deutsch and Sun, 1992;
Tanaka et al. 1997). This suggests that PACAP-induced enhancement of PC12 cell
survival is mediated primarily by the PACAP receptor, which has a high affinity for
PACAP and a low affinity for VIP. Overall however, it is clear that PACAP and VIP
are likely to play significant functional roles in the development and regulation of the
sympathetic nervous system.
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Within the CNS, immunoreactivity for VIP and PACAP has been
demonstrated in early developing rat brain and spinal cord (Fuji et al. 1985; Hill et al.
1994), consistent with a neuronal growth factor property for these peptides. Indeed,
in DRG cell cultures, VIP and PACAP have been shown to be important regulators
of sensory neurone survival. PACAP appears to have a protective role, protecting
developing DRG neurones from death in dissociated cell cultures and stimulating
neurite outgrowth (Lioudyno et al. 1998). In addition, PACAP has the ability to
induce the expression of CGRP-ir in DRG explants (Lioudyno et al. 1998),
highlighting a potentially important role for PACAP in the phenotypic plasticity
which follows nerve injury. PACAP can also promote cell survival and neurite
outgrowth in cultured immature cerebellar granule cells (Gonzalez et al. 1997;
Vaudry et al. 1988), implicating PACAP as an important mediator within the brain as
well as the spinal cord. The majority of the literature however, suggests that VIP and
PACAP influence the development of the nervous system in an indirect manner, by
causing the release of trophic factors such as cytokines from non-neuronal cells
(particularly astrocytes) (Brenneman et al. 1987;1990; Pellegri et al. 1998; Tatsuno et
al. 1996; Waschek, 1996). Thus their neurotrophic property may not be their main
function within CNS neurones of the normal adult. Even so, this still highlights a
significant role for VIP and PACAP which may be extremely important in the




1.6 Pharmacology of Neuropathic Pain
The development of neuropathic pain may rely upon many different factors,
and often the aetiology is not known. Possible causes include trauma or disease-
evoked damage, ischaemia, inflammation, crushing or constriction to peripheral
nerves, posterior roots, spinal cord or to certain regions of the brain, or may be a
secondary result of specific disease processes or systemic disorders such as diabetes,
rheumatoid arthritis, alcohol or viral infections (Scadding, 1984). The pathological
changes which then occur both centrally and peripherally, lead to painful neuropathic
symptoms which are characterised by several different types of pain sensation:
• Spontaneous pain: this may be a continuous superficial burning pain and/or deep
aching pain, or it may be episodic attacks.
• Hyperalgesia: an exaggerated response to a painful stimulus whether it be
mechanical, chemical or thermal in nature.
• Allodynia: pain in response to a normally innocuous mechanical or thermal
stimulus.
The duration of these abnormal pain states can range from months to years or
even decades (Scadding, 1994), as the pathological conditions often persist long after
healing of the damaged peripheral tissue or nerve.
Empirical findings have strongly implicated an important role for the
sympathetic nervous system (SNS) in the development of some forms of neuropathic
pain (see (Bennett, 1991) for review). This has led to the commonly used term
sympathetically maintained pain (SMP), as opposed to sympathetically independent
pain which appears to have no sympathetic involvement. Neuropathic patients very
often display signs of abnormal sympathetic activity such as abnormal skin
temperature and trophic skin changes (Wakisaka et al. 1991). In addition, chemical
or surgical sympathectomies often relieve the painful symptoms which ensue
peripheral nerve injury (Kim et al. 1993; 1997; Shir and Seltzer, 1991). There is also
a wide range of evidence for changes in sympathetic nerves following peripheral
nerve injury, and possible interactions between the sympathetic nervous system and
the development of chronic pain (See (McMahon, 1991) for review). Possible
contributing factors from the SNS include:
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• the influence of adrenergic receptors on sensory neurones which may enhance
ectopic discharge
• indirect coupling of sympathetic and sensory neurones through sympathetic fibre
sprouting
• sensitisation of nociceptive afferents and dorsal horn neurones by mediators of the
SNS (e.g. noradrenaline)
These factors will be considered in more detail in section 1.6.3.
Cold allodynia appears to be a striking feature in neuropathic pain in humans
(Engkvist et al. 1985; Frost et al. 1988), particularly in patients with SMP. Very
little is known about the mechanisms underlying cold pain. It appears that cold pain
sensation in humans can have various qualities including cold aching, burning and
prickling sensations, which would suggest the involvement ofmultiple classes of
nociceptors (Chery-Croze, 1983; Davis, 1988). In humans, it has been demonstrated
that normally innocuous cool stimuli evoke a sensation ofburning pain during
ischemic nerve block of conduction in A fibres (A(3 and A5) (Wahren et al. 1989;
Yarnitsky and Ochoa, 1990). This implies that at least some heat-sensitive C
nociceptors are excited by innocuous cold stimuli but that this activity is normally
inhibited by simultaneous activation of cold-sensitive A fibres. It is therefore likely
that at least one mechanism underlying cold hyperalgesia associated with large fibre
neuropathy, is the loss of inhibitory modulation at the central level normally
provided by cold-sensitive A-fibres (Ochoa and Yamitsky, 1994). In normal rats it is
the small diameter nociceptive afferents which transmit cold sensory information,
and saphenous nerve recordings have revealed that the cold threshold for many
nociceptors is below 12°C, with a large proportion of nociceptors not being excited
until stimulus temperatures approach 0°C and below (Simone and Kajander, 1996;
1997). In behavioural tests of conscious animals which have undergone a chronic
constriction injury, it appears that this threshold has been altered as the majority of
animals now show aversive behavioural responses to temperatures above 0°C (Attal
et al. 1990; Bennett and Xie, 1988), signifying a change in sensitivity.
The mechanisms underlying chronic neuropathic pain states are poorly
understood and so treatment is often unsatisfactory. Advances in the treatment of
painful neuropathies have been slow to evolve and are often limited in success.
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Classical opioid analgesics are often ineffective (Arner and Meyerson, 1988; Lee et
al. 1994; Mao et al. 1995), and anaesthetic nerve blocks or surgical sympathectomies
often provide only temporary relief (Dougherty et al. 1992a; Loh and Nathan, 1978;
Luo and Wiesenfeld-Hallin, 1995). However, more successful methods of treatment
do exist, including the use of anticonvulsant drugs (Fields et al. 1997; McQuay et al.
1995; Tanelian and Brose, 1991) and the tricyclic antidepressants (McQuay et al.
1996).
There appear to be many contributing factors to the development and
maintenance of neuropathic pain states and each individual case may be subtly
different in character. The efficacy of analgesic agents therefore may be highly
dependent on the particular cause of the neuropathy, making the development of
potential treatments even more complicated.
A large number of the painful neuropathies which afflict humans are a result
of trauma or disease that produces only a partial nerve injury. Much of the present
knowledge of neuropathic pain has come from the development of animal models of
nerve injury which mimic the clinical conditions seen in man. These models have
provided the means with which to analyse some of the mechanisms behind the
hyperalgesia and allodynia induced by nerve injury, and therefore have greatly
improved the understanding of the neural mechanisms underlying neuropathic pain
states.
1.6.1 Animal Models of Neuropathic Pain
Neuropathies induced by damage to parts of the central nervous system are
particularly common in humans, and a number of useful animal models have been
developed which involve experimental damage to certain parts of the brain and/or
spinal cord. One of the first models ofperipheral nerve injury to undergo extensive
investigation, was that of complete nerve section or axotomy (Wall et al. 1979).
Axotomy of the rat sciatic nerve results in marked plasticity within the CNS
including biochemical, structural and functional changes (Devor, 1994). However,
the major disadvantage of this model is that it is very difficult to correlate the
physiological changes with the occurrence ofpain, as parallel behavioural testing can
not be performed as the whole limb is denervated as a result of the nerve
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manipulation. The degree of autotomy (where the animals gnaw at their denervated
hindlimb) has been used as an indicator ofpain, with a scoring system to grade the
severity of self-mutilation. However there is much debate as to whether or not
autotomy is a true representation of painful sensation, or if it is simply due to the
animal ceasing to recognise its own limb due to the complete denervation (Coderre et
al. 1986; Rodin and Kruger, 1984). Several animal models now exist using a partial
nerve injury, which allows some correlation of the central changes which occur
following nerve injury, with the severity of the pain-related behaviour. A variety of
tests can be performed on the affected, ipsilateral hindlimb which measure
differences in the altered behaviour of these animals to mechanical, thermal or
chemical stimuli. Three primary models exist so far, all of which involve sciatic
nerve manipulation and produce abnormal pain states in the ipsilateral hindlimb:-
1. The chronic constriction injury (CCI) model
The chronic constriction injury (CCI) model of Bennett and Xie (1988) is one
of the more commonly used models in scientific investigations. This model is
produced by loosely tying 4 chromic cat gut ligatures around the common sciatic
nerve, at mid thigh level. Within one week the animals show altered spontaneous
behaviours consistent with the presence of neuropathic pain. The affected limb is
demonstrably hyperalgesic, and mechanical and thermal allodynia (both hot and
cold) are also present (Attal et al. 1990; Bennett and Xie, 1988). In addition, the
animals tend to hold their affected hindlimb in a protective position, with the toes
ventroflexed. This abnormal behaviour is thought to be indicative of the presence of
spontaneous pain, and a scoring index for the severity of this abnormal posture in
relation to spontaneous pain has been used (Attal et al. 1990). These behavioural
changes manifest within 36 hours of the nerve constriction, are most pronounced 10-
14 days after induction of the injury and can last for up to three months. An
important feature of this model is that the ligatures do not completely sever the nerve
and so many of the axons within the nerve are left in continuity. There appears to be
a partial, selective involvement of the SNS in this model, as chemical or surgical
sympathectomies only appear to alleviate the increased responses to thermal stimuli,
while having no effect on the lowered thresholds to mechanical stimuli or the
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behavioural abnormalities relating to spontaneous pain (Desmeules et al. 1995; Neil
et al. 1991; Perrot et al. 1993).
2. Partial Nerve Ligation (PNL)
Partial nerve ligation (PNL) (Seltzer et al. 1990) involves a tight ligation of
approximately one third to one half of the sciatic nerve with an 8-0 silk suture, at a
site just distal to the point at which the posterior biceps-semitendinosus nerve
branches off. Within a few days mechanical allodynia and hyperalgesia, as well as
thermal (heat) hyperalgesia develop in the ipsilateral hindlimb, and these abnormal
pain states can last for up to 7 months (Seltzer et al. 1990). There is no evidence of
cold allodynia in these animals. However, the animals do display abnormal
grooming of the affected hindlimb, including licking and biting, as well as holding
the affected hindlimb in a protective manner, which is thought to be indicative of the
presence of spontaneous pain. No signs of autotomy are apparent in PNL animals. A
marked feature of PNL, is the development ofbilateral 'mirror' effects (Seltzer et al.
1990). There also appears to be an important contribution from the SNS in the
development of these pain related behaviours, as chemical or surgical
sympathectomy has been shown to alleviate or prevent the development of
neuropathic pain (Shir and Seltzer, 1991).
3. Spinal Nerve Ligation (SNL)
Spinal nerve ligation (SNL) involves the tight ligation of either the L5, or the
L5 and L6 spinal nerves contributing to the common sciatic nerve just distal to the
DRG (Kim and Chung, 1992), thereby transecting all axons within the nerve. These
animals develop abnormal grooming behaviours including licking and biting, which
may be representative of spontaneous pain (Na et al. 1996). There is however, no
sign of autotomy. The rats display a quick onset (within the first 1-2 days following
surgery) ofbehavioural signs of mechanical and thermal (heat) allodynia, but no cold
hypersensitivity in the ipsilateral hindlimb. These abnormal pain states can last for
up to 5 months (Kim and Chung, 1992). The development of these abnormal pain
behaviours is dependent on innervation by the sympathetic nervous system as
surgical lumbar sympathectomy almost completely abolishes them (Choi et al. 1994;
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Kim and Chung, 1991; Kim et al. 1993). This marked sympathetic involvement
makes the SNL model a useful model for investigating the contribution of the
sympathetic nervous system in the development of neuropathic pain. The main
benefit ofusing this model is the fact that the surgery is standardised, with the same
group of fibres being affected every time. However, the surgical procedure is
considerably more extensive than that of the other two models.
Other Animal Models:-
A number of other neuropathic animal models exist but appear to be less extensively
studied. Diabetic/neuropathic rodents are easily obtained and a number of different
models exist (Watkins, 1990):
1. An inbred BB/Wistar strain of albino rats become spontaneously diabetic, and
show behavioural signs of hyperalgesia and allodynia (Wuarin-Bierman et al.
1987).
2. Sand rats develop diabetes when fed ordinary rat lab chow, and again develop
hypersensitivity to mechanical and thermal stimuli (Wuarin-Bierman et al. 1987).
3. Animals with experimentally-induced diabetes are produced following injection
of B cell toxins, e.g. alloxan or streptozocin (Courteix et al. 1993), resulting in
the development ofmechanical and thermal hyperalgesia/allodynia.
However, the control of diabetes in these animals may also influence the
development of neuropathic pain states directly or indirectly, making interpretation
of experimental results more complicated. There are also animal models of
peripheral nerve injury due to trauma, disease, metabolic disorders and toxins
(Scadding, 1994), but none of these models appear to produce disorders ofpain
sensation like those which accompany the peripheral neuropathies in humans.
The Bennett and Xie model was chosen for use in the current investigations
because it has been extensively studied and so allows the integration of the present
results with previous findings. In addition, this model is relatively safe and simple to
set up, with a low incidence of autotomy, wound infection or morbidity, and the
affected hindlimb is easily accessible for behavioural studies.
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1.6.2 Plasticity Following Peripheral Nerve Injury
1.6.2.1 Aetiology of Nerve Injury
Chronic constriction of the common rat sciatic nerve results in the
development of a number of abnormal pain symptoms within a few days following
nerve injury, including mechanical and thermal hyperalgesia and allodynia, as well as
behavioural signs of spontaneous pain (Attal et al. 1990; Bennett and Xie, 1988).
Several aspects of the nerve injury may contribute to the development of these
abnormal pain symptoms.
The inflammatory response appears to play a major role in the development
of neuropathic pain states, as daily injections of the anti-inflammatory agent
dexamethasone, decreased the inflammatory response induced by chromic gut
sutures, and subsequently blocked the development of guarding behaviour and
thermal hyperalgesia in rats (Clatworthy et al. 1995). In contrast, application of
cotton sutures soaked in Complete Freund's Adjuvant (CFA) resulted in
augmentation of these abnormal pain behaviours (Clatworthy et al. 1995).
Changes in local blood flow through the injured nerve may also contribute to
the sensory changes, as there is some evidence of decreased blood flow at the nerve
injury site at a time when thermal hyperalgesia is evident (Myers et al. 1988).
Finally the type of suture material also appears to be important. Kajander et
al. (1996) used chromic cat gut, plain gut or polyglactin sutures as ligatures in the
chronic constriction injury model ofneuropathy. They found that the subsequent
abnormal paw position varied between the different test groups. Animals with
chromic gut ligatures spent more time with their affected hind paw in abnormal
positions than the other groups, and although the animals with plain gut or
polyglactin ligatures spent more time with their hindlimb in abnormal positions
relative to control animals, the affects on paw position were much greater in rats with
chromic gut ligatures (Kajander et al. 1996). In addition, the use of chromic gut
ligatures results in marked decreases in the levels of SP- and CGRP-ir in the spinal
cord, while polygalactin or plain gut sutures appear to have no such effect on the
expression of these peptides (Xu et al. 1996). As all types of suture appear to induce
abnormal behavioural responses, the physical constriction of the nerve is likely to
play an important part in their development. However, these results also suggest that
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the chemical constituents of the chromic gut sutures may also have an effect,
possibly on neuronal function and thereby influencing neuroma development and the
inflammatory response. Indeed, Maves et al. (1995) have reported that providing an
acidic environment around the rat sciatic nerve for 7 days will result in the
progressive development of thermal hyperalgesia in these animals.
1.6.2.2 Morphological Changes Following CCI
The rat sciatic nerve originates from spinal segments L4-L6 and contains
fibres of sensory, motor and sympathetic origin. At the mid-thigh level, it comprises
of approximately 27 000 axons ofwhich 6% are motor axons, 23% are myelinated
sensory axons, 48% are unmyelinated sensory axons while 23% represent
unmyelinated sympathetic axons (Schmalbruch, 1986).
There are marked morphological changes in the fibre composition of the
sciatic nerve following CCI, and these changes have been well documented, allowing
speculation as to the fibre type(s) involved in the development of the abnormal pain
states which accompany peripheral nerve damage.
There are two main stages involved in the pathological changes of the sciatic
nerve following CCI (Coggeshall et al.1993). The first is an early degenerative stage
which is thought to be a direct result of the inflammation and swelling which occur at
the site of nerve injury following application of the chromic cat gut ligatures, and
appears to induce a slow strangulation of the axons underneath. This swelling can
last up to 28 days post operatively (PO) and is maximal at day 3 PO, by which time a
mass of connective tissue and a neuroma are often apparent (Coggeshall et al.1993).
The sciatic nerve undergoes marked anatomical changes, distal to the site ofnerve
injury, at this time. From day 3 to two weeks after nerve ligation, there is a steady
and extensive decrease in axon numbers of all types. The most prominent change is
a profound loss of large myelinated axons, namely the Ap fibres, distal to the lesion
while the smaller myelinated and unmyelinated fibres appear to be less affected. At
the electron microscope level, the few remaining large diameter Ap fibres were seen
to be in an advanced state of degeneration (Basbaum et al. 1991). This near complete
loss of large myelinated fibres distal to the ligature, could result in the loss of central
inhibitory controls which are normally exerted by the large diameter primary
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afferents (see Section 1.3.1). However, the development of the chronic pain state can
not be solely related to the loss of large diameter afferents, as all fibre types are
affected to some degree. There is a significant decrease in the number of small
myelinated A8 fibres, although to a lesser extent than that of the A(3 fibres, in
addition to the disruption and damage of a number of small unmyelinated fibres (i.e.
the C-fibres). The effect ofnerve ligation on the smaller myelinated fibres varied
and was greatly affected by which fascicle was studied. It is possible that the whole
population of A5 fibres may not have been counted as some of these fibres may have
been mistaken for unmyelinated C-fibres if they were seen at different stages of
degeneration/regeneration and therefore had thin myelin sheaths. 1cm or more
proximal to the nerve injury, the morphology of the nerve appeared normal
(Basbaum et al. 1991; Coggeshall et al. 1993; Gautron et al. 1990), with no sign of
degenerating fibres, which suggests that most of the damaged fibres had survived
centrally.
The second stage ofpathological change is the regenerative phase. This
generally occurs from approximately day 28 PO onwards, when the sutures have
been reabsorbed and the neuroma and swelling have subsided (Coggeshall et al.
1993). This coincides with fibre regeneration and the recovery of axonal numbers,
and probably accounts for the eventual recovery ofnormal sensation within the
affected limb (Guilbaud et al. 1993).
The time-course of these morphological changes within the injured nerve has
been studied in parallel with the behavioural changes which develop. The associated
behavioural studies have revealed that the onset of hyperalgesia is generally maximal
at days 10-14 PO (Attal et al. 1990; Bennett and Xie, 1988), the time point which
correlates with the initial fibre loss and predominant loss of large myelinated fibres
(Basbaum et al. 1991; Coggeshall et al. 1993; Gautron et al. 1990). Guilbaud's
group found that behavioural signs of hot and cold allodynia/hyperalgesia and
mechanical hypersensitivity in the CCI model were maximal at week 2 PO, with a
progressive recovery from week 3-4 PO onwards (Guilbaud et al. 1993). At week 2
there is a massive Wallerian degeneration of large myelinated fibres, with
regeneration occurring from week 3 PO onwards (Ramer et al. 1997), which
coincides with these behavioural changes. However the largest fibres still had not
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completely recovered by week 15 PO and this contrasts with the disappearance of
abnormal nociceptive behaviours and subsequent recovery from neuropathic pain
states seen at approximately weeks 8-10 PO (Guilbaud et al.1993). So the damage to
nerve fibres does appear to be of some importance, as the development of abnormal
pain states appears to be linked to the presence of degenerating or regenerating A-
fibres, however, there does not appear to be a strong correlation between the time
course ofmorphological changes overall and neuropathic syndromes. It is likely that
these morphological changes are an important link in the development and
maintenance of neuropathic pain but that other additional factors are also involved.
1.6.2.3 Neuropeptide Plasticity
Investigations in animals with peripheral nerve injury have revealed a number
of different neurochemical changes within the spinal cord and DRG that may be of
important physiological significance (see figure 1.7). Following peripheral axotomy
long-lasting changes in the production and expression of neuropeptides and their
receptors are seen in primary afferent sensory neurones (Hokfelt et al. 1994). In
addition, changes in the peripheral and central transport of these substances results in
marked plasticity within the spinal cord as well. The main changes observed
following complete nerve transection or partial nerve constriction include a down-
regulation of the excitatory peptides SP and CGRP, as well as decreased SOM, while
levels of VIP, PACAP, NPY, galanin and CCK are all seen to increase.
Substance P (SP): SP is found in approximately 30% of small to medium
diameter DRG neurones normally (Ju et al. 1987; Smith et al. 1993). Following
axotomy there is a significant decrease in the expression of SP mRNA in these DRG,
which is most pronounced at day 10-14 PO and is accompanied by a parallel
decrease in SP levels in the spinal dorsal horn (Barbut, 1981; Jessel et al. 1979;
Noguchi et al. 1993; Shehab and Atkinson, 1986b). A similar marked decrease in SP
production by primary afferent neurones is seen following CCI (Cameron et al.
1991; 1997; Nahin et al.1994), with a significant decrease in the density of SP-ir
fibres in the ipsilateral spinal cord (Kajander and Xu, 1995), but the reductions do
not appear to be as great as those seen following axotomy. This is most likely due to
the fact that CCI only produces a partial denervation and so fewer small diameter
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primary afferents will be injured than in axotomy. This major decrease may reflect a
lesser role for SP in nociceptive processing in neuropathy.
CGRP: CGRP is one of the most abundant neuropeptides in the DRG
normally, where it is seen to co-exist with SP, SOM and galanin (Ju et al. 1987;
Smith et al. 1993; Villar et al. 1989). Axotomy results in a marked decrease in the
expression of CGRP mRNA in primary sensory neurones (Noguchi et al. 1989; 1990;
1993; Shehab and Atkinson 1986b), which is maximal between days 7-14 PO While
decreased levels of CGRP-ir in the superficial dorsal hom are usually apparent by
day 10 PO (Kajander and Xu, 1995; Shehab, and Atkinson, 1986b; Zhang et al.
1995b). A similar change has also been observed following chronic constriction of
the sciatic nerve with approximately 50% reductions in the levels of CGRP mRNA in
the DRG reported within 7-14 days following nerve injury (Nahin et al. 1994).
However, subsequent decreases in the immunohistochemical staining for this peptide
in the spinal dorsal horn have not been observed until approximately 60 days after
the chronic constriction injury (Kajander and Xu, 1995).
Somatostatin (SOM): SOM is normally present in approximately 20% of
small to medium diameter DRG (Ju et al. 1987; Smith et al. 1993). Nerve transection
results in a marked decrease in the production of SOM by primary afferent neurones
in rat and monkey DRG, with a corresponding decrease in SOM-ir in the superficial
dorsal horn (Shehab and Atkinson, 1986b; Villar et al. 1989; Zhang et al. 1993b).
VIP: VIP-ir is present at relatively low levels in the superficial dorsal horn
(Knyihar-Csillik et al. 1993) and primary afferent neurones (Fuji et al. 1985) of
normal animals. Following axotomy there is a significant increase of VIP expression
in small to medium diameter DRG neurones, where it is often co-localised with
galanin (Nahin et al. 1994; Zhang et al. 1995a). There is also a corresponding
increase in VIP-ir in the superficial dorsal horn (Knyihar-Csillik et al. 1993; Shehab
and Atkinson, 1986a; 1986b). In double labelling studies using the retrograde
transport of True Blue with VIP immunohistochemistry, it was revealed that VIP
expression only occurs in cells which have had their axons cut in the peripheral part
of the sciatic nerve (Shehab et al. 1986). This suggests that sensory neurones may
express VIP as a direct response to axonal injury. Indeed VIP-ir has been shown to
increase in the dorsal hom following nerve crush, but decreases to control levels as
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soon as fibre regeneration has occurred (Knyihar-Csillik et al. 1991; 1993). VIP
predominantly has an excitatory role (see section 1.5.4), and so it is possible that this
peptide takes over the role of SP as a primary neurotransmitter within the CNS of
neuropathic animals. In addition, it may also be an important neurotrophic factor and
so may play a role in the regenerative processes which follow nerve injury.
PACAP: Abundant PACAP-ir fibres have been demonstrated in the normal
superficial dorsal horn (Mulder et al. 1994; Zhang Q et al. 1995), and approximately
10% of DRG neurones express this peptide. Axotomy results in a rapid and
prominent increase in PACAP mRNA in approximately 75% of DRG cells from as
early as 15 hours PO, with a maximum increase at day 3 PO which begins to
decrease by day 10 PO (Zhang Q et al. 1995). PACAP levels appear to return to
control values by week 4 PO. PACAP is seen to co-exist with VIP, NPY and GAL
to varying degrees (Zhang Q et al. 1995), but its time course of expression is
considerably different to that of these other neuropeptides. The function of PACAP
within the CNS is not altogether clear as it may have inhibitory or excitatory
properties (see section 1.5.4), but the rapid onset of PACAP expression suggests that
it may be important in the early phases of adaptation to nerve injury.
CCK\ CCK is present in relatively low amounts in DRG normally (Fuji et al.
1985; Ju et al. 1987). Intrathecal CCK has been shown to have an excitatory role in
flexor reflex studies (Weisenfeld-Hallin and Duranti, 1987). Following peripheral
nerve injury the expression of CCK mRNA markedly increases in primary afferent
neurones (Villar et al. 1989). The role of CCK in neuropathy is not clear (see
(Wiesenfeld-Hallin and Xu, 1996a) for review) but it appears to decrease the
analgesic effect of morphine and P-endorphin (Faris et al. 1983). In addition,
antagonists of the CCK-B receptor (which is the prevalent form of CCK receptor
within the rat spinal cord) potentiate opioid analgesics and prevent the development
of morphine tolerance (Baber et al. 1989; Dourish et al.1990; Weisenfeld-Hallin et al.
1990d). This interactive role of CCK, and the fact that its levels are dramatically up-
regulated following nerve injury may therefore help to explain the decreased efficacy
of opioid treatment commonly observed in neuropathic patients.
Galanin: Galanin is a C-terminally amidated 29 amino acid peptide, the
binding sites of which show dense labelling in laminae I-III and moderate labelling
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in laminae IV-V of the rat dorsal horn (Kar and Quirion, 1994; 1995). Galanin
receptors are also widely distributed throughout the CNS, particularly in the
superficial dorsal horn (Weisenfeld-Hallin et al. 1992; Zhang et al. 1995c). It is
normally present in approximately 23% of small to medium diameter DRG neurones,
where it co-exists with several other neurotransmitters including CGRP and SP (Ju et
al. 1987; Zhang et al. 1993a; 1995c). Galanin levels have been shown to be
decreased, at least in part, by neonatal capsaicin treatment, particularly in laminae I-
II of the spinal dorsal horn (Skofitsch and Jacobowitz, 1985), and so galanin may be
an important mediator ofprimary afferent C-fibres. Peripheral nerve injury leads to
an increase in galanin mRNA expression within DRG cells within 24 hours (mainly
in small to medium diameter neurones, but also in a few large cells), as well as in the
ipsilateral dorsal horn (Ma and Bisby, 1997; Nahin et al. 1994; Romualdi et al. 1990;
Zhang et al. 1995b). The pattern of co-expression of galanin and the other
neuropeptides also changes following nerve injury with less CGRP/GAL co-
expression and an increase in the co-existence of galanin with NPY and VIP (Nahin
et al. 1994). The role of galanin within the CNS is not very clear as functional
studies have provided variable results depending on the preparation and dose used,
and the effect studied. In rats with an intact nerve, intrathecal galanin produces brief
facilitatory effects at low doses, which become inhibitory as the dose increases, such
that at very high doses galanin exerts a purely inhibitory effect (Weisenfeld-Hallin et
al. 1988;89). In addition, in both electrophysiological and behavioural studies,
galanin was seen to inhibit the analgesic effect ofmorphine on noxious thermal and
mechanical stimuli (Weisenfeld-Hallin et al, 1990c), while having no effect alone on
these nociceptive inputs. Galanin may also be an important modulator of excitatory
neuropeptide action, as pre-administration of galanin intrathecally has been shown to
antagonise the excitatory effects of SP and CGRP on the flexor reflex (Weisenfeld-
Hallin et al. 1990a; Xu et al. 1989; 1990). The inhibitory role of galanin is much
more pronounced following nerve injury however, as the facilitatory effect of the
galanin antagonist M-35 on CS-induced reflex facilitation is much more pronounced
following sciatic nerve section (Wiesenfeld-Hallin and Xu, 1996b), with the
magnitude of reflex depression being significantly greater, and with a more rapid
onset than the effect seen in animals with an intact nerve. In addition, the VIP-
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induced flexor reflex could be inhibited by galanin antagonists following axotomy
(Xu et al. 1990), which corresponds with the increased expression of VIP- and GAL-
ir in DRG following nerve injury, where these peptides are seen to co-exist in many
cells. This suggests that galanin's functional role becomes more important following
nerve injury, and that this peptide may play an important regulatory role trying to
counteract the effects of excitatory neurotransmitters within the CNS.
Neuropeptide Y (NPY): NPY is a 36 amino acid peptide with a large number
of different NPY receptor subtypes, suggesting a diverse range of functional effects
for this peptide within the body. NPY is one of the most abundant peptides in the
mammalian peripheral and central nervous system (Allen et al. 1983; 1984). Within
the CNS, NPY-ir fibres show dense labelling in the substantia gelatinosa,
dorsolateral funiculus and the dorsal grey commisure in lumbosacral spinal cord
(DeQuidt and Emson, 1986). This peptide is normally found predominantly within
intrinsic neurones of the spinal dorsal hom (Gibson et al. 1984), where it may co¬
exist with galanin (Zhang X et al ,1993b; 1995c) or even GABA (Laing et al. 1994;
Rowan et al. 1993), and is virtually undetectable in normal DRG neurones. High
levels ofNPY are also found within sympathetic ganglia and tissue, with dense
sympathetic innervation in guinea-pig, cat, pig and man (Lundberg et al. 1983),
suggesting an important role for NPY in the regulation of the SNS. Following nerve
injury there is a dramatic up-regulation of the levels of NPY in axons and varicosities
of laminae III-V of the dorsal hom, as well as the induction ofNPY-ir in many large
or medium diameter primary afferent neurones (Kar and Quirion, 1992; Nahin et al.
1994; Zhang et al. 1995a). NPY is thought to play an inhibitory role predominantly
within the CNS, as systemic administration of this peptide shows marked
antinociceptive effects (Hua et all991). However, intrathecal NPY has been shown
to have a dose-dependent biphasic effect on the spinal nociceptive flexor reflex, with
brief facilitation of the flexor reflex at low dose (10/100ng) but intense and
prolonged depression of the spinal mediated reflex at higher doses (1/lOp.g) (Xu et al.
1994).
Figure 1.8 represents a schematic illustration of the changes in the principal
primary afferent neurotransmitters following peripheral nerve injury.
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1.6.2.4 Factors Affecting Neuropeptide Plasticity Following Nerve Injury
Several different mechanisms may be involved in the marked changes in
DRG gene expression following nerve injury. Prime candidates in this regulation are
the neurotrophins. Peripheral nerve injury has also been shown to produce marked
changes in the expression of neurotrophins and their receptors in DRG neurones,
including nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF) and
leukaemia inhibitory factor (LIF) (Cameron et al. 1997; 1991; Nahin et al.1994;
Sebert and Shooter, 1993). Such factors may influence DRG cells and may be
released from central processes to exert an effect in the CNS, or may be transported
down peripheral axons to the site of injury, where they may regulate the activity of
various non-neuronal cells.
Certainly in the case of VIP, there is strong evidence that the up-regulation of
VIP expression is mediated by factor(s) carried by retrograde axoplasmic transport to
DRG cells, as axotomy or nerve crush produce increased VIP levels which return to
control values after nerve regeneration (Knyihar-Csillik et al. 1991; 1993).
The expression of SP by DRG neurones in vivo appears to depend strongly
on the availability ofNGF (Lindsay and Harmar, 1989; Otten et al. 1980; Verge et al.
1995). Intrathecal NGF has been shown to prevent the axotomy-induced decrease in
levels of CGRP and SP (Fitzgerald et al. 1985) while application of anti-NGF to the
cut end of the nerve encourages the change in SP/CGRP levels (Goedert et al. 1984;
Schwartz et al. 1982). So it is possible that nerve injury interrupts the supply of
retrogradely transported NGF, and this may directly or indirectly contribute to the
observed decreases in SP and CGRP. The levels of expression of VIP however,
appear to be under some other form of regulatory role, as changes in the density of
VIP-ir in adult DRG neurones in culture appears to be independent of the presence or
absence ofNGF (Mulderry and Lindsay, 1990), contrasting with the very marked
dependency on NGF observed for SP/CGRP.
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Figure 1.7
Schematic of the Principal Changes within the CNS Following Peripheral Nerve
Injury
Schematic drawing of a small and large primary sensory neurone in a dorsal root
ganglion (DRG) sending a central branch to the dorsal horn of the spinal cord and
with a peripheral branch which has been sectioned (axotomy). The main changes
which occur within the central nervous system are highlighted in this schematic.
The changes in levels of peptides and their receptors are indicated by arrows. Thus
in small diameter DRG neurones the level of substance P (SP), calcitonin gene-
related peptide (CGRP) and somatostatin (SOM) are decreased, along with
neuropeptide Y (NPY) receptor mRNA. In contrast levels of vasoactive intestinal
polypeptide (VIP), pituitary adenylate cyclase activating polypeptide (PACAP) and
galanin (GAL) are markedly increased, with modest increase in cholecystokinin
(CCK) and NPY. In the large diameter DRG there is a prominent increase in the
levels ofNPY and the NPY receptor, along with smaller increases in VIP and GAL,
while the expression of CGRP is seen to decrease.
Structural and neurochemical reorganisation within the spinal cord and the damaged
nerve, as indicated, ultimately contribute to the development of spontaneous ectopic
firing in Afibres and an increased hyperexcitability of C fibres, as well as providing
the potential for the development of abnormal Ap fibre responses, including a loss of
inhibitory properties.
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Figure 1.8
Schematic Model of the Principal Primary Afferent Neurotransmitters
A schematic illustration of the major neurotransmitters/modulators released from
intact and axotomised primary afferents.
Abbreviations:
a-amino-3-hydroxy-5-isoxazole-4-propionate (AMPA); calcitonin gene-related
peptide (CGRP); cholecystokinin (CCK); Galanin (GAL); glutamate (GLUT);
metabotropic glutamate receptor (mGluR); neurokinin (NK); neurokinin A (NKA);
N-methyl-D-aspartate (NMDA); neuropeptide Y (NPY); somatostatin (SOM);
substance P (SP); pituitary adenylate cyclase activating polypeptide
(PACAP);receptor (R); vasoactive intestinal polypeptide (VIP)



















In contrast, the axotomy-induced increases in VIP and galanin appear to be
mediated at least in part by LIF, particularly within the SNS, as mice in which the
LIF gene has been disrupted by gene targeting show a marked impairment in the
upregulation of VIP and galanin in the SCG and sensory neurones following
axotomy (Sun et al. 1994b; Sun and Zigmond, 1996a; 1996b; Zigmond and Sun,
1997). Whether or not PACAP synthesis and receptor expression is also LIF-
regulated remains to be determined.
Other factors which may play a role either directly or indirectly in nerve
injury-induced neuropeptide plasticity include growth-associated protein 43 (GAP-
43) and choline acetyl transferase (ChAT) which also appear to be up-regulated in
the dorsal horn following nerve injury (Cameron et al. 1997). In addition ciliary
neurotrophic factor (CNTF), which has been isolated from rat sciatic nerve extract
(Manthorpe et al. 1986) has been shown to induce SP, and inhibit NPY synthesis in
sympathetic ganglia cultures (Rao et al. 1992), and so may be another important
regulatory factor in the alteration of DRG gene expression associated with nerve
injury. It is clear however, that there are different controls for the expression of the
different neuropeptides and it may be a combination of a variety of effects which
finally determine the overall expression ofprimary afferent neuroactive substances
following nerve injury.
1.6.3 Possible Factors Contributing to the Development of Neuropathic Pain
1.6.3.1 Sympathetic Nervous System (SNS)
There is a wide variety of evidence to suggest a strong link between the SNS
and the pain related behaviours of neuropathy. Surgical or chemical
sympathectomies (with guanethidine for instance) have been shown to significantly
decrease the abnormal pain behaviours which develop following a number of
different animal models of neuropathy (Kim et al. 1993; 1997; Kim and Chung,
1991; Shir and Seltzer, 1991), implying that the SNS may play an important role in
the development of neuropathic pain states. The involvement of the SNS does
appear to be quite variable however, and factors which appear to have an influence
on this involvement include the site of nerve injury and distance from the spinal cord,
and the type of injury (Kim et al. 1997). The variable degree of sympathetic
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involvement in neuropathic pain may explain the variable effects of sympathetic
manipulation in the treatment of neuropathic pain states (Loh and Nathan, 1978; Luo
and Wiesenfeld-Hallin, 1995). Peripheral nerve injury has been shown to result in
sprouting of sympathetic efferents into DRG neurones, from as early as day 4 PO in
the CCI model, coinciding with the time when neuropathic pain behaviours are
developing (Mclauchlan et al. 1993; Ramer and Bisby, 1997). Electrical stimulation
of these sprouts subsequently evoked firing ofmyelinated primary afferent neurones,
which was blocked following phentolamine treatment (Ramer and Bisby, 1997), and
so these sympathetic efferent sprouts appear to represent a functional coupling of
noradrenergic neurones with primary afferent fibres in the DRG. It is therefore
possible that alterations in sympathetic innervation in DRG following nerve injury,
may be involved in the generation of spontaneous activity in the injured nerve (see
following section).
1.6.3.2 Changes in Primary Afferent Responsiveness Following Nerve Injury
It is possible that the spontaneous activity of injured primary afferents may
greatly contribute to the induction and maintenance of the allodynic and hyperalgesic
states which follow nerve injury, as well as contributing to the abnormal behaviours
thought to be indicative of spontaneous pain.
Electrophysiological studies have revealed that following peripheral nerve
injury there is an abnormally high level of spontaneous activity within primary
sensory neurones (Laird and Bennett, 1993; Palecek et al. 1992). This abnormal
activity appears to be principally mediated by A(3 and A8 fibres (Kajander and
Bennett, 1992; Kajander et al. 1992) which develop abnormal spontaneous activity
from as early as day 1 and 3 PO. This spontaneous activity continues for at least
several weeks post injury. Spontaneous discharges from C-fibres begin to contribute
slightly later than those ofA-fibres, from approximately day 10 PO onwards (Xie
and Xiao, 1990), which corresponds with the maximal behavioural changes observed
in the CCI model (Attal et al. 1990; Bennett and Xie, 1988).
The site of initiation of this abnormal activity is under debate.
Electrophysiological recordings from primary afferents within the sciatic nerve have
suggested that the spontaneous activity originates at the site ofnerve injury, as the
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majority of axons did not respond to electrical stimulation distal to the lesion. Xie
and Xiao (1990) also report ectopic spontaneous discharge at the site of the
constriction injury between days 6-44 PO. However other groups (Kajander et al.
1992; Zhang JM et al. 1997) believe that this ectopic discharge originates from the
DRG, as transection distal to the DRG failed to halt the spontaneous activity while
transection proximal to the DRG resulted in the abolition of this abnormal discharge.
It seems likely that both the injury site and the DRG contribute to afferent ectopic
firing (Tal and Eliav, 1996), and this subsequent hyperexcitability of neuronal
elements involved in the processing of sensory information, may therefore contribute
significantly to the production of spontaneous pain manifestations and hyperalgesia
by triggering and maintaining central sensitisation.
As stated earlier, it appears that the SNS may play a major role in maintaining
the ectopic firing ofprimary afferents through inappropriate functional connections
following the sprouting of sympathetic efferents. McLauchlan et al. (1993) revealed
that in axotomised animals, noradrenergic axons sprout into the DRG and greatly
increase the number ofbasket-like endings around the neuronal cell body, thereby
providing a coupling pathway for sympathetic-sensory fibres within the DRG. A
similar, but slightly more rapid sprouting of sympathetic axons in DRG was also
observed following CCI (Ramer and Bisby, 1997). Evidence for a direct coupling of
these two systems has been shown using recording experiments where the ectopic
discharge of injured axons could be altered by electrical stimulation of the
sympathetic trunk (Devor and Janig, 1981; Devor et al. 1994; Habler et al. 1987;
Korenman and Devor, 1981). Michaelis et al. (1996) found that the nerve injury-
triggered sympathetic coupling within rat DRG changed with time, and that the
excitatory coupling observed within the first few weeks of nerve injury, was
subsequently replaced by an inhibitory coupling by day 60 PO. This would suggest
then that the SNS may play an important role in the induction and maintenance of
neuropathic pain states, but that this role may change following the regenerative
changes which ultimately lead to the recovery ofnormal sensation
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1.6.3.3 Degenerative Changes within the CNS Following Nerve Injury
Alterations in inhibitory influences
Chronic constriction of the rat sciatic nerve can result in a number of
degenerative changes. As discussed previously, there are marked morphological
changes within the sciatic nerve fibres, particularly in the Ap range. But there is also
some evidence that lesions of peripheral nerves can induce a series of complex
changes centrally. Degeneration affecting the central terminals ofprimary sensory
neurones may be initiated at different times and in different neurones of the affected
population following nerve injury (Aldskogius et al. 1985). CCI has been shown to
cause transsynaptic degeneration of spinal dorsal horn neurones in laminae I-III
(Sugimoto et al. 1990) from as early as day 8 PO. This may be an excitotoxic effect
due to excessive levels ofpostsynaptic depolarisation as a result of primary afferent
ectopic discharge, or may be due to a disruption in the communication between the
cell body and the central nervous system following axonal degeneration. This
transsynaptic degeneration may have a direct influence on local and descending
systems within the spinal cord, resulting in altered processing of sensory information.
There is currently conflicting evidence on the effects of CCI on the levels of
inhibitory transmitters within the spinal cord. Immunohistochemical studies have
revealed an almost complete loss of GABA-containing cells in laminae I-III of the
ipsilateral dorsal horn following nerve injury (Ibuki et al, 1997), while
radioimmunoassays have shown an increase in the levels of glycine and GABA
within the spinal cord for up to 30 days PO (Satoh and Omote, 1996). In addition,
this group also demonstrated a significant decrease in the paw withdrawal latency to
thermal stimuli in CCI animals following intrathecal application of the GABA and
glycine antagonists strychnine and bicuculline on day 7 PO (Satoh and Omote,
1996). This suggests that glycine and GABA still have the ability to exert intrinsic
inhibitory modulatory effects in these animals. However, these tests were not
repeated at week 2 PO, when the abnormal pain behaviours and morphological
changes within the injured nerve are at their maximum, and so it is possible that these
inhibitory effects of GABA and glycine may become altered as the neuropathic pain
states develop. Subsequent alterations in the number of inhibitory neurones, the
effects of ascending and descending systems to and from the brain, and changes in
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the pattern of neurotransmitter co-existence, may all lead to impaired inhibitory
function and central hyperexcitabilty following peripheral nerve injury.
Changes in Afifibre properties
There is strong evidence to implicate a role for A(5 fibres in the mediation of
abnormal allodynic states. Selective blockade of Ap fibres (but not of A8 and C
fibres) within the peripheral nerve of neuropathic patients, using local anaesthetic or
ischemic nerve blocks, has been shown to markedly inhibit mechanical allodynia
(Campbell et al. 1988; Gracely et al. 1992). This altered role of Ap fibres is thought
to perhaps be a result of altered central processing, such that the activation of the
large myelinated afferent fibres now leads to painful sensations. Such central
changes may be a result of the degeneration of large myelinated axons following
nerve injury, which could then result in the loss of inhibitory control of these fibres at
the spinal cord level. Indeed, electrophysiological studies have revealed that
electrically stimulated Ap fibres show a powerful inhibition of A- and C-fibre-
evoked activity of dorsal hom neurones in normal animals. However in rats with a
transected nerve the activation ofAp afferents showed no inhibitory effects or weak,
shorter effects on A- or C-fibre-evoked neuronal activity (Woolf and Wall, 1982).
The degenerating fibres may even change properties following nerve injury. Na et al.
(1993) detected an unusual type ofmechanoreceptor in nerve-injured rats, which had
characteristics similar to those of the rapidly adapting (RA) mechanoreceptor, but
which produced an abnormal irregular discharge following activation. They named
these receptors modified rapidly adapting mechanoreceptors, and suggested that they
are abnormal RA mechanoreceptors, produced in response to nerve injury, which
may play a contributing factor in the signalling of mechanical allodynia.
1.6.3.4. Regenerative Changes within the CNS Following Nerve Injury
Animals which undergo CCI show a gradual recovery, usually within 3
months of the original nerve injury. This suggests that nerve injury also induces a
number of regenerative changes. Indeed, nerve injury has been shown to increase the
expression of a number of factors associated with survival and regeneration including
neurotrophic and other growth factors (Cameron et al. 1997; Ji et al. 1996; Sebert and
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Shooter, 1993). As stated earlier, such factors include NGF, BDNF, LIF and GAP-
43, all of which are important in the regulation of cell/fibre growth and survival.
A possible aversive reaction to the rapid up-regulation of growth factors to try
and counteract the damaging effects of nerve injury, is the abnormal sprouting of
axotomised large myelinated fibres. Woolf et al. (1992) provided the first evidence
of Ap-fibre sprouting following transection of the rat sciatic nerve. Using HRP-
labelling, they demonstrated that a number of A|3 fibres sprouted, within a week of
axotomy, from lamina III into lamina II of the spinal dorsal horn, an area where small
diameter nociceptive afferents usually terminate, and that by week 2 there were dense
extensions of these Ap fibres (Woolf et al. 1992). This has since been confirmed by
a number of other investigations (Koerber et al. 1994; Shortland and Woolf, 1993).
A study into the time course of sprouting revealed that the effect was maximal at
week 2 post injury, and persisted for over 6 months (Woolf et al. 1995), with a total
recovery by 9 months. So this A fibre reorganisation is a prominent and long-lasting,
but not permanent, feature of peripheral nerve injury.
Three different types of sprouting now seem to exist (Woolf et al. 1995):
1. Regenerative sprouting which involves the re-growth of an injured axon back to
its own or new targets
2. Collateral sprouting, where the growth of the processes and terminals from an
uninjured nerve grow into a denervated region
3. Conditioned collateral sprouting, which appears to be induced by injury to the
peripheral processes of the sensory nerve and results in the sprouting of uninjured
central sensory axons
This A fibre sprouting is clearly conditioned collateral sprouting and may
result in low threshold mechanical fibres establishing functional contacts with
nociceptive neurones in lamina II of the dorsal horn, thereby resulting in the
production of inappropriate responses to innocuous stimuli. However, the fact that
this sprouting is still evident up to 6 months after the original nerve injury, a time
point when the abnormal neuropathic pain states no longer exist, suggests that this
reorganisation is not the only contributing factor to the development and
maintenance of neuropathic pain states.
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The aetiology ofneuropathic pain is clearly extremely complex and a wide
variety of different factors appear to be involved in the induction and maintenance of
the abnormal pain states. Much work still needs to be done to determine the
principal contributing factors involved in neuropathy so that more effective and
longer-lasting treatments can be evolved.
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1.7 Aims of Current Work
Previous work indicates that VIP and PACAP may play a significant role in
the regulation of nociceptive transmission at the spinal cord level. This study aimed
to investigate the possible involvement of VIP/PACAP and their receptors in
mediating the responses of dorsal hom neurones to a variety of sustained cutaneous
stimuli in both normal and neuropathic animals, and to identify specific changes in
the expression of the three VIP/PACAP receptor subtypes following a chronic
constriction injury to the rat sciatic nerve. To do this:-
1. A behavioural model of neuropathy was produced by loose ligation of the rat
common sciatic nerve, to provide a number of test animals which displayed
positive signs ofmechanical and thermal allodynia, as well as mechanical
hyperalgesia, within their affected hindlimbs.
2. Electrophysiological techniques were employed to determine the role of
VIP/PACAP in the transmission of sensory information by investigating the
effects of selective VIPl5 VIP2 and PACAP receptor antagonists on the sensory-
induced responses of dorsal hom neurones, in both normal and neuropathic
animals.
3. The responses ofmultireceptive dorsal hom neurones to selective VIP,, VIP2 and
PACAP receptor agonists were then investigated to provide an insight into the
expression of the three receptor subtypes and to try and ascertain any changes in
receptor expression following nerve injury
4. The detailed distribution ofVIP/PACAP receptor expression in the spinal cord
was assessed for the first time, using in situ hybridisation histochemistry. The
expression of VIP!, VIP2 and PACAP receptor mRNA was measured within the
rat dorsal hom of normal and neuropathic spinal cord, enabling us to observe any
changes in receptor mRNA expression following nerve injury.
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Chapter 2 Materials
All reagents used were of the highest analytical grade and were supplied by
Sigma Chemical Company, Poole, UK., unless otherwise stated.
2.1 Anaesthetics
Urethane, a-chloralose, Halothane (Zeneca Ltd., Cheshire, UK), Sagatal (Rhone
Merieux Ltd., Essex, UK)
2.2 Sterile Surgery
• 4/0 sterile chromic catgut and 4/0 violet coated vicryl (Ethicon Ltd., Edinburgh,
UK)
• Hibitane (Zeneca Ltd., Cheshire, UK)
• Sterile gowns, biogel gloves, hats, face masks and drapes (Elospital Management
and Supplies, Glasgow, UK)
2.3 Electrophysiology
• Glass capillaries (Clark Electromedical Ltd., Reading, UK)
• Platinum wire (Goodfellow Metals, Cambridge, UK)
• Allyl isothiocyanate (mustard oil) (Aldrich Chemical Company, UK)
• Liquid Paraffin (Thornton and Ross, Huddersfield, UK)
• Agar (Unipath Ltd., Basingstoke, UK)
2.4 Drugs for Ionophoresis
Agonists: - porcine VIP
- PACAP-38 (Bachem (UK) Ltd, Essex, UK)
- Selective VIP! receptor agonist [Arg16] chicken secretin
- Selective VIP2 receptor agonist [Ac-His1, Glu8, Lys12, Nle17, Ala19]
VIP (1-24), Asp, Leu, Lys, Lys, Gly, Gly, Thr NH2 (lactam 21-25):
Ro 25-1553
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(The selective VIP] and VIP2 agonists were synthesised by Philippe
Gourlet, Ph.D., Laboratory of Biological Chemistry and Nutrition,
Universite Libre de Bruxelles, Belgium).
Antagonists: - VIP (6-28), [p-Chloro-D-Phe6, Leu17]-VIP and PACAP (6-38) (all
Bachem (UK) Ltd, Essex, UK)
- Selective VIP! receptor antagonist [Ac-His1, D-Phe2, Lys15, Arg16,
Leu17] VIP(3-7)/GRF(8-27): PG 97-269
- Selective VIP2 receptor antagonist (des l-4)[Glu8, Lys12, Arg16,
Nle17, Ala19] VIP(l-24) Asp, Leu, Lys, Lys, Gly, Gly, Thr NH2
(lactam 21-25): des(l-4) Arg16 Ro 25-1553
(The selective VIP] and VIP2 antagonists were both synthesised by
Philippe Gourlet, Ph.D., Laboratory of Biological Chemistry and
Nutrition, Universite Libre de Bruxelles, Belgium).
2.5 In Situ Hybridisation Histochemistry (ISHH)
• Oligodeoxyribonucleotide probes were supplied by Oswel Research Products,
Southampton, UK. The probes were aliquoted into 200pl samples and stored at
-70°C until required.
• Deoxyadenosine [a-35S]-triphosphate ([a-35S]-dATP: specific activity 1-1.3 x 103
Ci/mmol) was supplied by NEN Dupont (UK) Ltd., Hounslow, and was stored at -
20°C prior to use.
• Recombinant terminal deoxynucleotidyl transferase (rTdt) enzyme and tailing
buffer (GibcoBRL, Life Technologies Ltd., Paisley, UK)
• Nu-clean D25 spin columns (Scientific Imaging Systems Ltd., Cambridge, UK)
• Optiphase 'Supermix' liquid scintillation cocktail (Fisher Chemicals, Leics., UK)
• Absolute alcohol ANALAR grade (Hayman Ltd., Essex, UK)
• Acetic anhydride (BDH Laboratory Supplies, Poole, UK)
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2.6 ISHH Stock Solutions
• DEPC (Diethyl Pyrocarbonate) HzO: all solutions were made up with distilled
water (dH20) which had previously been treated with the nuclease inhibitor
DEPC, to minimise the risk of ribonuclease (RNase) contamination. 10-12 drops
of diethyl pyrocarbonate were added per litre (1) of dH20 and the solution was left
to stir overnight under a fume hood before being autoclaved to destroy any last
traces of DEPC.
• 0.1M Phosphate-Buffered Saline (PBS): 100ml of 0.2M sodium phosphate,
monobasic, anhydrous was mixed with 400ml 0.2M sodium phosphate, dibasic,
anhydrous and 9g sodium chloride, made up to 11 total volume with DEPC H20,
filtered and then autoclaved.
• 4% Paraformaldehyde (PF) in 0.1M PBS: 20g of PF was dissolved in 400ml of
0.1M PBS at 60°C. After cooling to room temperature, the pH was adjusted to 7.4
before completing the volume to 500ml with 0.1M PBS.
• De-ionised formamide: formamide was de-ionised with lg of mixed-bed anion
exchange resin (Bio-RAD Laboratories, California, USA) per 10ml of formamide,
for 1 hour at room temperature, filtered twice through Whatman No. 1 filter paper,
then stored in sterile pots at -70°C in 20ml aliquots, ready for use.
• Tris-HCl 1M: 60.5g of Tris base was dissolved in 400ml DEPC H20, then
adjusted to pH 7.6 before completing the volume to 500ml with DEPC H20.
• Ethylenediamine tetra acetic acid (EDTA) 250mM: 9.305g of EDTA (disodium
salt) was dissolved in 80ml DEPC H20, adjusted to pH 7.6 and then made up to
100ml with DEPC H20.
• Tris-EDTA (TE) Buffer: 2.5ml 1M Tris-HCl, pH7.6 and 5ml 250mM EDTA,
pH 7.6 were added to 20ml DEPC H20. The resulting solution was then aliquoted
into 2ml Eppendorf tubes and stored at -20°C until required.
• 2x Hybridisation buffer was made up to the following concentration prior to use
and immediately stored at -20°C in 2ml aliquots, until use: dextran sulphate
(10%; wt:vol), sodium chloride (600mM), Tris pH 7.6 (lOmM), EDTA (ImM),
Denhardt's solution (1% solution of Bovine Serum Albunim (BSA), Ficoll and
Polyvinyl pyrrolidone (PVP))(0.1% ; wt:vol), salmon sperm DNA (0.01%;
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wt:vol), Bakers yeast tRNA (0.005%; wt:vol) and glycogen (0.0005%;
wt:vol)(Boehringer Mannheim, UK Diagnostics and Biochemical, Lewes, UK).
• 20x Standard Saline Citrate (SSC): 3M sodium chloride and 0.3M sodium
citrate were made up in 800ml DEPC H20, the pH adjusted to 7 and the solution
autoclaved before being stored at room temperature until required.
• 1M Dithiothreoitol (DTT): 1.54 g of DDT was dissolved in 10ml of DEPC H20,
then stored in lOOpl aliquots at -20°C until required.
• Triethanolamine (TEA): 10M TEA (BDH Laboratory Supplies, Poole, UK) was
diluted to a 1M solution with DEPC H20 and the pH adjusted to 8 with NaOH.
This solution was then further diluted to 0.1 M on the day of acetylation.
2.7 Developer and fixer
• LM-1 Hypercoat nuclear emulsion and Hyperfilm (3-max (Amersham
International, Bucks, UK)
• Kodak D-19 developer powder (H.A. West (x-ray), Edinburgh, UK)
• Ilford Hypam K5 rapid fixer (diluted 1 in 5 in dH20) (Ilford Ltd., Cheshire, UK)
2.8 Staining solutions
• Solochrome Cyanin: 0.2g Solochrome cyanin RS (Edward Gurr) was dissolved
in 96ml dH20 with 4ml 10% iron alum and 0.5ml concentrated sulphuric acid.
• 10% Iron alum (ammonium ferric sulphate): lOg of iron alum (Merk Ltd., Leics,
UK) dissolved in 100ml dH20.
• Mayer's hematoxylin solution (0.1% certified hematoxylin with stabilisers)
(Sigma Diagnostics, St. Louis, USA)
• Eosin (5% aqueous), Xylene and DePex mounting medium (BDH Laboratory
Supplies, Poole, UK)
• Perfex mounting medium (Cell Path Pic., Herts, UK)
2.9 Miscellaneous
• Freezing spray (Greenhill Chemical Products Ltd., Burton-on-Trent, UK)
• Isopentane (Merk Ltd., Leics, UK)
• Decon 90 (Decon Laboratories Ltd., Hove, UK)
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• Cryo-M-Bed embedding compound (Bright Instrument Company Ltd.,
Huntingdon, UK)
• Poly-L-lysine coated microscope slides, glass coverslips (22 x 50mm) and Silica
gel (BDH Laboratory Supplies, Poole, UK)
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Chapter 3 Investigation of the chronic constriction injury
model of neuropathic pain - a behavioural and histological
study
3.1 Aim
These experiments were carried out to produce an animal model of chronic,
peripheral mononeuropathy which exhibits symptoms ofneuropathic pain similar to
those seen in man, and to investigate, using a variety of different quantifiable tests,
the abnormal pain-related behaviours observed. The model under investigation is the
chronic constriction injury (CCI) model of Bennett and Xie (1988) and involves
loose ligation of the common sciatic nerve in the rat. The symptoms, which persist
for up to three months, include spontaneous pain and lowered thresholds and
exaggerated responses to mechanical and thermal stimuli (Attal et al. 1990; Bennett
and Xie, 1988). It is a relatively simple surgical procedure and the affected hind limb
is easily accessible for behavioural and experimental testing, therefore allowing




Adult male Wistar rats were used (Charles River, UK). They were housed in
standard laboratory cages in groups of 3-4, in a controlled environment with a natural
12 hour day/night cycle and temperature range 22-24°C. Food and water were
supplied ad libitum.
3.2.2 Surgical Preparation of Animals with an Experimental Peripheral
Mononeuropathy
The surgical procedure was carried out on 76 male Wistar rats weighing 200-
25 Og on the day of surgery. Rats were initially anaesthetised with sodium
pentobarbital (50mg/kg i.p.) and then supplemented as necessary with halothane.
The right hind limb was shaved and the skin sterilised by wiping with Hibitane pre-
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operative skin disinfectant (0.5% in 70% alcohol). Under aseptic conditions, the
right sciatic nerve was exposed by blunt dissection at mid-thigh level, immediately
proximal to the point of bifurcation, and approximately 1cm of nerve freed of
adhering connective tissue. Four chromic cat gut (4.0) ligatures were then tied
loosely around the nerve spaced at approximately 1mm intervals. Care was taken to
tie the ligatures so as to barely constrict the nerve, as viewed under x40
magnification, thus ensuring that the circulation through the superficial epineurium
was not completely blocked. The overlying muscle and skin were then closed in
layers with sterile suture thread, and the wound re-sterilised with Hibitane to prevent
any infection. The animals were then placed in recovery cages for 24 hours, with
soft padding for bedding, before being returned to their normal cages. In the 5 sham-
operated animals, the same exposure of the right sciatic nerve was made but no
ligatures were applied. The animals were allowed three full days to recover from
surgery before the behavioural testing was recommenced.
3.2.3 Behavioural Tests
Behavioural signs representing three different components of neuropathic
pain were investigated: cold allodynia, mechanical allodynia and mechanical
hyperalgesia. The animals were tested one day pre surgery then every 1 or 2 days
post surgery, and the ipsilateral responses were compared to pre-operative baselines
and/or the unaffected contralateral hind limb response.
(i) General observations
Daily inspections were made for signs of autotomy, and notes were also made
of the animal's gait, and the posture and condition of the affected hind limb.
(ii) Cold allodynia
To detect the presence of cold allodynia, the rat's response to cold iced water
was evaluated. This was determined using a cold water bath. Rats were placed in a
clear plastic tank on an aluminium floor which was raised by a wire mesh stage and
chilled by ice water. The ice water covered the metal plate by approximately 8mm,
to ensure that both the glabrous and hairy skin of the animals' feet were in contact
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with the cold water, and a constant temperature of 3-4°C was maintained. The floor
felt distinctly cool to the human touch but did not feel painful over the period of time
tested. The animals were given a few moments to acclimatise to their new
surroundings and then a measurement was taken of the Suspended Paw Elevation
Time (SPET) during a 20 second test period, that is the time the paw was elevated in
a defensive posture following the presumably noxious cold stimulus. The animals
were placed in the tank for 4 x 20 second intervals, with at least a 10 minute wait in
between each test to allow the animal's paw to return to body temperature before the
next test. The data was averaged and then pooled for each test day to produce a
distribution curve showing the duration of suspended paw elevation in response to a
cold stimuli with respect to the onset of neuropathy following sciatic nerve ligation.
(iii) Mechanical allodynia
To quantify the mechanical sensitivity of the foot, the withdrawal threshold in
response to a normally innocuous mechanical stimuli was measured. Mechanical
stimuli were applied using a set of calibrated von Frey filaments (a series of nylon
monofilaments of increasing stiffness which exert defined levels of force as they are
pressed to the point where they bend). We used the standard Semmes-Weinstein set
of von Frey hairs (Stoelting, Wood Dale, Illnois, USA), in the range which produced
bending forces of 0.41-125.89g. Each animal was placed in a wire mesh cage which
allowed the rat to walk freely and the experimenter to reach the plantar surface of the
foot from beneath, unobserved by the rat. Each filament was indented on the mid-
plantar surface of the foot until it started to bend. This was repeated 8-10 times at a
frequency of approximately 1Hz. The filaments were applied in ascending order
starting from the weakest, and a response was characterised as a quick, robust paw
flick. The response threshold was defined as being the lowest force of 2 or more
consecutive von Frey filaments to produce a response.
(iv) Mechanical hyperalgesia
Mechanical pain thresholds were determined using the pin prick method (as
previously described by Seltzer et al. 1990). Again the animals were placed in a wire
mesh cage allowing them to walk freely, and a slightly blunted needle was gently
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applied to the mid-plantar foot from beneath the cage, to elicit a single prick. The
withdrawal response was graded accordingly: (1) a quick and robust paw flick; (2) a
longer-lasting response, but one in which the animal replaced its paw within 2-3
seconds; (3) a prolonged response where the affected paw was held in the air for
more than 5 seconds before being replaced, indicative of an exaggerated painful
response. To ensure that this test did not have any long term effects on the receptive
field properties of the rat paws, this test was only carried out once on the pre¬
operative day and once again when the animal displayed strong signs of mechanical
and cold allodynia.
3.2.4 Statistics
In each behavioural study, data was pooled for each test day. Group averages
are shown ± the standard error of the mean (SEM). The Mann-Whitney rank sum
test was performed to determine any significant differences between ipsilateral and
contralateral hind limb values (p < 0.05). A Kruskal-Wallis one way analysis of
variance (ANOVA) on ranks, followed by Dunn's post-hoc pairwise comparison was
then carried out (p < 0.05), to determine group values at different time points which
differed from the pre-surgery control group.
3.2.5 Sciatic Nerve Dissection
Peripheral nerve histology was carried out on 6 neuropathic rats.
Approximately 2 weeks after the ligatures were tied, when the animals showed clear
signs of mechanical hyperalgesia and cold allodynia (as determined by the
behavioural testing), the rats were administered a lethal dose of sodium pentobarbital.
The sciatic nerve was then immediately exposed by blunt dissection and the nerve
containing the ligatures was removed along with approximately 1cm ofnerve
proximal and distal to the ligatures. The excised nerves were immediately fixed in
10% formal saline. Two sciatic nerves were also removed from animals which did
not have an experimental peripheral neuropathy, to act as controls. In these animals,
euthanased as above, the sciatic nerve was exposed at mid-thigh level and
approximately 2cm of nerve in length was freed of connective tissue and removed,
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immediately proximal to the point of bifurcation. Once again the nerves were fixed
immediately in 10% formal saline.
Wax-embedded, transverse sections (8pm thick) of the sciatic nerve proximal
and distal to the ligatures, were mounted on glass slides. Sections were hydrated by
immersing in 2 changes of xylene, followed by immersion in absolute alcohol, 70%
alcohol and finally placing the sections in running tap water. The sections were then
immersed in Solochrome cyanin for 10 minutes, rinsed in tap water and then
differentiated in 10% iron alum for 5 minutes, to stain myelin a dark purple colour.
The sections were then counterstained with eosin, dehydrated through ascending
concentrations of alcohol (70%, 90% and absolute alcohol), then cleared in xylene
before being mounted in Perfex mounting medium, for light microscopic evaluation.
3.3 Results
3.3.1 General Observations
The majority of nerve-injured animals showed the behavioural alterations
characteristic of the CCI model. All of the animals which underwent the surgery
were very protective of their affected hind paw, guarding it from incidental contact
and rarely, if ever, extending the ipsilateral limb. The affected paw was generally
held awkwardly with the toes tightly drawn together and ventroflexed. The animals
walked with a definite limp/hop and a number of rats walked without allowing the
affected paw to touch the floor at all. These abnormalities in posture are thought to
be indicative of spontaneous pain (Attal et al. 1990).
With these exceptions, the animals' health and behaviour were generally
normal and there were no apparent signs of debilitating pain or distress. The level of
general activity appeared to be normal, and the animals could be handled without
evoking squealing or biting. In addition, the animals appeared to gain weight in
accordance with control animals.
A small number of nerve-injured animals (n=5) exhibited autotomy, with
distal phalange injury to one or more of the toes on the affected hind paw. These
animals were immediately sacrificed and were not included in any of the studies.
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3.3.2 Cold Allodynia
The quantitative assessment of cold allodynia, using a cold water bath,
revealed a reduced threshold to the cold stimulus in the nerve injured hind paw of the
majority of animals, while unoperated control rats showed no such response.
Unoperated control rats and sham treated animals, showed no pain-related
behavioural responses when placed in the cold water bath, and explored the new
territory without any apparent signs of distress. During their time in the tank, none
of the animals lifted any of their paws out of the water either briefly or for an
extended period of time, other than to walk about.
When the nerve damaged rats were placed in the cold water bath however,
obvious behavioural changes were apparent. The increased sensitivity to cold was
clearly visible from as early as day 4 post-operatively (D4 PO) when the majority of
animals began to lift their affected paw out of the water for a few seconds for each
test period. Maximal responses were observed from approximately D8 PO onwards,
and were generally still high at D15 PO (Figure 3.1). Animals which displayed a
marked response to the cold stimuli were generally used for electrophysiological or
histological studies by D15 PO, and so the time course of development of cold
allodynia measured in these animals does not extend past this time point. From D8
PO onwards, the animals which had developed cold allodynia displayed cold-evoked
withdrawals which were significantly increased. Many of the animals did not place
their affected paw in the cold water at all and the average SPET was 10.6 ±1.0 sec.
During the tests, several of the animals repeatedly licked the affected hind paw or
were seen to flick their paw in the air as if they were trying to remove any traces of
the cold water, indicating that the normally innocuous cold stimulus was in fact
evoking a painful response. These abnormal pain behaviours were not accompanied
by vocalisations however, and the general level of activity within the tank appeared
to be similar to that of the control animals. The cold test did not appear to elicit any
pain-related responses from the hind limb on the contralateral control side.
There did appear to be a degree of variability in the cold response of the
nerve-injured animals, with a small proportion of the animals developing poor
withdrawal responses of less than 5sec for the whole test period. These animals were
not included in any of the electrophysiological or histological studies.
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3.3.3 Mechanical Allodynia
Prior to the experimental nerve injury, the animals displayed an average
withdrawal threshold of 62.8 ± 9.1g in the left paw and 53.9 ± 8.0g in the right hind
paw, with no significant difference between right and left hind limb values (Figure
3.2).
After surgery however, there was a very clear decrease in the response
threshold of the nerve-injured side with respect to time. From as early as D4 PO,
there was a significant reduction in the withdrawal threshold of the ipsilateral hind
paw (18.4 ± 3.0g) when compared with the contralateral hind limb value (56.8 ±
5.6g; Mann-Whitney rank sum test, p < 0.05) or pre-operative values (Kruskal-Wallis
one way ANOVA, p < 0.05). The threshold continued to decline over the next few
days, with maximal differences from D8 PO onwards when the animals displayed an
average withdrawal threshold of 3.5 ± 1.4g in the nerve-injured limb. So forces that
the rats rarely (if ever) responded to before the nerve injury now clearly evoked pain-
related withdrawal reflexes, indicative of mechanical allodynia.
There were no significant differences between the threshold values of the
contralateral hind limb in the nerve injured animals compared to pre-surgery values,
over the two week test period.
3.3.4 Mechanical Hyperalgesia
When applied to the volar skin of the experimenter's hand, the pin prick
stimulus produced a brief sensation that was sharp and barely painful. The normal
response of control animals following a noxious pin prick to the plantar surface of
their hind paws, was a quick, robust paw flick (Grade 1 response). This brisk
withdrawal reflex was always of small amplitude and very short duration.
After surgery the response of the nerve-injured paw was obviously different
from control withdrawal reflexes. Following the brief noxious stimulus, the nerve-
injured animals held their affected paws in the air for an extended period of time
(Grade 3 response), often for more than 15sec, while the response of the contralateral
control paw was indistinguishable from that of control or pre-surgery (Grade 1
response). In addition, all the responses of abnormally long duration were also of
abnormally great amplitude. In the normal reflex response the animals lifted their
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paws approximately 1mm off the floor, while the abnormal reflexes brought the paw
some 5-10mm off the floor. This test was used in a restricted fashion when there
were clear signs of allodynia, as the animals appeared to show some signs of
discomfort during these tests, and the exaggerated response was occasionally
accompanied by vocalisation. For this reason there was not enough data to produce a
time course of development ofmechanical hyperalgesia. But it was clear that all of
the animals which displayed strong signs of thermal and mechanical allodynia, also
showed strong signs of mechanical hyperalgesia between D8-D15 PO.
3.3.5 Sciatic nerve histology
Histological sections of the rat sciatic nerve 2 weeks after a chronic
constriction injury when behavioural changes are most prominent, revealed clear
structural differences distal to the nerve ligature (Figure 3.3).
Light-microscopic examination of the cross-sectional area of the sciatic nerve
distal to the ligatures showed a marked reduction in the number of large myelinated
fibres compared to control nerve sections. The degree of severity of axonal
degeneration appeared to vary slightly from one nerve to the next, but the general
pattern ofpathological changes within the sciatic nerve was clearly evident each
time, that is a significant loss of large myelinated fibres distal to the ligatures.
The cross-sections of sciatic nerve taken 1cm or more proximal to the
constriction injury, appeared morphologically similar to normal sections. The
distribution of myelinated fibres did not appear to be affected in these sections when
viewed under the light microscope.
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Figure 3.1
Time course of the development of cold allodynia following an experimental
mononeuropathy
Values represent the suspended paw elevation time (SPET) in response to the animal
being placed in a cold water bath for a 20 second period. Responses were obtained
for each animal, data combined, and the resultant group means utilised to produce a
time course of the development of cold allodynia for the days following sciatic nerve
injury. Part A shows the development of a marked cold allodynic response in
neuropathic animals (n=50). Data was analysed using the Kruskal-Wallis one way
ANOVA on ranks to determine any significant differences between post-operative
and pre-operative values (* p < 0.05; ** p < 0.01). Part B shows the less marked
cold allodynic response of a separate population of animals which did not appear to





































Time course of mechanical allodynia development following an experimental
peripheral mononeuropathy
Data is plotted as the withdrawal threshold (g) to repetitive von Frey filament
stimulation in the days following a chronic constriction injury, for 26 neuropathic
animals. Group means ± SEM are plotted for each time course. Filled circles
represent ipsilateral hind paw values while open circles represent the contralateral
control data.
Data was analysed using the Kruskal-Wallis one way ANOVA to isolate groups that
differ from the pre-operative control group (p < 0.01), and ** indicates significant
differences between ipsilateral and contralateral values (Mann-Whitney rank sum
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Axonal pathology of the rat sciatic nerve following a chronic constriction injury
as viewed under the light microscope
Transverse sections of rat sciatic nerve at the ligature level: Part A represents control
sections from untreated animals, while B and C are proximal and distal sections
respectively, from a ligated nerve at the second post-operative week. 8pm thin
sections were stained with Solochrome cyanin and iron alum, then counter-stained
with eosin. Note the significant loss of large myelinated fibres (myelin is stained a
dark purple colour) distal to the ligature (C(i) and C(ii)) with respect to control (A(i)
and A(ii)), while the sections proximal to the ligatures (B(i)and B(ii)) are almost




These results are broadly consistent with previous data which has shown the
development of abnormal behavioural responses in animals which have undergone an
experimental peripheral mononeuropathy (Attal et al. 1990; Bennett and Xie, 1988).
The data provide strong evidence that a chronic constriction injury produces
cold allodynia in the affected hind limb of the rat. Exposure to the ice-cold water
was not immediately noxious to the touch of uninjured humans and did not evoke
any behavioural changes in the control or sham rats nor in the contralateral control
limb of the nerve-injured animals. However, the majority of animals with an
experimental neuropathy clearly behaved as if the cold water was eliciting pain in
their affected hind limbs. As the neuropathy developed, the animals' threshold to the
cold stimulus decreased, indicative of the development of cold allodynia.
There did appear to be some variability in the responses of individual animals
to the cold stimulus, which has been reported previously (Bennett and Xie, 1988).
Approximately one quarter of the nerve-injured animals failed to develop a strong
cold allodynic response, that is to develop an average SPET of more than 5 sec for at
least 3 consecutive days. It is not known why some animals appeared to be less
responsive to the cold stimulus while mechanical allodynia was observed in all cases
(see below). It has been speculated that the development of the abnormal pain
behaviours following a CCI may result from the loss of inhibitory controls normally
exerted by the large primary afferent fibres (Gautron et al. 1990), as it is the
pathology of these fibres which is most greatly affected following nerve ligation
(Basbaum et al. 1991; Coggeshall et al. 1993). The variability in behavioural
patterns therefore may be due to slight differences in the "tightness" of the nerve
ligatures, as it was difficult to ascertain a common "pressure" when tying the
ligatures in individual animals. So it is possible that variations in ligation tightness
may lead to differences in the degree of degeneration within the nerve and
subsequently differences in the development of the chronic pain conditions.
The development ofmechanical allodynia was revealed by testing the rat's
withdrawal threshold following application of calibrated von Frey filaments in the
innocuous range. The nerve-injured rats displayed a significantly lowered threshold
to von Frey hair application from as early as D4 PO, again showing maximal effects
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from D8 PO onwards. There appeared to be much less variation in the data collected
for the mechanical testing as compared with the cold thermal test, with every nerve-
injured rat showing a reduction in withdrawal threshold to some degree over the time
period tested. Even those animals which produced a poor cold allodynic response,
displayed a significantly reduced mechanical threshold.
In addition to the development of mechanical and thermal allodynia, the
experimental neuropathy clearly produced a mechanical hyperalgesia, as application
of a noxious pin-prick to the affected hind paw produced increased paw withdrawal
latencies in all the animals tested. The magnitude and duration of the responses were
obviously exaggerated in comparison to those of control rats; changes indicative of
the development of hyperalgesia.
The abnormal position of the nerve-injured paw of the rat may reflect the
development of another pain-state, as this presumably pain-relieving behaviour is
thought to be indicative of spontaneous pain (Attal et al. 1990). It is possible that
these abnormalities may be due to motor impairments following the nerve damage,
but this seems unlikely as the rat holds the affected limb in particular protective
positions rather than dragging the hind limb, as would be expected were it due to
weaknesses in the dorsiflexor muscles of the hind limb. It seems more likely that the
abnormal position of the paw predominantly reflects a reluctance of the rat to press
its paw on to the ground, and that it is indeed protective guarding behaviour.
The time course of these pain-related disorders appears to be roughly
comparable throughout the range ofbehavioural tests employed. Rats demonstrating
both mechanical and thermal allodynia, as well as hyperalgesia, showed maximal
responses over the second postoperative week, with obvious changes evident from as
early as the fourth post-operative day. The histological alterations in the rat sciatic
nerve following a CCI also appear to have a time course which parallels the
development of the clinical signs (Coggeshall et al. 1993), and so we chose to look
at the pathology of the nerve at D14 PO, the time of maximum behavioural changes.
The morphological changes which result within the sciatic nerve following
CCI have been well documented, and allow us to speculate as to which fibre types
are involved in the development of hyperalgesia and allodynia, the abnormal pain
syndromes which accompany peripheral nerve damage.
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Despite some variability between experimental animals in our sciatic nerve
study, the dissections generally documented a dramatic loss of large myelinated
fibres distal to the nerve ligatures 14 days after chronic constriction of the sciatic
nerve, while there were no apparent signs of degeneration in the nerve 1cm or more
proximal to the constriction. These results are in agreement with previous studies
which have also shown that the predominant effect on nerve pathology following a
chronic constriction injury is a massive degeneration of large myelinated axons
(Basbaum et al. 1991; Gautron et al. 1990). The main consequence of these
pathological changes could be a deficit in the control of noxious information at the
spinal cord level, brought about by a lack of inhibitory influence from large diameter
primary afferents due to their demyelination and loss. Indeed, the development of
the behaviour pain states correlates with the initial fibre loss and predominant loss of
large myelinated fibres (Coggeshall et al. 1993), but small myelinated and
unmyelinated fibres are also affected to some degree (Basbaum et al. 1991; Carlton
et al. 1991). So it is likely that the development of the abnormal pain states
following a peripheral nerve injury, is the result ofboth afferent volleys in the small
AS- and C-fibre afferents that are spared, as well as the loss of inhibitory control
normally mediated by the large myelinated fibres. It is impossible from these
anatomical studies alone, to speculate as to the predominance of one fibre type
involvement above another in the production of the behavioural symptoms.
This study provides further behavioural evidence that the experimental
peripheral neuropathy produced by sciatic nerve ligation, produces significant pain-
related behavioural changes in the rat. These include hyperalgesia and allodynia to
mechanical and thermal stimuli, as well as abnormalities in posture which may be
considered as "spontaneous" pain-related behaviour. These symptoms appear to
have a similar time-course of development showing maximal changes between D8-
D15 post-surgery, a time when there are marked signs of degeneration within the
affected nerve. The degree of variability case-to-case, in both the behavioural and
histological studies, highlights the complexity behind the development of
neuropathy. However, the pain-related behaviours documented here are also
common in clinical causalgia in humans, making this CCI model of experimental
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neuropathy a useful model for investigating the factors influencing the development
and maintenance of neuropathic pain.
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Chapter 4 The effects of VIP/PACAP receptor antagonists
on sensory stimulus-induced responses of dorsal horn
neurones in normal rats
4.1 Aim
The purpose of these experiments was to investigate the role of VIPb VIP2
and PACAP receptors in the transmission of sensory information within the spinal
cord of rats. Selective antagonists for the three receptor subtypes were
ionophoretically applied to the sustained activity of dorsal horn neurones induced by
sensory stimuli, and their effects compared. Neuronal activity was induced by (i)
innocuous brushing of the cutaneous receptive field or (ii) topical application of the
chemical algogen mustard oil.
4.2 Methods
4.2.1 Animals
As in section 3.2.1.
4.2.2 Surgical Procedure for Electrophysiological Preparation
Details of all reagents can be found in Chapter 2, sections 2.1 and 2.7.
Experiments were carried out on 37 male Wistar rats (296g-394g), anaesthetised with
intravenous a-chloralose (60mg kg-1) and urethane (1.2g kg"1) following induction
with halothane. A tracheotomy was performed to maintain an unobstructed airway
throughout the experiment, and the rat was allowed to breathe freely, although
oxygen (0.1 lmin-1) was passed over the end of the cannula to enrich the inspired air.
The animal was mounted in a rigid, stereotaxic frame with its head stabilised using
nose and ear bars, and the core body temperature was maintained at 37-38°C by
means of a thermostatically controlled heated blanket and rectal probe. Spinal
segment L2 was identified by locating the floating rib and the thoraco-lumbar spinal
column was then supported using 3 pairs of swan-necked clamps on alternate
segments, with the middle set of clamps supporting segment L2. A pool was made
with skin flaps around the area of interest and a dorsal laminectomy performed under
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X 12.5 magnification to expose segments L1-L4. To improve the stability of the
preparation for extracellular recording, agar solution (2% in 0.9% saline solution) at
39°C was injected under the most rostral vertebrae and then poured over the entire
pool, including the spinal cord. Once cooled, a core of agar was removed to expose
the area of cord from which the recordings would be made, the dura carefully cut and
a pool of 37°C liquid paraffin applied to the exposed area to prevent dehydration.
Supplementary doses of a-chloralose were given in 0.3ml aliquots as required, with
this need being determined by assessment of the animal's blink reflex.
4.2.3 Extracellular Recording and Ionophoresis of Drugs
Extracellular recordings were made from single dorsal horn neurones, using
the central barrel (4M NaCl, pH 4.0-4.5) of 7-barrelled glass microelectrodes, with
tip sizes 4.0-5.5pm. One side barrel contained 1M NaCl (pH 4.0-4.5) for automatic
current balancing using a Neurophore BH2 Ionophoresis System (Medical Systems
Corporation, New York). A second side barrel contained 2% Pontamine Sky Blue
(PSB) in 0.5M sodium acetate for histological marking of recording sites (see section
4.2.8). The remaining barrels contained the drugs for ionophoresis.
Recordings were made at depths of 0-1000pm from the spinal cord surface
(as monitored by the microdrive reading), and cellular activity was observed on an
oscilloscope screen (Tektronix). The output activity from the oscilloscope was
continually monitored using a D.130 Digitimer Spike Processor, with the spike
discriminator adjusted so that the activity of one neurone was isolated (as viewed by
markers on the oscilloscope) for counting. Neuronal firing rate was continuously
plotted on-line via a customised analysis program (Scap 90; Dr M Dutia, Department
ofPhysiology, University of Edinburgh) on an IBM PS/2-70-121 computer. This
program allowed markers to be added as data was collected, while an on-line




Schematic of the Protocol for the Electrophysiological Recording Experiments
Schematic representation of the recording set up for the electrophysiology
experiments. The spinal cord vertebrae were stabilised using 3 pairs of swan necked
clamps and a laminectomy performed to reveal lumbar segments L1-L4. Skin flaps
were used to produce a pool around the area of interest, and this pool was filled with
a 2% agar solution to provide stability during the recording. Following the removal
of the agar core above the recording area, the dura was removed and the exposed
spinal cord covered in 37°C paraffin oil.
Extracellular recordings were made via a 7-barelled glass micro-electrode, and the
recording signal amplified 1000 times before being transmitted to a spike processor
where the number of action potentials per second were counted. Neuronal firing rate,
along with the analogue signal from the ionophoresis barrels, was continuously













4.2.4 Drugs for Ionophoresis
All solutions were 0.25mM in distilled water, pH adjusted to 4.5 with
hydrochloric acid (HC1):
VIPj receptor antagonist: [p-Cl-D-Phe6,Leu17]-VIP (Pandol et al. 1986)
General VIP receptor antagonist. VIP (6-28) (Fishbein et al. 1994)
VIP2 receptor antagonist: (des l-4)[Glu8, Lys12, Arg16, Nle17, Ala19]VIP(l-
24)(lactam 21-25) (des (1-4) Arg16 Ro 25-1553) (Gourlet and Robberecht -
unpublished data)
PACAP receptor antagonist: PACAP (6-38) (Robberecht et al. 1992)
All peptides were ejected using positive currents and a retention current of
-12nA was applied to each barrel when not in use. The resistance of the side barrels
was monitored regularly and electrodes with resistance values exceeding 45MQ were
rejected. The antagonists were applied during sustained responses to sensory inputs,
initially starting at 30nA and increasing to 45 or 60nA, until clear effects were seen.
The antagonists were usually ejected for one and a half to two minutes in order to
assess any maintained inhibition. If inhibition was present, ionophoresis of the
peptide was stopped to look for recovery.
4.2.5 Controls
1M NaCl and pH 4.5 H20 were ionophoresd from +30 to +60nA for current
and vehicle controls respectively. These controls were carried out on both brush- and
mustard oil-induced activity.
4.2.6 Identification of Neuronal Receptive Fields
Neuronal receptive fields were initially located by widespread manual
brushing of the ipsilateral hind limb, while simultaneously lowering the electrode
into the spinal cord using the microdrive. Neurones were then further examined with
noxious pinch and heat (48°C, 10 sec). The heat stimulus was applied using a ramp-
driven Peltier device (Medical Instruments, Yale University, USA) with a contact
area of 1cm2. The Peltier probe, while in contact with the animal's skin, was raised
from a resting temperature of 32°C to 48°C (ramp rate 5°C/sec) for 10 seconds. The
neurones were subsequently classified according to their sensory input with non-
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nociceptive neurones being those which responded only to light brushing of the hairs
of the cutaneous receptive field, while those which responded to brush, noxious
pinch, and/or noxious heat inputs were classed as being multireceptive. No noci-
specific neurones were investigated in this experiment due to the searching strategy
used.
4.2.7 Quantification of Neuronal Responses to Cutaneous Sensory Stimuli
Following identification of the neurones (as described above), sustained
sensory stimuli were applied to the cutaneous receptive field. Sustained innocuous
inputs were provided by positioning a rotating, motorised brush, on to the centre of
the receptive field. Noxious sensory inputs were produced by topical application of
the chemical algogen mustard oil, allyl isothiocyanate (8% in paraffin oil).
Mustard oil is a chemical irritant which when administered topically, intra-
articularly or intramuscularly will selectively activate C-afferent fibres (Woolf and
Wall, 1986). Repeated applications of mustard oil were made to an area of
approximately 2cm2 covering the identified neuronal receptive field, and after 2-7
applications, separated by 5 minute intervals, a steady elevated firing rate (3-45 Hz)
was maintained. This sustained level of C-fibre activation is thought to be analogous
to the ongoing C-fibre activity observed following electrical wind-up, and is a useful
model to simulate the development of central sensitisation (Woolf and Wall, 1986).
"Windup" is the term used to describe the increased responsiveness of a neurone due
to repetitive stimulation of C-afferent fibres (Mendell, 1966), and such mechanisms
are thought to contribute to the development of prolonged states of nociception
(including hyperalgesia and allodynia) (Torebjork et al. 1992) as well as to the
development of central hypersensitivity to sensory inputs (Davies and Lodge, 1987)
4.2.8 Histological Identification of Recording Sites
Following the completion of electrophysiological recording in a number of
animals, the recording area was marked by ionophoretic ejection of Pontamine Sky
Blue (PSB) (2% in 0.5M sodium acetate) to allow the histological identification of
electrode placement. PSB was ejected at a current of lOpA for 10-15mins to mark
the area of interest. The appropriate spinal cord section was then removed, rostro-
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caudally marked then rapidly frozen with an aerosol spot freezing spray and fixed in
10% formal saline.
The tissue was mounted in 0.25% agar solution on a freezing microtome, and
sections of 52pm cut. Sections with the blue spot were placed on poly-L-lysine
slides and stained with 1% neutral red for light microscopic evaluation of the laminar
position of the recording site.
4.2.9 Analysis of Results
Individual records were made for each neurone. Sustained firing was
recorded as the action potentials per second (rate) integrated over 1000msec bins,
plotted against time. Analysis was carried out off-line using the Scap-90 program.
The inhibitory effect of the antagonists on evoked (brush or mustard oil) activity, was
assessed by comparing the mean firing levels in the 30 sec period encompassing the
greatest inhibition, to the mean evoked activity in the 30 sec period immediately
prior to antagonist administration. The change in activity was expressed as a
percentage of the control value for each cell, and then pooled to find the mean ±
SEM. The raw data was analysed using the paired Student /-test to compare drug and
pre-drug values. Values of p < 0.05 were considered significant.
4.3 Results
4.3.1 Characterisation of Neurones
A total of 104 neurones from 37 rats were examined in this study. The vast
majority of neurones were within laminae III-V of the dorsal horn, as determined by
histological marking with PSB, and corresponding to microdrive electrode depth
readings of 200-1000pm from the spinal cord surface. These microdrive readings
have also been shown to correlate well with the depth of the electrode tip in the
spinal cord in a number of other electrophysiological studies within our laboratory
(Munro et al. 1993: Young et al. 1994; 1995b; 1997).
The 'receptive field' was defined as the total area in which a response from an
isolated dorsal horn neurone could be elicited, following application of cutaneous
sensory stimuli. All of the neurones investigated here responded readily to
innocuous brushing of the cutaneous receptive field, and the majority of cells also
108
displayed nociceptive responses. 31 were classed as non-nociceptive neurones
(responding to innocuous brush only) while 73 were classed as multireceptive. No
noci-specific neurones were examined in this study. Only neurones with receptive
fields on hairy skin were used, to facilitate classification and the reproducibility of
responses to mustard oil application.
Prior to stimulation of the neurone by a sensory input, recording was started
to determine the basal firing level. All neurones tested displayed a low basal firing
rate of 0-1Hz.
4.3.2 Effects of VIP!, VIP2 and PACAP Receptor Antagonists on Sustained
Neuronal Firing to Innocuous Brush Stimulation in Non-nociceptive Neurones
A total of 31 non-nociceptive neurones from 18 rats was investigated in this
study. Neuronal firing was evoked by stimulating the cutaneous receptive field using
a motorised, rotating brush. This activity was recorded for one minute before drug
application, and control activity was in the range 5-28Hz. The effects of three
VIP/PACAP receptor antagonists were assessed (See Figure 4.2): [p-Cl-D-
Phe6,Leu17]-VIP, an antagonist with modest selectivity for the VIP] receptor (Usdin
et al. 1994), VIP (6-28) which appears to show no preferential affinity to any of the
VIP/PACAP receptor subtypes (Fishbein et al. 1994), and PACAP (6-38), a PACAP
receptor- and, to a lesser degree, VIP2 receptor-selective antagonist (Robberecht et al.
1992). All three antagonists were ionophoresed with ejection currents of +30 to
+60nA.
No significant change (p < 0.05; paired Student Mest) was observed in
neuronal firing for any of the three antagonists following their application to
sustained neuronal firing, induced by innocuous brush. [p-Cl-D-Phe6,Leu17]-VIP
showed a mean percentage inhibition of 8 ± 3% (n=14), VIP(6-28) exhibited 8 ± 5%
inhibition (n=8), while PACAP(6-38) had a mean percentage inhibition of 9 ± 4%
(n=ll).
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4.3.3 Effects of VIP!, VIP2 and PACAP Receptor Antagonists on Sustained
Neuronal Firing of Multireceptive Neurones Induced by Brush or Mustard Oil
A total of 73 neurones from 32 rats were studied in this investigation, and as
far as possible paired brush- and mustard oil-induced responses from the same
neurone were investigated. Sustained neuronal firing was induced either by (i)
stimulation of the cutaneous receptive field using a motorised, rotating brush, or (ii)
topical application of the chemical algogen mustard oil. One minute of this evoked
activity was recorded before applying any compounds. Four antagonists were
assessed: [p-Cl-D-Phe6,Leu17]-VIP, VIP (6-28), PACAP (6-38), and the novel VIP2
selective antagonist des(l-4) Arg16 Ro 25-1553 (Gourlet and Robberecht -
unpublished data). All four antagonists were ionophoresed at ejection currents of
+30 to +65nA.
Control, brush-induced activity (4-33Hz) was significantly inhibited by
ionophoretic application of [p-Cl-D-Phe6,Leu17]-VIP by 56 ± 6 % (n=18), VIP (6-28)
by 66 ± 5% (n=14) and PACAP (6-38) by 51 ± 8% (n=23)(mean ± SEM; p < 0.01,
paired Student t-test on raw data). Recovery was observed in all cases, with the
majority of cells returning to control firing levels within approximately 90sec.
However, ionophoresis of the VIP2 receptor selective antagonist, in the same current
range, failed to inhibit such firing (n=10). Figure 4.3 shows typical examples.
In contrast, all four VIP/PACAP receptor antagonists significantly inhibited mustard
oil-induced activity (3-45Hz) of dorsal horn neurones (see Figure 4.4). [p-Cl-D-
Phe6,Leu17]-VIP showed 64 ± 8% inhibition (n=10), VIP(6-28) showed 69 ± 9%
inhibition (n=10), PACAP (6-38) showed an inhibition of 63 ± 8%(n=12), while
des(l-4) Arg16 Ro 25-1553 inhibited mustard oil-induced activity by 36 ± 7% (n=10).
Again, the activity of all neurones returned to control levels within approximately 2
minutes of terminating drug application.
4.3.4 Current and Vehicle Controls
Ionophoresis of vehicle (pH 4.5 H20) or Na+ ions, in the range +30 to
+60nA, had no detectable effect on the brush or mustard-oil induced activity of those
neurones tested.




Effects of ionophoretically-applied VIP/PACAP receptor antagonists on
sustained brush-evoked responses of non-nociceptive dorsal horn neurones
Records of ongoing firing of individual neurones are displayed as number of action
potentials per second (A/s), integrated over 1000msec bins, plotted against time.
Parts (a), (b) and (c) show the generally-observed lack of effect of [p-Cl-D-
Phe6,Leu17]-VIP, VIP (6-28) and PACAP (6-38) respectively, when applied to the
sustained innocuous brush-evoked activity of dorsal hom neurones. Each trace is























Effects of ionophoretically-applied VIP/PACAP receptor antagonists on
sustained brush-evoked responses of multireceptive dorsal horn neurones
Records of ongoing firing of individual neurones are displayed as number of action
potentials per second (A/s), integrated over 1000msec bins, plotted against time.
Parts (a), (b) and (c) show the marked inhibitory effects of [p-Cl-D-Phe6,Leu17]-VIP,
VIP (6-28) and PACAP (6-38) respectively, when applied to the sustained neuronal
firing evoked by innocuous brushing of the cutaneous receptive field. Part (d) shows
the generally-observed lack of effect of des(l-4) Arg16 Ro 25-1553 on brush-induced
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Effects of ionophoretically-applied VIP/PACAP receptor antagonists on
sustained mustard oil-induced activity of multireceptive dorsal horn neurones
Records of ongoing firing of individual neurones are displayed as number of action
potentials per second (A/s), integrated over 1000msec bins, plotted against time.
6 17
Parts (a), (b), (c) and (d) show the marked inhibitory effects of [p-Cl-D-Phe ,Leu ]-
VIP, VIP (6-28), PACAP (6-38) and des(l-4) Arg16 Ro 25-1553 respectively, when
applied to the sustained neuronal firing evoked by noxious mustard oil application to
the cutaneous receptive field. All examples show a significant inhibition of neuronal
firing during antagonist application, with recovery to pre-drug control levels within
approximately 1 minute of terminating antagonist application.
These traces represent paired responses from the neurones used in Figure 4.3; that is,
both brush and mustard oil responses were tested in the same neurone for each
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Summary histogram showing the overall effects of ionophoretically applied
VIP/PACAP receptor antagonists on sustained sensory-induced responses of
dorsal horn neurones
Summary histogram showing the mean percentage inhibition of the control neuronal
firing rate of (A) non-nociceptive and (B) multireceptive dorsal horn neurones, in






des(l-4) Arg Ro 25-1553 are shown.
The three antagonists tested showed negligible effects when applied to sustained
neuronal activity of non-nociceptive neurones (A). Both brush and mustard oil-
induced activity was significantly inhibited (paired student Mest on raw data; ** p <
0.01) by [p-Cl-D-Phe6,Leu17]-VIP, VIP (6-28) and PACAP (6-38), while only
mustard oil-induced activity was inhibited by des(l-4) Arg16 Ro 25-1553 (* p <
0.05).
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4.4 Discussion
VIP and PACAP are recognised by a family of three receptors, namely the
VIP], VIP2 and PACAP receptors. Binding sites for VIP and PACAP ligands have
been shown to be present in the rat spinal cord, particularly in the lumbar and sacral
segments, with the highest concentration in laminae I and II of the dorsal horn (Kar
and Quirion 1995; Moller et al. 1993; Yashpal et al. 1991). The mRNA for VIP]
(Ishihara et al. 1992), VIP2 (Sheward et al. 1995) and PACAP receptors (Arimura
and Shioda, 1995) is also expressed in spinal cord (particularly in the dorsal horn).
These receptors appear to have distinct distributions throughout the peripheral and
central nervous systems (Arimura and Shioda, 1995; Sheward et al. 1995; Usdin et
al. 1994). This may suggest that the different receptor subtypes may each play
specific functional roles within the CNS. The development ofnovel selective
antagonists for the VIP], VIP2 and PACAP receptors, has allowed us to address the
role of each receptor subtype in the modulation of sensory processing within the
spinal dorsal horn of normal animals.
The population of neurones investigated in this study comprised both non-
nociceptive and multireceptive cells. From these studies it appears that there is a
clear correlation between the type of dorsal horn neurone and the effect mediated by
VIP/PACAP receptor antagonists in normal animals. None of the antagonists used
here showed any inhibitory effects on the brush-induced activation of non-
nociceptive dorsal horn neurones. It is not altogether surprising that the antagonists
had little or no effect on neurones with a non-noxious input, i.e. those innervated by
the larger Ap fibres, as histological evidence so far has limited the presence of these
peptides to small diameter nerve fibres (Fuji et al. 1983; Gibson et al. 1981; Staun-
Olsen et al. 1985).
In contrast, all of the antagonists tested showed marked inhibition of at least
one aspect of sensory stimulation of multireceptive neurones. This would suggest
that VIP and PACAP may be largely restricted to modulating neuronal pathways
concerned with the regulation of C-fibre-mediated transmission, and highlights the
possibility that VIP/PACAP receptors may be important modulators in the
transmission of nociceptive information.
119
Nociceptive afferents, including C-fibres, terminate in the superficial layers
of the spinal dorsal horn (Cervero and Iggo, 1980), and previous evidence has
already demonstrated that both VIP and PACAP are found in small diameter fibres
(Fuji et al. 1983; Gibson et al. 1981; Staun-Olsen et al. 1985), inferred to be the A8-
and C-fibres associated with polymodal and mechanical nociceptors. The majority of
VIP- and PACAP-ir fibres are present in laminae I and II of the rat spinal dorsal horn
(Moller et al. 1993; Yaksh et al. 1982), with additional fibres being found around the
central canal and in lamina VII. These histological findings alone provide grounds
for suggesting a role for these peptides in the control of sensory transmission, the
present antagonist study has now provided physiological evidence.
Despite the fact that VIP and PACAP are present in relatively low abundance
under normal circumstances (Noguchi et al. 1993; Mulder et al. 1994), the present
results provide clear evidence for the presence ofVIP/PACAP receptor subtypes on
dorsal horn neurones under normal conditions. From these data we have shown that
the activity of multireceptive neurones is clearly mediated or promoted, at least in
part, by VIP/PACAP receptors. Variations in the effects of the antagonists for each
of the three receptor subtypes, suggest differential roles for VIP,, VIP2 and PACAP
receptors.
Antagonists selective for the VIP! and PACAP receptor subtypes showed a
marked inhibition of the neuronal firing induced by either innocuous brush or
mustard oil application, to a similar extent in each case. This non-selective effect,
suggests that VIP] and PACAP receptors may exert a generalised modulation of
multireceptive dorsal horn neurone responses in normal animals.
In contrast, the novel VIP2 receptor selective antagonist examined here,
appears to exert a much more specific regulatory role, showing negligible effects on
brush-induced activity, while markedly inhibiting the cell firing induced by topical
application of the chemical irritant mustard oil. This would imply that VIP2
receptors may play a specific role in the modulation/mediation ofnociceptive C-fibre
dependent inputs, therefore implicating the VIP2 receptor as a potential site to be
targeted by novel analgesics.
Functional studies have already provided evidence for a regulatory role of
VIP and PACAP in the transmission of nociceptive information at the spinal cord
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level. Intrathecal administration of VIP is known to facilitate thermal but not
mechanical nociceptive reflexes in the rat (Cridland and Henry, 1988; Wiesenfeld-
Hallin, 1987), while an intrathecal injection of PACAP-38 has been shown to
produce thermal hyperalgesia in the mouse (Narita et al. 1996).
The functional role of VIP is thought to become more apparent following
nerve injury however, when the levels of this peptide are greatly increased within the
spinal cord. Wiesenfeld-Hallin et al. (1991), demonstrated that in decerebrate,
spinalised, unanaesthetised rats with an intact sciatic nerve, the SP antagonist
Spantide II attenuated facilitation of the flexor reflex induced by either intrathecal
application of SP or by a brief conditioning electrical stimulus, while the VIP
antagonist (Ac-Tyr1, D-Phe2)-GRF (l-29)-NH2 appeared to be ineffective. Following
axotomy however, intrathecal application of (Ac-Tyr1, D-Phe2)-GRF (l-29)-NH2 was
shown to antagonise the conditioning induced facilitation of the flexor reflex, while
the SP antagonist showed no such effect. So it would appear that after peripheral
nerve section, the role of excitatory mediator of flexor reflex facilitation, is
transferred from SP to VIP. This may reflect a transfer from SP to VIP as the most
functionally important neuropeptide of C afferents following nerve injury, paralleling
the decrease in SP and marked increase in VIP levels, that is observed within the
spinal dorsal hom and small dorsal root ganglion cells (Hokfelt et al. 1994).
The role of PACAP in normal animals is a little less clear. The reported
effects of intrathecal PACAP on spinal nociceptive reflexes are somewhat variable
from different groups of investigators. Zhang et al. (1993) found PACAP-27 and
PACAP-38 (0.63 -5pmol) to have anti-nociceptive effects on the C-fibre mediated
flexion reflex, when given i.p. In addition they also found intrathecal PACAP-27 (up
to 5pmol) to cause a dose-dependent suppression of formalin-induced (5% formalin
solution s.c.) pain related behaviours (Zhang et al. 1996). However, even very high
doses of PACAP-27 (approximately 15.5 nmol) could not completely abolish the
response to formalin, and the high doses used appeared to cause some motor effects,
as shown using the placing/stepping reflex (Yamamoto and Tatsuno, 1995). On the
other hand, Weisenfeld-Hallin et al. (1996) have reported PACAP-27 to cause a
dose-dependent facilitation of the flexor reflex, in decerebrate, spinalised rats at
relatively low doses (lOng-lOpg), and as stated previously, a single intrathecal
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injection of PACAP-38 (0.05pg) can induce hyperalgesia in the mouse (Narita et al.
1996). The data obtained in our study are more consistent with the latter
observations, as antagonists selective for the PACAP receptor were shown to have
inhibitory effects on the transmission of sensory information within the dorsal spinal
cord. We can only suggest that the variations in the results provided by Zhang et al.
may be due to variations in the preparation, recording techniques and of course the
high doses of PACAP used. In addition, it is important to consider that PACAP-38
and PACAP-27 are potent agonists for VIP! and VIP2 receptors as well as the
PACAP receptor.
The firing rate of the majority of neurones tested returned to control levels
almost immediately the antagonist application was terminated. This suggests that the
VIP/PACAP receptors may be expressed on the recorded neurones themselves, and
that VIP and PACAP may act directly on dorsal horn neurones. However, we can
not rule out the possibility that the peptides may be acting indirectly via
neighbouring interneurones to regulate the recording neurones. The receptors may
well be expressed on other generally excitatory neurones, or the peptides may even
act via a cascade of inhibitory interneurones to exert a disinhibitory influence.
Our results further support the previous evidence that VIP/PACAP receptors
may play important physiological roles as neurotransmitters within the CNS. From
this study it is apparent that VIP/PACAP receptor antagonists have the ability to act
selectively on the normal reception of sensory inputs by multireceptive neurones, and
so have the potential to play important neurotransmitter roles at the spinal cord level.
The receptor selectivity of the antagonists used, provides new insights into the type
of VIP/PACAP receptors functionally important in regulating the transmission of
sensory information by dorsal horn neurones, in normal rats.
It appears from these data, that the vast majority of multireceptive dorsal hom
neurones are regulated by VIP], VIP2 and PACAP receptors to some degree. The
selective inhibitory effect of des (1-4) Arg16 Ro 25-1553 on mustard oil-induced
activity of dorsal horn neurones, highlights a potentially important role for the VIP2
receptor in the transmission of nociceptive sensory information in normal rats. This
predicts that high affinity VIP2 receptor antagonists could act as selective analgesics,
particularly reducing C-fibre mediated pain. In contrast, the VIP! and PACAP
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receptor antagonists are rather non-selective inhibitors of sensory inputs and so
appear to be less promising as drug candidates in normal pain states.
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Chapter 5 The effects of VIP/PACAP receptor antagonists
on sensory stimulus-induced responses of dorsal horn
neurones in neuropathic rats
5.1 Aim
The purpose of these experiments was to investigate the role of VIPj, VIP2
and PACAP receptors in the transmission of sensory information within the spinal
cord of neuropathic rats. Selective antagonists for the three receptor subtypes, were
ionophoretically applied to the sustained activity of rat spinal dorsal horn neurones,
2-3 weeks following sciatic nerve injury. Neuronal activity was induced by (i) light
brushing of the cutaneous receptive field, (ii) cold stimulation via a thermal Peltier
probe or (iii) topical application of the chemical algogen mustard oil.
5.2 methods
5.2.1 Animals
As in section 3.2.1
5.2.2 Surgical Preparation of Animals with an Experimental Peripheral
Mononeuropathy
The animals used in this study underwent a unilateral hindlimb chronic
constriction injury (CCI) as outlined in section 3.2.2. Only nerve-injured animals
which showed strong signs ofmechanical hyperalgesia and cold and mechanical
allodynia (as determined by the behavioural testing (see section 3.2.3)) were used for
electrophysiological recordings (n=33). All the animals used for electrophysiological
recordings displayed an average suspended paw elevation time (SPET) of 8 seconds
or more to innocuous cold stimulation on the day of recording, while the average
withdrawal threshold to von Frey filaments was 2.7 ± 0.5g (compared to mean pre-
surgery values of 53.9 ± 8.0g). In addition, the CCI animals displayed an
exaggerated response to pin prick in the ipsilateral foot. That is they held their
affected paw in the air for over 5 seconds following the noxious pin prick stimulus
(grade 3 response). All contralateral responses were instantaneous, short-lived paw
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flicks (grade 1 response), as were responses to pin prick challenges in normal
animals
5.2.3 General Methods
Regarding surgical procedures, electrophysiological recording techniques,
quantification of neuronal responses to evoked activity, histological identification of
recording sites and analysis of results, please refer to section 4.2.
In addition to the sustained brush- and mustard oil-induced responses, pulses
ofpotentially noxious cold inputs were applied by means of a ramp-driven Peltier
device, with a contact area of 1cm2. The Peltier probe was placed in contact with the
receptive field located on the hind limb of the animal; the probe was then
periodically cooled from a base temperature of 32°C (ramp rate 5°C/sec) and
maintained at the test temperature of approximately 5°C for 10 second intervals. The
stimuli were applied every 2 minutes to give reproducible peaks of evoked activity
(5.3-28.3 Hz), and the probe was maintained at 32°C in between each test. Because
of the permanent contact between the probe and the receptive field, the neurones
displayed a slightly higher basal firing rate than during the other tests (1.2-5.8 Hz),
which was subtracted from the test firing rates during analysis. Where possible, all
three sensory inputs were tested on the same neurone. This was the case for the
majority of neurones tested. However in a small number only two of the three tests
were carried out.
5.2.4 Drugs for Ionophoresis
All drug solutions were 0.25mM in distilled water, pH 4.5, and drugs were
ejected using positive currents:
VIPi receptor antagonists: [p-Cl-D-Phe6,Leu17]-VIP (Pandol et al. 1986) and
[Ac-His1, D-Phe2, Lys15, Arg16, Leu17]VIP (3-7)GRF (8-27): PG 97-269 (Gourlet et
al. 1997(c))
VIP2 receptor antagonist: des (1-4) Arg16 Ro 25-1553 (Gourlet and
Robberecht - unpublished data)
PACAP receptor antagonist: PACAP (6-38) (Robberecht et al. 1992)
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5.2.5 Controls
1M NaCl and pH 4.5 H20 were ionophoresed from +30 to +60nA for current
and vehicle controls respectively. These controls were carried out on brush-, cold-
and mustard oil-induced activity.
5.3 Results
5.3.1 Characterisation of Neurones
These results are based on data obtained from a total of 36 neurones in 33
neuropathic animals which had undergone sciatic nerve ligation 12-18 days
previously. Extracellular recordings were made from single neurones located in the
dorsal horn ipsilateral to the nerve injury, and in segments L4-L5. Microelectrode
depths ranged from 200- 1000pm from the surface of the spinal cord, corresponding
to laminae III-V of the dorsal hom. All neurones tested displayed low basal firing
rates of 0-1 Hz.
Only truly multireceptive neurones were studied in this investigation, i.e.
those neurones which responded strongly to light brushing, noxious pinch and/or
noxious heat inputs to the cutaneous receptive field. No noci-specific or non-
nociceptive neurones were investigated in these experiments. In general, the
neurones investigated had receptive fields on the lower part of the ipsilateral limb
(ankle and hairy foot) corresponding to the area innervated by the constricted part of
the sciatic nerve (Schmalbruch, 1986). To facilitate classification and the
reproducibility of responses to mustard oil application, only neurones with receptive
fields on hairy skin were used.
5.3.2 Effects of VIPj, VIP2 and PACAP Receptor Antagonists on Sustained
Neuronal Firing Induced by Brush, Cold or Mustard Oil Application
Neuronal firing was induced by stimulating the cutaneous receptive field
using (i) a motorised, rotating brush, (ii) a thermally-maintained Peltier device (to
produce approximately 10 second pulses of activity) or (iii) topical application of the
chemical algogen mustard oil. Generally, one minute of this activity was recorded
before application of the antagonists was commenced, or in the case of the cold
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stimulus, at least two consecutive control pulses of similar magnitude. The
antagonist effects were then assessed with respect to control, pre-drug firing rates.
(i) Brush-induced Activity
All four antagonists showed negligible effects when applied to the sustained-
brush-evoked activity of dorsal hom neurones, ipsilateral to the nerve injury in CCI
animals: [p-Cl-D-Phe6,Leu17]-VIP displayed 11 ± 3% inhibition (n=13), PG 97-269
inhibited brush-evoked activity by 10 ± 4% (n=7), des(l-4) Arg16 Ro 25-1553
displayed 6 ± 3% inhibition (n=10), while the mean percentage inhibition for
PACAP (6-38) was 14 ± 7% (n=14) (See Figure 5.1).
(ii) Cold-induced Activity
Over half (56%) of the dorsal horn neurones tested responded strongly to a
cold stimulus of approximately 5°C when applied to the receptive field via a Peltier
device. There was some variability in the firing responses of the dorsal hom
neurones tested, with some cells being more susceptible to the decreasing
temperature while others had a greater firing activity during the sustained cold
response. However, all neurones used produced consistent responses following each
cold stimulus, giving reproducible peaks of activity of 5.3-28.3 Hz. A small
proportion (9%) of cells showed only transient responses to the cold stimulus, while
the remaining 35% appeared to have no response. The VIP! and PACAP receptor
antagonists showed significant inhibitory effects of a similar magnitude when applied
to the repeated cold-evoked activity. The VIP! antagonists [p-Cl-D-Phe6,Leu17]-VIP
and PG 97-269 reduced the control firing rates by 25 ± 4% (n=10) and 25 ± 6% (n=7)
respectively (see Figure 5.2a), while PACAP (6-38) inhibited the cold response by
an average of 27 ± 8% (n=8) (Figure 5.2b). The selective VIP2 receptor antagonist,
des(l-4) Arg16 Ro 25-1553 however, showed little effect on cold-induced activity of
dorsal hom neurones (12 ± 4% (n=10)) as shown in Figure 5.2c.
(iii) Mustard oil-induced Activity
Application of [p-Cl-D-Phe6,Leu17]-VIP or PG 97-269 significantly inhibited
mustard oil-induced activity by 26 ± 6% (n=9) and 30 ± 6% (n=13) respectively.
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Des(l-4) Arg16 Ro 25-1553 and PACAP (6-38) were slightly more effective,
displaying mean percentage inhibitions of 44 ± 5% (n=12) and 40 ± 6% (n=12)
respectively. See Figure 5.3.
Figure 5.4 is a summary histogram of the results, indicating the overall effects
of all four peptide receptor antagonists on the stimulus-evoked activity of dorsal hom
neurones in neuropathic animals.
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Figure 5.1
Effects of ionophoretically-applied VIP/PACAP receptor antagonists on
sustained brush-evoked responses of dorsal horn neurones in CCI animals
Records of ongoing firing of individual neurones are displayed as number of action
potentials per second (A/s), integrated over 1000msec bins, plotted against time.
These traces show the generally-observed lack of effect of ionophoretic application
of (a) [p-Cl-D-Phe6,Leu17]-VIP, (b) PG 97-269 (a selective VIP] receptor
antagonist), (c) des(l-4) Arg16 Ro 25-1553 (a selective VIP2 receptor antagonist) and
PACAP (6-38) on the sustained neuronal firing induced by a motorised rotating
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Effects of ionophoretically-applied VIPj receptor antagonists on cold-induced
neuronal firing of dorsal horn neurones in CCI animals
Records of ongoing firing of individual neurones are displayed as number of action
potentials per second (A/s), integrated over 1000msec bins, plotted against time.
Parts (a)(i) and (ii) show the typical inhibitory effects of the VIP! receptor
antagonists [p-Cl-D-Phe6,Leu17]-VIP and PG 97-269 respectively, on 10 second
pulses of neuronal activity induced by repeated stimulation of the cutaneous
receptive field by a cold Peltier probe at 5°C (| ). The x-axis breaks represent the 8
and 5 minute recovery periods required for neuronal firing rates to return to pre-drug
control levels for [p-Cl-D-Phe6,Leu17]-VIP and PG 97-269 respectively. These










Effects of ionophoretically-applied PACAP receptor antagonist on cold-induced
neuronal firing of dorsal horn neurones in CCI animals
Records of ongoing firing of individual neurones are displayed as number of action
potentials per second (A/s), integrated over 1000msec bins, plotted against time.
Part (b)shows the marked inhibitory effect of ionophoretic application of PACAP (6-
38) on the 10 second pulses of neuronal activity induced by repeated stimulation of
the cutaneous receptive field by a cold Peltier probe at 5°C (| ). These results are






Effects of ionophoretically-applied VIP2 receptor antagonist on cold-induced
neuronal firing of dorsal horn neurones in CCI animals
Records of ongoing firing of individual neurones are displayed as number of action
potentials per second (A/s), integrated over 1000msec bins, plotted against time.
Part (c) shows the generally observed lack of effect of the selective VIP2 receptor
antagonist des(l-4) Arg16 Ro 25-1553 on the 10 second pulses of neuronal activity
induced by repeated stimulation of the cutaneous receptive field by a cold Peltier








Effects of ionophoretically-applied VIP/PACAP receptor antagonists on the
sustained mustard oil-induced activity of dorsal horn neurones in CCI animals
Records of ongoing firing of individual neurones are displayed as number of action
potentials per second (A/s), integrated over 1000msec bins, plotted against time.
These traces represent the significant inhibitory effects of (a) [p-Cl-D-Phe6,Leu17]-
VIP, (b) PG 97-269, (c) des(l-4) Arg16 Ro 25-1553 and PACAP (6-38) on the
sustained mustard oil-induced activity of multireceptive dorsal hom neurones. Each
trace is from a different neurone and is entirely typical of the results obtained in the









Summary histogram showing the overall effects of ionophoretically-applied
VIP/PACAP receptor antagonists on sensory-induced responses of dorsal horn
neurones in CCI animals
Summary histogram showing the mean percentage inhibition of control neuronal
firing rate. These data are taken from animals which had undergone sciatic nerve
constriction 2-3 weeks previously.
Effects of the antagonists [p-Cl-D-Phe6,Leu17]-VIP, PG 97-269, des(l-4) Arg16 Ro
25-1553 and PACAP (6-38) are shown on the multireceptive dorsal horn activity
induced by (J ) motorised, rotating brush, ([] ) stimulation of the receptive field
with a cold Peltier probe or ( ^ ) topical application of the chemical irritant mustard
oil.
All four antagonists showed negligible effects when applied to the sustained neuronal
firing induced by a rotating brush. [p-Cl-D-Phe6,Leu17]-VIP and PG 97-269 inhibited
cold- and mustard oil-induced activity to similar extents while PACAP (6-38) had a
more marked inhibitory effect on mustard oil-evoked activity than on cold-evoked.
In contrast, the novel VIP2 receptor antagonist des(l-4) Arg16 Ro 25-1553,
selectively inhibited mustard oil-induced activity only.
Raw data was analysed to determine significant differences in neuronal firing before




These results provide further evidence of a modulatory role for VIP/PACAP
and their receptors within the dorsal spinal cord, as well as providing new insight
into the functional differences between the three receptor subtypes, VIP!, VIP2 and
PACAP following an experimental peripheral mononeuropathy.
The profile of influence of VIP/PACAP receptors on sensory processing is
clearly very different from that of other modulators such as the opioid and tachykinin
peptides (Fleetwood-Walker et al. 1988; 1993), since aspects of neuropathic pain
appear to be resistant to classical opioid analgesics (Arner and Meyerson, 1988; Mao
et al. 1995). Since VIP/PACAP expression is increased in dorsal root ganglia
following peripheral nerve injury (Noguchi et al. 1989; Zhang Q et al. 1995), we
investigated whether VIP/PACAP receptors might be critical regulators of the
amplified sensory responses following neuropathy. Novel, selective antagonists for
the VIPj, VIP2 and PACAP receptors were used to ascertain the role of each of the
receptor subtypes in the modulation of sensory processing (particularly of noxious
information) within the spinal dorsal horn of rats which had undergone a chronic
constriction injury (CCI) of the sciatic nerve 2-3 weeks previously.
The population of neurones investigated in this study consisted solely of
multireceptive neurones. No non-nociceptive neurones were studied as the vast
majority of neurones examined appeared to be multireceptive, that is they responded
to some form of noxious input. In addition, because of the reduced threshold
observed in these animals to the von Frey filaments (indicative of mechanical
allodynia), it is likely that the brush response could now be perceived as noxious and
so the study concentrated on the responses ofmultireceptive cells. Of course it was
not possible to determine what the properties of these recorded neurones were prior
to nerve injury.
The effects of VIP], VIP2 and PACAP receptor antagonists changed markedly
in the nerve injured animals. The most obvious difference being the lack of effect of
any of the four antagonists used on the brush-induced activity of dorsal horn
neurones. This contrasts markedly with the prominent inhibitory effects of the VIP]
and PACAP, but not the VIP2 receptor antagonists in normal animals. As stated
earlier, the behavioural changes exhibited in these animals make it difficult to
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ascertain whether the brush stimulus is still innocuous, but the reduced threshold to
von Frey hairs, indicative of mechanical allodynia, is consistent with the idea that
this stimulus may now be noxious. From these experiments it is impossible to
determine which fibre type is responsible for the transmission of brush-induced
information. Although the CCI model causes more marked degeneration of Ap than
C or AS fibres (Basbaum et al. 1991; Coggeshall et al. 1993), a gradual recovery
perhaps including regeneration and sprouting, does occur (Coggeshall et al. 1993;
Koerber et al. 1994; Woolf et al. 1995). The neuropathy-induced increases in VIP
and PACAP peptide expression are predominantly in small to medium diameter
DRG cells, suggesting that VIP/PACAP are not likely candidates for direct mediators
of the brush response in neuropathic animals unless new fibre types become involved
in the input. It appears more likely that the mechanisms by which responses to low
threshold inputs are amplified in neuropathy, act to curtail the inhibitory modulation
normally exerted by VIP] and PACAP receptors on dorsal horn neurones. Whether
this involves altered expression of these receptors or changes in their functional
influence is not yet clear.
Cold allodynia appears to be a striking feature of neuropathy in humans
(Frost et al. 1988; Engkvist et al. 1985), particularly in patients with sympathetically
maintained pain (SMP). Very little is known about the mechanisms underlying this
cold pain. In normal rats it is the small diameter nociceptive afferents which transmit
cold sensory information, and saphenous nerve recordings have revealed that the cold
threshold for many nociceptors is below 12°C, with a large proportion of AS
nociceptors only firing at temperatures below 0°C (Simone and Kajander,
1996;1997).
The fibre types involved in the transmission of the cold response in
neuropathic conditions are not clear. In humans, A fibre blocks have been shown to
elevate the threshold temperature response of unmyelinated fibres such that cold
stimulation now induces a noxious, burning sensation (Wahren et al. 1989). So it is
possible that the exaggerated response to cold (allodynia) in neuropathic patients may
be predominantly mediated by C-nociceptors. Furthermore, nerve recordings in the
rat would suggest that activity induced by temperatures above 0°C, temperatures
which now appear to elicit a withdrawal response indicative of cold allodynia in
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nerve-injured animals, is transmitted primarily by C-frbres (Simone and Kajander,
1996). In the CCI model of neuropathy, C-fibre involvement is much more likely,
due to the predominant loss and/or damage of myelinated fibres induced by the
constriction injury (Basbaum et al. 1991; Gautron et al. 1990). In addition, an animal
model of chronic pain due to ischemic spinal cord injury (Xu et al. 1992b) has shown
that in these animals capsaicin-sensitive afferents mediate chronic cold allodynia
(Hao et al. 1996), highlighting the involvement of C nociceptors.
Whatever the fibre type involved in the transmission of cold sensory
information, there is a selective effect of the receptor subtype antagonists with regard
to the regulation of the cold response in CCI animals. The cold-induced activity of
multireceptive dorsal horn neurones was inhibited by only the VIP] and PACAP
receptor antagonists, while the VIP2 receptor antagonist showed negligible effects.
The sensitivity of the cold response in CCI animals to VIP] and PACAP
receptor antagonists resembles that of the C-fibre (mustard oil) response (see below),
and differs from the complete insensitivity of the antagonists on the brush-evoked
response. This is consistent with the idea that the central changes induced by
neuropathy act to rather selectively exempt low threshold brush responses from the
normally significant modulatory influence of VIP]/PACAP receptors. The VIP2
receptor antagonist, in contrast, had no effect on cold responses of CCI animals,
which would suggest that the VIP2 receptor is not involved to any major extent in the
regulation of cold allodynia in neuropathic animals.
All four antagonists significantly inhibited the mustard oil-induced activity of
dorsal horn neurones of CCI rats. This implies that VIPb VIP2 and PACAP
receptors may all be involved with the transmission or modulation ofnociceptive, C-
fibre-mediated information at the spinal cord level. PACAP (6-38) and the VIP2
receptor antagonist appeared to be the most effective, but the inhibitory effects of [p-
Cl-D-Phe6,Leu17]-VIP and the more selective VIP] receptor antagonist were still
significant. The inhibitory effect of the VIP2 receptor antagonist on mustard oil, but
not on cold responses of CCI animals, indicates a selective involvement of VIP2
receptors in the former input pathway and suggests that the fibre types mediating
these two inputs may be distinct sub-populations. The clear inhibitory effects of
PACAP (6-38) correspond well to the observation that PACAP-like
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immunoreactivity can be evoked in the rat spinal cord by capsaicin (Zhang YZ et al.
1997). This is consistent with the idea that any release ofPACAP here may be from
primary sensory afferents and highlights the possibility that this peptide may be
involved in sensory neurotransmission or modulation.
In conclusion, these results provide evidence for regulatory roles of the
VIP/PACAP receptors in the transmission of sensory information at the spinal cord
level in neuropathic rats. The differential inhibitory effects of these receptor
antagonists on cold- and mustard oil-induced activity of dorsal horn neurones in CCI
animals highlights a possible role for specific VIP/PACAP receptor subtypes in the
development of the abnormal sensory states which develop following nerve injury.
Importantly, these experiments underline the potential importance ofVIP!,
VIP2 and PACAP receptor antagonists as new analgesics for use in currently
intractable neuropathic pain states. The results predict that VIP2 receptor antagonists
should act as selective analgesics, strongly reducing polymodal C-fibre-mediated
pain (but not other responses) in neuropathy, where hyperalgesia (resistant to classic
analgesics) is an important feature. In contrast, while VIPi/PACAP receptor
antagonists are rather non-selective inhibitors of sensory inputs in the normal state
(see Chapter 4), they appear to have the useful property of attenuating certain
aspects of allodynia (cold response) as well as polymodal C-fibre responses, while
preserving low threshold mechanical responses. Drugs targeted against these
receptors then, may prove to have novel unique profiles of effectiveness against the
neuropathic pain states (hyperalgesia and cold allodynia) which develop following
nerve damage or injury.
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Chapter 6 - The Effects of Ionophoretically-Applied
VIP/PACAP Receptor Agonists on Dorsal Horn Neurones in
Normal and Neuropathic Animals
6.1 Aim
The aim of this study was to demonstrate the presence of VIP!, VIP2 and
PACAP receptors within the dorsal spinal cord and to try to define any changes in
responsiveness of dorsal horn neurones mediated by the three receptor subtypes in
neuropathic, compared to normal rats. Electrophysiological studies were performed
using novel selective agonists for the three receptor subtypes in control animals, and




Recordings were made from a total of 17 animals in this study (as in section
3.2.1).
6.2.2 Surgical Preparation of Animals with an Experimental Peripheral
Mononeuropathy
The 8 neuropathic animals used in this study underwent a chronic constriction
injury (CCI) as outlined in section 3.2.2. Only nerve-injured animals which showed
strong signs of mechanical hyperalgesia in response to noxious pin-prick (Grade 3
response), cold allodynia (SPET of 8 sec or more) and mechanical allodynia
(significantly reduced paw withdrawal threshold to von Frey filaments) were used for




Regarding surgical procedures, electrophysiological recording techniques,
histological identification of recording sites and identification of neuronal receptive
fields, please refer to section 4.2.
6.2.4 Drugs for Ionophoresis
All drug solutions were 0.5mM in distilled water and pH adjusted to 4.5 with
HC1:
VIPj receptor agonist: [Argl6] chicken secretin (Gourlet et al. 1997a)
VIP2 receptor agonist: [Ac-His1, Glu8, Lys12, Nle17, Ala19] VIP(l-24), Asp, Leu, Lys,
Lys, Gly, Gly, Thr NH2 (lactam 21-25): Ro 25-1553 (Gourlet et al. 1997b)
PACAP (and VIP) receptor agonist: PACAP-38 (Kimura et al. 1990)
All agonists were ejected using positive currents and a retention current of
-12nA was applied to each barrel when not in use. The resistance of the side barrels
was monitored regularly.
The agonists were ionophoresed at increasing currents from a starting current
of 30nA and increasing to 45 and 60nA if necessary at 90 second intervals, until
activation was achieved. A recovery period of at least 10 minutes was generally
allowed before application of the next agonist, and the order of agonist testing was
randomly varied fore each neurone. The percentage of dorsal horn neurones
activated was then calculated for each receptor agonist.
6.2.5 Analysis of Results
Individual recordings were made for each neurone. The excitatory effect of
the agonists was assessed by comparing the mean firing level in the 30 sec period
encompassing the greatest activation, to the mean basal activity in the 30 sec period
immediately prior to agonist administration. Activation was characterised as a
significant increase in firing rate (paired Student's f-test: p < 0.05) from basal levels,
which then returned to pre-drug levels following termination of peptide ionophoresis.
The mean fold increase in firing rate of the activated cells was then calculated for
each agonist. Statistically significant differences in the fold increase, between
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neuropathic and normal animals, for each receptor agonist, were determined by the
Mann Whitney U test (* p < 0.05).
6.3 Results
6.3.1 Characterisation of Neurones
A total of 42 multireceptive neurones was tested in 9 control animals. Results
in the neuropathic model were based on data obtained from 25 multireceptive
neurones from 8 neuropathic animals. No non-nociceptive cells were examined in
this study. All neurones displayed a low basal firing rate of 0-1 Hz, and current
control tests had no detectable effect on any of the neurones tested. In the vast
majority of cases, the cells were tested with all three receptor agonists, with currents
ranging from 30-65nA. The order of agonist testing was varied for each individual
neurone. The vast majority of neurones were found within laminae III-V of the dorsal
horn (corresponding to microdrive electrode depth readings of 200-1000pm from the
spinal cord surface).
6.3.2 Effects of Ionophoretic Application of Selective VIPi, VIP2 and PACAP
Receptor Agonists in Normal and CCI Animals
Excitation of the dorsal horn neurones was observed as the initiation of firing
of a previously quiescent cell or as a significant increase in basal firing rates. The
majority of cells that were activated responded within 3 minutes of agonist
application but occasionally up to 8 minutes was needed to see a response.
In normal animals, approximately one third of the neurones tested (38%)
could not be activated by any of the three receptor agonists. Of the remaining cells,
[Arg16] chicken secretin (the VIP, receptor agonist), Ro 25-1553 (the VIP2 receptor
agonist), and PACAP-38 were all found to have excitatory effects (see Figure 6.1),
although on different proportions of neurones and to different extents. [Arg16]
chicken secretin, activated 34% of the total number of neurones tested with a mean
14-fold increase in cell activity, while Ro 25-1553 had a less marked effect,
activating only 21% of neurones with an average 4-fold increase in firing. PACAP-
38 had a much more marked effect, activating 58% of all dorsal horn neurones tested.
Those neurones activated showed an approximate 22-fold increase in firing, often
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with extremely long-lasting effects, with excitation often continuing for several
minutes after application of the agonist was terminated.
In CCI animals (similar to results in controls) a subpopulation of all neurones
tested (28%) could not be activated by application of any of the three agonists.
However the proportions of cells activated by [Arg16] chicken secretin and Ro 25-
1553 were seen to change quite markedly. The number of dorsal horn neurones
activated by [Arg16] chicken secretin decreased slightly from 34% to 20%, while Ro
25-1553 was now seen to excite 44% of cells, double that seen in normal animals.
These changes in the effectiveness of the selective receptor agonists, may reflect
changes in the expression of the VIPj and VIP2 receptors in the spinal dorsal hom
following a neuropathic injury, or in factors able to modulate their cellular influence.
As well as the changes in the proportion of cells activated by each of the receptor
agonists, there were also notable changes in the course of activation for [Arg16]
chicken secretin and Ro 25-1553 (see Figure 6.2). Excitation caused by [Arg16]
chicken secretin in the neuropathic animals, was generally longer lasting,
sometimes taking several minutes for the firing to return to control levels compared
with the almost instantaneous recovery following activation of normal dorsal horn
neurones. Ro 25-1553 also had a much more marked effect on dorsal horn neurones
following neuropathy. The activation of the neurones often could not be stabilised
due to the agonists pronounced excitatory effects (now showing an average 21-fold
increase in activity compared to 4-fold at equivalent currents in normal control
animals).
In comparison, the number of cells excited by PACAP-38 remained relatively
unchanged at 61% (58% in controls), implying that expression of the PACAP
receptor may not be significantly altered in neuropathic conditions. Similarly, those
neurones activated showed an average 18-fold increase in firing (compared to the 22-
fold increase seen in normals), and the course of activation by PACAP-38 also
remained the same, with a number of the cells again being activated in a prolonged
fashion.
Table 6.1 shows a direct comparison of the effects of the selective
VIP/PACAP receptor subtype agonists on dorsal horn neurones in normal versus
neuropathic animals.
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In both normal and CCI animals, the vast majority of dorsal horn neurones
were tested with all three receptor agonists, and the combinations of effective
agonist-induced activation appeared to vary from one cell to the next. A small
percentage of the neurones could be activated by all three receptor agonists, while
others were activated by VIP! and VIP2 receptor agonists only, VIP, and PACAP
receptor agonists or VIP2 and PACAP receptor agonists. This suggests that rat dorsal
horn neurones may co-express the different receptor subtypes. Indeed, none of the
cells tested appeared to be solely activated by either the VIP, or VIP2 receptor
agonists only, yet a small proportion of neurones were activated solely by PACAP-
38. However, as this agonist has a high affinity for the VIP, and VIP2 receptors, as
well as the PACAP receptor, there could still be co-expression of VIP/PACAP
receptor subtypes on these neurones.
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Figure 6.1
Effects of ionophoretically-applied VIP/PACAP receptor agonists on spinal
dorsal horn neurones in normal animals
Records of ongoing firing of individual neurones are displayed as number of action
potentials per second (A/s), integrated over 1000msec bins, plotted against time.
Parts (a) to (c) show the typical excitatory effects observed following ionophoretic
application of the selective receptor agonists on multireceptive dorsal horn neurones
in normal animals. Part (a) shows the typical neuronal response to application of the
selective VIP] receptor agonist ([Arg16] chicken secretin). Part (b) shows the
commonly-observed effect of the VIP2 receptor agonist (Ro 25-1553), which is
small but significantly different to pre-drug values (p < 0.05; paired Student Z-test),


















Effects of ionophoretically-applied VIP/PACAP receptor agonists on spinal
dorsal horn neurones in CCI animals
Records of ongoing firing of individual neurones are displayed as number of action
potentials per second (A/s), integrated over 1000msec bins, plotted against time.
Parts (a) to (c) show the typical excitatory effects observed following ionophoretic
application of the selective VIP! ([Arg16] chicken secretin), VIP2 (Ro 25-1553) and
PACAP (PACAP-38) receptor agonists respectively, on multireceptive dorsal hom
neurones in animals which have undergone a sciatic nerve constriction injury 2-3
weeks previously. Note the marked excitatory effect ofRo 25-1553 (Part (b)) which
is significantly greater than the response observed in normal animals (p < 0.05;
Mann Whitney U-test). In contrast, the typical PACAP-38 mediated response is very
similar to that observed in the normal animals, with a large proportion of the

















Summary table showing the overall effects of the selective VIPl5 VIP2 and
PACAP receptor agonists in the rat spinal dorsal horn
Summary table showing the percentage of dorsal hom neurones activated by [Arg16]
chicken secretin, Ro 25-1553 and PACAP-38 in the spinal cord of control animals
(n=9) compared to CCI animals (n=8).
Also shown is the mean fold increase in neuronal firing rate following cell activation
by each agonist. Statistically significant differences between normal and neuropathic
animals were determined by the Mann Whitney U test (* p < 0.05).
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Receptor Agonist
[Arg16] chicken Ro 25-1553 PACAP-38
secretin (VIPi) (VIP2) (PACAP)
Proportion of dorsal Control 34% (14/41) 21% (8/38) 58% (11/19)
horn neurones
activated Neuropathic 20% (5/25) 44% (11/25) 61% (11/18)
fold increase in Control 13 ± 4 4 ±1 21 ±6
firing rate of
activated cells Neuropathic 8 ± 3 *20 ±7 17 ± 3
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6.4 Discussion
VIP and the two alternatively processed forms of the PACAP precursor
(PACAP-27 and PACAP-38) are recognised by a family of three G-protein-coupled
receptors (Harmar and Lutz, 1994), namely the PACAP receptor, which displays a
much greater affinity for the two forms of PACAP than for VIP (Shivers et al. 1991;
Hashimoto et al. 1993), and the VIP! (Ishihara et al. 1992) and VIP2 (Lutz et al.
1993) receptors which display no marked selectivity for any one of the peptide
ligands. It has been shown that these receptors have distinct distributions throughout
both the peripheral and central nervous systems (Cauvin et al. 1991; Usdin et al.
1994), suggesting specific functional roles for each of the three receptor subtypes.
Using newly-developed, selective agonists for the three receptors, we
investigated the responsiveness ofmultireceptive rat dorsal horn neurones in both
normal and neuropathic animals, to try to elucidate any changes in receptor
sensitivity before and after peripheral nerve damage.
The potential for VIP to act as a neurotransmitter has been shown on
numerous occasions. Direct application of this peptide onto a variety of cells of the
CNS (by ionophoresis or perfusion), has demonstrated an excitatory effect of VIP.
Such cells include dorsal horn neurones (Jeftinija et al. 1982), cerebral cortex
neurones (Murphy et al. 1993; Phillis et al. 1998) and neurones in the trigeminal
nucleus caudalis (Salt and Hill, 1981). In addition, PACAP-38 has since been
reported to cause a prominent increase in neuronal discharge of a number of
sympathetic preganglionic neurones (SPN), during in vitro whole-cell recordings
(Lai et al. 1997). In agreement with these original studies we have found both VIP
and PACAP to be effective excitants of dorsal horn neurones.
Despite the relatively low abundance ofVIP and PACAP in the spinal cord
and DRG under normal conditions (Mulder et al. 1994; Noguchi et al. 1993), the
present results provide clear evidence for the presence ofVIP/PACAP receptor
subtypes on dorsal horn neurones in normal rats. In addition we have shown
differential responses to application of the selective agonists used for each of the
receptor subtypes.
In normal animals, all three agonists showed excitatory effects to some
degree. PACAP-38 appeared to be the most effective excitant, activating
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approximately 60% of the dorsal hom neurones tested, when used at the same
concentration and similar ionophoretic currents as the other receptor agonists. In the
majority of cases, PACAP was also found to have a longer duration of action than
[Arg16] chicken secretin or Ro 25-1553, lasting for up to 20 minutes in some cases,
despite terminating application of the agonist. This prolonged action of PACAP-38
may suggest a longer term regulatory role for PACAP, and is consistent with the idea
that PACAP maybe involved in some aspects of the sensitisation of central sensory
neurones. Therefore the PACAP receptor may be an important target for attenuating
the development of the long-lasting pain states which ensue from nerve damage or
injury.
The total population of neurones activated by PACAP-38 remained relatively
unchanged in neuropathic animals as compared to normal, that is approximately two-
thirds of the dorsal hom neurones tested. Similarly the degree of cell activation
remained the same, suggesting that the expression of the PACAP receptor may not be
markedly altered following nerve injury, despite the dramatic up-regulation of the
peptide in sensory neurones and nerve fibres (Zhang et al. 1996; Zhang Q et al.
1995). However, since PACAP-38 is a potent agonist for all three receptor subtypes
(Kimura et al. 1990), it cannot be concluded with certainty that its excitatory effects
are solely PACAP-receptor-mediated, VIP! and VIP2 receptor influences may well
also contribute to the effects observed. Nevertheless, the effects of PACAP-38 were
again, often much more pronounced than those of the VIP! and VIP2 receptor
agonists.
This long-lasting effect of PACAP-38 has similarly been reported during in
vitro whole-cell SPN recordings, where PACAP-38 caused a prominent increase in
neuronal discharge of a number of SPN, lasting over 1 hour in some neurones (Lai et
al. 1997). Interestingly, it has been shown that PACAP-38 is much more resistant to
degradation by neutral endopeptidases than VIP (Gourlet et al. 1997d). This could
explain the longer duration excitation seen with PACAP-38 (as opposed to the effects
of the VIPi and VIP2 agonists), and would be consistent with a longer term
modulatory role of PACAP in vivo.
The most notable difference in this agonist study was the doubling in the
percentage of dorsal hom neurones activated by the selective VIP2 receptor agonist
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Ro-25 1553 in CCI compared to normal animals. Only one fifth of the neurones
tested were activated by Ro-25 1553 in normal animals, with a 4 fold increase in
firing from pre-drug levels. In contrast, more than 40% were activated in nerve-
injured animals, and the degree of activation was significantly higher than that
observed in normal animals. These results suggest that the expression of the VIP2
receptor may well be up-regulated in the spinal dorsal horn following nerve injury.
In contrast, the proportion of dorsal horn neurones activated by the VIP!
receptor agonist [Arg16] chicken secretin was seen to decrease in the neuropathic
compared to normal animals, suggesting that the expression of the VIP! receptor may
be decreased following a CCI. The fold increase in the firing rate of activated cells
was also seen to decrease, but this may simply be a direct result of a decrease in VIPi
receptor expression. It is not clear why a small proportion of the cells appeared to
have a longer-term activation following application of the VIP! agonist in CCI
animals, it may be that the agonist has a slight cross-over action at the VIP2 receptor,
or it may be that the VIP degradation process is somehow delayed due to the marked
upregulation of a number of different growth factors in the spinal cord following
peripheral nerve injury, which would enable a longer-term activation of the receptors
compared to normal conditions.
The differences in the proportions of neurones activated by the three receptor
agonists, both in normal and neuropathic animals, implies that the expression of
receptor subtypes is non-uniform throughout the cord, and that individual neurones
may each express their own combination of receptor subtypes. Indeed,
approximately 30% of the total number of dorsal horn neurones tested, in both
neuropathic and normal animals, could not be activated by any of the three receptor
agonists, suggesting that some dorsal hom neurones do not express the VIP/PACAP
receptors at all. On the other hand, other neurones appeared to be responsive to all
three agonists, which may indicate the expression of VIPi, VIP2 and PACAP
receptors. It is not clear whether PACAP or VIP receptors mediate dual regulation of
individual cells. Facilitatory or synergistic properties were not addressed in this
study due to the relatively high currents which would be required for ionophoresis of
two agonists simultaneously. It must be noted that this is a general overview of the
responses of dorsal horn neurones, and may not necessarily be a direct representation
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of the topography of receptor expression within the dorsal horn. The efficiency of
electrophoretic transport out of the electrodes is likely to differ for the three receptor
agonists, and as stated previously there may well be differences in the enzymatic
degradation processes for the three agonists, so care must be taken when making
comparisons.
However, in previous studies, the effects of the antagonists [p-Cl-D-
Phe6,Leu17]-VIP and PACAP (6-38) were assessed on a number of dorsal horn
neurones activated by porcine VIP (n=6) or PACAP-38 (n=5), to try and ascertain the
specificity of these receptor agonists. This study revealed that [p-Cl-D-Phe6,Leu17]-
VIP, but not PACAP (6-38), significantly inhibited VIP-induced neuronal firing by
approximately 50%, while PACAP (6-38) selectively inhibited PACAP-38-induced
activity by an average 30% (Dickinson et al. 1997). Unfortunately, time did not
allow the repetition of these agonist/antagonist experiments on the novel selective
VIP,/VIP2 receptor agonists.
In conclusion, VIPi, VIP2 and PACAP receptor agonists all have marked
excitatory effects on multireceptive dorsal horn neurones, in both normal and
neuropathic animals. The altered responsiveness of these neurones to the VIPj and
VIP2 receptor selective agonists following CCI, suggests that the spinal expression of
these proteins may be altered following peripheral nerve injury. These data suggest
that VIP2 receptor expression increases following nerve injury, while expression of
the VIP! receptor decreases. This altered expression of the receptor subtypes may
contribute significantly to the modification of sensory processing that ensue in the
dorsal horn following neuropathy, and in the pain states which subsequently
develop.
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Chapter 7 Differential Expression of VIP„ VIP2 and
PACAP Receptor mRNA after Peripheral Nerve Injury - an In
Situ Hybridisation Study
7.1 Aim
The object of these experiments was to evaluate any changes in the
distribution of VIP!, VIP2 and PACAP receptor mRNA expression within the rat
spinal cord following a peripheral mononeuropathy, using in situ hybridisation
histochemistry (ISHH). Oligonucleotide probes, targeted at specific sequences of
mRNA for the three receptor subtypes, were used to determine the distribution of




4 rats with unilateral hindlimb CCI were prepared as outlined in section 3.2.2.
Control samples were taken from 3 untreated male rats (see Section 3.2.1).
7.2.2 Tissue Removal and Sectioning
Details of all reagents can be found in Chapter 2, sections 2.1 and 2.5-2.9. A
section of spinal cord, incorporating segments L2-L4, was removed from animals
deeply anaesthetised with fluothane, using sterile surgical instruments. One sample
was taken from each rat and then the animal was immediately killed by
exsanguination. The spinal cord section was mounted vertically (rostral end down)
on to a labelled, autoclaved metal chuck using Cryo-M-Bed embedding medium, and
then rapidly frozen for 3-5 minutes in isopentane which had previously been cooled
to between -40°C and -45 °C on dry ice. The frozen cord and chuck were then
wrapped in clingfilm and stored in a labelled Steriseal pot at -70°C until required for
cutting.
Transverse sections of 12pm thickness were cut using a Cryotechnics Bright
cryostat, which constantly maintained the uncut tissue and cut sections at
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approximately -18°C. A new disposable blade was fitted for each new segment and
cleaned regularly with ethanol to prevent ribonuclease (RNase) contamination of the
tissue. Sections were thaw-mounted onto clean, poly-L-lysine coated glass slides,
with each slide holding 10-12 sections.
At regular intervals (approximately 350pm) one or two sections were cut for
histological examination under the light microscope, to verify tissue integrity and
orientation. These sections were fixed in 10% formal saline for 5 minutes, stained
with haematoxylin and eosin, dehydrated through increasing concentrations of
ethanol, then mounted in DePeX mounting medium under a coverslip and retained
for future histological reference.
In addition, two brains were obtained from untreated male rats, which were
sacrificed by rapid decapitation following initial anaesthesia with fluothane. Brains
were mounted transversely on the cerebellum/brainstem on autoclaved metal chucks
using Cryo-M-Bed embedding medium, and then rapidly frozen for 5 minutes in
previously cooled isopentane (as with the spinal cord sections). Tissue was sectioned
coronally according to stereotaxic areas as defined by Paxinos and Watson (1986), at
12pm thickness on a cryostat, using the same method as outlined above for spinal
cord tissue, but with two brain sections thaw-mounted per slide. Sections were taken
which included brain regions ofparticular interest, including the dentate gyms and
hippocampus, areas found to contain high concentrations of PACAP-ir (Cauvin et al.
1991; Masuo et al. 1991; 1992).
All material was maintained at -18°C in the cryostat during the cutting
session, and thereafter was stored in sealed Kartell boxes with dessicant at -70°C
until required for hybridisation.
7.2.3 Oligonucleotide Probes
Oligonucleotide probes for VIPi, VIP2 and PACAP receptor mRNA were
synthesised and HPLC purified by Oswel Chemicals. Each probe was dissolved in
approximately 1ml of sterile water, at a given concentration (pg/ml). The specificity
of each probe was confirmed by homology screening of Genobase/EMBL sequences.
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One 48mer VIP! receptor oligonucleotide probe was used, complementary to
bases 1289-1336 of the rat VIP! receptor mRNA sequence (Ishihara et al. 1992). See
Figure 7.1(a). The given concentration of this probe was 389pg/ml.
Two VIP2 receptor probes were used (Figure 7.1(b)). A 47mer and a 44mer
oligonucleotide complementary to nucleotides 163-209 and 1346-1389 of the rat
VIP2 receptor mRNA sequence respectively (Lutz et al. 1993).
Finally, to allow for increased sensitivity, a mix of five probes (was required
for detection of PACAP receptor mRNA (Hosoya et al. 1993). These probes were
49, 45, 45, 42 and 48 bases long and were complementary to nucleotides 167-215,
544-588, 767-811, 1034-1075 and 1481-1528 respectively (See Figure 7.1 (c)).
162
Figure 7.1(a)
Amino Acid Sequence of Rat VIPj Receptor mRNA
DNA sequence (in black: bases 1151-1438) of rat VIP] receptor mRNA (Ishihara et
al. 1992) showing the sequence (in red) chosen for the VIP] receptor antisense
oligonucleotide probe. This complementary base probe is highly selective for rat
VIP] receptor mRNA as determined by Genobase/EMBL screening.
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1151 AACTTCAAGG CCCAGGTGAA AATGGTCTTC GAACTTGTCG TGGGCTCTTT
CCAGGGTTTC GTGGTGGCCA TCCTCTACTG CTTCCTCAAT GGTGAGGTGC
AGGCGGAGCT GCGGCGGAAG TGGCGGCGTT GGCATCTGCA GGGCGTCCTG
GT CCCGCAGGAC
GGCTGGAGCT CCAAATCCCA GCATCCGTGG GGAGGCAGCA ACGGCGCCAC
CCGACCTCGA GGTTTAGGGT CGTAGGCACC CCTCCG
ATGCAGCACG CAGGTATCCA TGCTGACCCG CGTCAGCCCG AGCGCACGCC
GCTCCTCCAG CTTCCAAGCG GAGGTCTCCC TGGTCTGA 1438
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Figure 7.1(b)
Amino Acid Sequence of Rat VIP2 Receptor mRNA
DNA sequence (in black: bases 91-310 and 1292-1480) of rat VIP2 receptor mRNA
(Lutz et al. 1993) showing the sequences (in red) chosen for the two VIP2 antisense
oligonucleotide probes. These complementary base probes are highly selective for
rat VIP2 receptor mRNA as determined by Genobase/EMBL screening.
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91 ACCGAGGCGG CACGCTGAGC CCAGGAATGAG GGCGTCGGTG GTGCTGACCT
GCTACTGCTG GTTGCTGGTG CGGGTGAGCA GCATCCACCC AGAATGCCGG
CCACTCGT CGTAGGTGGG TCTTACGGCC
TTTCATCTGG AAATACAGGA AGAGGAGACA AAATGCGCAG AGCTGCTAAG
AAAGTAGACC TTTATGTCC
CAGCCAAATG GAGAATCACA GAGCTTGCAG CGGTGTCTGG GACAACATCA
CATGCTGGCG CCCTGCAGAC 310
1291 GTGCCTGACC CAGCCTGGGA GCCGGGACTA CCGGCTGCAC AGCTGGTCCA
TGTCCCGGAA TGGCTCAGAA AGCGCCCTAC AGATACACCG TGGCTCCCGT
GCCTT ACCGAGTCTT TCGCGGGATG TCTATGTGGC ACCGAGGGC
ACCCAGTCCT TCCTGCAGTC AGAGACCTCA GTCATTTAGC TGTGTCCCTC
ATACAGAGCT GACAGTGCTG CTGGGTTTGA CATATGTGTT 1480
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Figure 7.1(c)
Amino Acid Sequence of Rat PACAP Receptor mRNA
Selected areas (bases 151-290, 501-640, 741-880, 1001-1100 and 1451-1580) of the
DNA sequence (in black) for rat PACAP receptor mRNA (Hosoya et al. 1993)
showing the sequences chosen (in red) for the five PACAP antisense oligonucleotide
probes. These complementary base probes are highly selective for rat PACAP
receptor mRNA as determined by Genobase/EMBL screening.
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151 CCTGACTGCT CTCCTGCTGC CTGTGGCTAT TGCTATGCAC TCTGACTGCA
GACG GACACCGATA ACGATACGTG AGACTGACGT
TCTTCAAGAA GGAGCAAGCC ATGTGCCTGG AGAGGATCCA GAGGGCCAAC
AGAAGTTCTT CCTCG
GACCTGATGG GACTAAACGA GTCTTCCCCA GGTTGCCCTG 290
501 CCTTCCCCCA CTACTTCGAT GCTTGTGGGT TTGATGATTA TGAGCCTGAG
CGGACTC
TCTGGAGATC AGGATTATTA CTACCTGTCG GTGAAGGCTC TCTACACAGT
AGACCTCTAG TCCTAATAAT GATGGACAGC CACTTCCG
CGGCTACAGC ACTTCCCTCG CCACCCTCAC TACTGCCATG 640
741 AGGACTGGAT CTTGTAGCGC GAGCAGGACA GCAGTCACTG CTTCGTTTCC
CTGT CGTCAGTGAC GAAGCAAAGG
ACCGTGGAGT GCAAAGCTGT CATGGTTTTC TTCCACTACT GCGTGGTGTC
TGGCACCTCA CGTTTCGACA G
CAACTACTTC TGGCTGTTCA TTGAAGGCCT GTACCTCTTT 880
1001 GATGCAGGAT GCTGGGATAT GAATGACAGC ACAGCTCTGT GGTGGGTGAT
CGAGACA CCACCCACTA
CAAAGGCCCC GTGGTTGGCT CTATAATGGT TAACTTTGTG 1090
GTTTCCGGGG CACCAACCGA GATAT
1451 TGGAGGAGCT GGAAGGTGAA CCGTTACCTC ACTATGGACT TCAAGCACCG
TGATACCTGA AGTTCGTGGC
GCACCCGTCC CTGGCCAGCA GTGGAGTAAA TGGGGGAACC CAGCTGTCCA
CGTGGGCAGG GACCGGTCGT CACCTCAT
TCCTGAGCAA GAGCAGCTCC CAGCTCCGCA 1580
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7.2.4 ISHH Detection of VIP/PACAP Receptor mRNA
ISHH steps were carried out sequentially, covering a period of four days for
each assay. Great care was taken to reduce the risk of contamination by RNases by
using sterile glassware and using dH20 treated with the nuclease inhibitor DEPC.
Recipes for all stock solutions can be found in section 2.6. Laboratory coats and
disposable gloves were worn at all times.
a) Probe labelling
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All probes were labelled with [ S]-dATP at their 3' ends using recombinant
terminal deoxynucleotidyl transferase (rTdT) to yield a specific activity of
approximately 2 x 106 cpm per lOOpl of hybridisation buffer. The following reaction
mix was incubated in a sterile Eppendorf tube at 37°C (with gentle agitation) for 1
hour: x pi of the appropriate oligonucleotide probe (calculated to ensure 3x more
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pmol [ S]-dATP than oligonucleotide), 10pl of potassium cacodylate tailing buffer
(TdT buffer), 4pl rTdT enzyme (15 units/pl), 4pl [35S]-dATP (70pmol; 1-1.3 x 103
Ci/mmol) and enough DEPC H20 to give a final volume of 48pl. Prior to incubation
the mixture was vortexed briefly then spun down (13 OOOg, 2-3 sees).
Following the initial incubation period, a further 2pl of [35S]-dATP and 2pl
of rTdT enzyme were added to the reaction mixture to optimise conditions. Again
the mixture was vortexed briefly then spun down (13 OOOg, 2-3 sees), before
continuing the incubation for another hour at 37°C (with gentle agitation). The
reaction was stopped by cooling on ice for 15 minutes.
At this time, 2 x lpl pre-spun samples were removed and placed on to fibre-
free filter paper in sterile Eppendorf tubes. 1ml of Optiphase scintillation cocktail
was added to each sample for scintillation counting. The radiolabeled
oligonucleotide probe was then separated from unincorporated nucleotides, by
purification through a Nu-Clean D25 disposable spun column. Each sample was
carefully pipetted on to the gel surface of individual columns, and then centrifuged
for 4 minutes at 3 500g, with the labelled sample being collected in a fresh
Eppendorf tube. 2 x lp.1 post-spun samples were then taken as before and 1ml of
Optiphase scintillation cocktail added to each sample for scintillation counting.
Counts per minute (cpm) were read using a 1450 Microbeta plus scintillation counter
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(Wallac, Finland) with customised software (Department of Veterinary Pathology,
niversity of Edinburgh). The difference between the pre- and post-spun samples
allowed the percentage incorporation of the radiolabel to be estimated (all probes
showed between 50-60% incorporation). The labelled probe was then stored at
-70°C until required (for a maximum of 14 days).
b) Post-fixing
Slides were brought to room temperature and immediately fixed in 4%
paraformaldehyde in PBS (0.1M; pH 7.4) for 10 minutes, then rinsed in two washes
of fresh PBS (0.1M; pH 7.4) of 5 minutes each. Non-specific binding of the probe to
the glass and tissue was reduced by treating the slides for 10 minutes in ethanolamine
solution (0.1M TEA and 0.026M acetic anhydride). Subsequently the sections were
dehydrated through increasing concentrations of ethanol (50%, 70%, 80%, 90% and
100%) each buffered with ammonium acetate (0.3M) for 2 minutes each, with a final
2 minute stage in 100% unbuffered ethanol. After blotting the slides, they were then
dried thoroughly with a hairdryer on cold setting for 1-2 hours.
c) Hybridisation
Previously-prepared stock solutions of hybridisation buffer and de-ionised
formamide (see section 2.6) were brought to room temperature then aliquoted
together to obtain a lx hybridisation buffer/40% de-ionised formamide solution:
dextran sulphate (10%; wt:vol), sodium chloride (600mM), Tris pH 7.6 (lOmM),
EDTA(lmM), Denhardt's solution (0.1% ; wt:vol), salmon sperm DNA (0.01%;
wt:vol), Bakers yeast tRNA (0.005%; wt:vol) glycogen (0.0005%; wt:vol) and
formamide (40%; wt:vol).
The radiolabeled probes were then added in a relative volume to give a final
count number of 2 x 106 cpm/lOOpl hybridisation buffer (the optimum concentration
of probe used was ascertained after carrying out a number of experiments with a
range of conditions, to establish which gave the clearest signal to background ratio).
The resulting hybridisation mixture was heated to 60-70°C for 10 minutes, to break
any hydrogen bonds, then subsequently cooled on ice for 1 minute before adding the
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reducing agent dithiothreitol (DTT; lOmM). This helped to protect the[ 35S]-dATP
from oxidation and ensured that the probe remained in a single stranded state even
after the solution had been cooled. lOOpl of this final solution was then carefully
pipetted along the bottom edge of each slide and a DEPC-treated coverslip lowered
gently onto the solution so that surface tension enabled the probe mixture to cover all
the sections.
Hybridisation was carried out in sealed containers containing 2 sheets of
Whatman (No. 1) filter paper saturated with a solution of 50% de-ionised formamide:
50% 4x SSC solution, at 37°C for 18 hours.
d) Post-hybridisation washes
Following the overnight incubation, the coverslips were removed and racks of
slides were washed in decreasing concentrations of SSC solutions (2xSSC; lxSSC;
0.5xSSC; pH 7) at 40°C for 2 hours each, to remove any excess hybridisation buffer
solution and any non-specifically bound probe. The slides were then blotted with
fibre-free paper and dehydrated through ascending concentrations of ethanol buffered
with 0.3M ammonium acetate (50%, 70%, 80%, 90%, 100%) for 2 minutes each and
lastly 100% absolute ethanol for 2 minutes, before being left to air dry overnight.
The following day, the slides were apposed to Hyperfilm P-max in a dark
room and left to develop in a sealed autoradiographic cassette with intensifying
screen for approximately 10 days at 4°C. The film was then developed using a
standard X-ray Film developing machine (Small Animal Clinic, Summerhall,
Edinburgh). The intensity of the latent image gave an insight as to how long to
appose the slides to autoradiographic emulsion, before developing.
e) Emulsion coating
Under darkroom conditions, the dried slides were dipped in 20ml of Ilford K5
liquid autoradiographic emulsion at 43 °C for approximately 5 seconds, blotted
lightly then left to dry in an upright position overnight, in the dark, before being
sealed in light-tight Kartell boxes containing silica gel desiccant, wrapped in black
plastic and stored at 4°C for 6-12 weeks, depending on the intensity of the
autoradiographic image developed previously.
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f) Developing and staining
Following the assigned exposure time (6 weeks for the VIP2 probes and 12
weeks for the VIP! and PACAP probes), the slides were brought to room
temperature, and the exposed silver grains were developed at 15°C in Kodak D-19
developer for 4 minutes, rinsed in distilled water for 30sec, then fixed in Ilford
Hypam K5 fixer (diluted 1:5 (vokvol) with distilled water) for 5 minutes. The
developed slides were then rinsed in copious amounts of distilled water (4x 10
minute washes) to remove all traces of the fixer . The slides were lightly counter-
stained with Mayer's haematoxylin (4 minutes) and 5% eosin (2-3secs), with distilled
water washes in between each stain, before being dehydrated through 50%, 70%,
90% and 100% ethanol (2 minutes each). The slides were then placed in fresh xylene
solution (2 minutes) and finally mounted in DePeX mounting medium.
7.2.5 Controls
Data for each rat were obtained from a number ofparallel assays to minimise
experimental variation, and hybridisation using coronal brain sections acted as
positive controls to verify the sensitivity of the ISHH methodology. In addition,
control experiments for the specificity of hybridisation were carried out in parallel, as
follows:
(a) RNase Control
In order to destroy all RNA in the cut spinal cord sections, 100pl ofRNaseA
solution (lmg/ml in PBS) was pipetted along the bottom edge of 3 slides and a
DEPC-treated coverslip lowered gently onto the solution so that surface tension
enabled the mixture to cover all the sections. The slides were then incubated at 37°C
for one hour, in boxes humidified with PBS. Following the incubation period, the
coverslips were carefully removed and the slides washed in 2x DEPC H20 for five
minutes each, before being blotted dry and then hybridised as normal with
radiolabeled probe. To reduce the risks of contamination however, the remaining
steps were carried out in Kartell and hybridisation boxes which were always kept
separate from the rest of the assay.
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(b) "Cold" Probe Controls
Radiolabeled probe for each receptor was mixed with a 10-fold Molar excess
of corresponding "cold" unlabelled probe, and the amount of hybridisation buffer
adjusted accordingly for each resulting hybridisation solution. The rest of the assay
was then continued as normal.
7.2.6 Analysis of Results
(a) Cell Counts
Positively-labelled cells were counted under the light microscope at x 40
magnification using a Whipple grid graticule (total area 30 625pm 2). Cells were
considered to be positively-labelled if the silver grains showed a dense pattern over
and around the cell nucleus, and if this pattern was obviously more dense than the
background silver grain expression.
Cell counts were carried out in two separate regions of the spinal dorsal horn,
namely the lateral edge of lamina II and the lateral edge of laminae III/IV. Counts
were made for each side of the neuropathic spinal cord sections (i.e. ipsilateral and
contralateral to the nerve injury), while for normal control tissue, counts were taken
randomly from either side of each section.
Raw data were collected as the number of VIP]/VIP2/PACAP receptor
mRNA expressing cells on the ipsilateral (experimental) side versus the number on
the corresponding contralateral (control) side for each section. In addition,
contralateral and normal control values were also compared. At least four spinal cord
sections per slide were counted, with one slide taken from each of 4 neuropathic or 3
control animals. Mean cell counts per animal were then calculated for each area of
analysis (i.e. lamina II or III/IV) for ipsilateral and contralateral neuropathic, and
control dorsal horn.
(b) Silver Grain Density
The silver grain density of the total area over and around the nucleus of each
positively-labelled cell, was measured using Image 1.49 software from Improvision,
on an Apple Macintosh computer. Silver grain measurements were taken from
positively-labelled cells in the lateral edges of lamina II and laminae III/IV. This
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area value, referred to as the silver grain density ((am2 per cell) reflected the degree
ofVIPj/VnyPACAP receptor mRNA expression.
Again, counts were made from the ipsilateral and contralateral sides of the
neuropathic spinal cord sections, and from normal control tissue. The same sections
used for the cell count measurements were correspondingly used in the silver grain
density analysis. Analysis was carried out by firstly capturing one image field in the
appropriate laminar area, using a CCD video camera (Sony, Japan) mounted on a
Zeiss Axioscope Microscope (x 40 magnification), with a Hamamatsu C2400 CCD
camera control. Each image was blank field adjusted to remove any artefacts present
within the camera set-up. The region of interest (ROI) was standardised for lamina II
and laminae III/IV measurements, as a circle with the average diameter of the dorsal
horn neurone nuclei in the area of interest. The density threshold was then selected
by determining the grey scale range which highlighted all silver grain particles,
including a small proportion of those seen as background expression (this threshold
fluctuated very little throughout each analysis session). Values were taken as pixel
counts and then converted to silver grain measurements by calculating the mean
number ofpixel grains per silver grain, in each area of analysis. Silver grain density
measurements were taken from 10 lamina II neurones and 6 large laminae III/IV
neurones. In all cases, the most highly-expressing cells in each area were utilised.
In addition, control background densities were measured from a non-
expressing cell within each area of analysis. These values were always
approximately one-fifth or less of the density values for positive cells.
Results were entered into a spreadsheet for statistical analysis, and the mean
number of silver grains per positively-labelled cell per section calculated.
Background values were subtracted from the total count values to give the net density
of expression per lamina II or laminae III/IV positively-labelled neurone. Finally,
the mean silver grain density of expressing cells per animal was calculated.
7.2.7 Statistics
Data are presented as the mean ± SEM for neuropathic (n=4) or control (n=3)
animals. Group means were analysed using the Jandell Scientific Sigmastat
program, and the data was tested for normal distribution. A two-tailed pairwise
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comparison t-test was used to determine ipsilateral versus contralateral differences in
the number of expressing cells as well as in the density of silver grains per
positively-labelled cell. The unpaired student r-test was used to test the significance
of contralateral versus control animal values. P < 0.05 was considered significantly
different.
7.3 Results
7.3.1 Distribution of VIPj, VIP2 and PACAP Receptor mRNA Expression
within the Normal Spinal Dorsal Horn
ISHH, using oligonucleotide probes complementary to specific areas of VIP!,
VIP2 and PACAP receptor mRNA, revealed that the basal expression ofmRNA for
all three receptors was differentially distributed throughout the spinal cord of normal
animals (See Figure 7.2).
The mRNA for the VIP] receptor appeared to show the most widespread
basal expression in the dorsal horn of normal animals, particularly in lamina II where
the average cell count for positively-labelled cells was 36 ± 5, compared to mean cell
counts of 8 ± 1 and 9 ± 3 for VIP2 and PACAP receptor mRNA respectively (See
Table 7.1 for raw data). However, in terms of hybridisation per cell (represented by
silver grain density per cell), VIP] receptor mRNA expression appeared to be greater
than that seen in the more superficial laminae, with an increased average silver grain
density of 22 ± 1 compared to 10 ± 1 in lamina II. Again, in laminae III/IV the
expression of mRNA for the VIP! receptor was higher than that seen for VIP2 and
PACAP receptors, with respect to both mean number ofpositively labelled cells (13
± 1 compared to 8 ± 1 and 6 ± 1 respectively) and average silver grain density (22 ±
1 compared to 15 ± 2 or 13 ± 4).
As mentioned, in contrast to VIPt receptor mRNA expression, there appeared
to be very few VIP2 positively-labelled neurones in lamma II of the lumbar spinal
dorsal horn. The average silver grain density for those which were apparently
expressing was only 4 ± 1, not quite 5-times the level of background silver grain
expression, the criteria set for identifying positively-labelled cells. From these data
then it would seem there is normally very little, if any VIP2 receptor expression in
lamina II. In contrast, the density of silver grain expression in laminae III/IV was
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much higher (average 15 + 2), suggesting that there may be differential expression of
VIP2 receptor mRNA in the deeper laminae of the normal spinal dorsal horn, but as
stated previously, the number of positively-expressing cells was still slightly less
than that seen for VIP!.
The overall density of silver grain deposition appeared to be very low for the
PACAP receptor mRNA. This low level of silver grain expression made it very
difficult to distinguish expressing, from non-expressing neurones within the spinal
cord. Similar to the VIP2 receptor expression, there were very few PACAP receptor
expressing neurones within lamina II of the dorsal horn, and those which did appear
to be positively-labelled displayed a very low silver grain density (mean 7 ± 1),
indicative of a low level of expression. The density of expression in laminae III/IV
was slightly higher (average 13 + 4), but there was also a greater degree of variability
within the values.
7.3.2 Distribution of mRNA for VIPj, VIP2 and PACAP Receptors within the
Spinal Dorsal Horn of CCI Animals
The expression of VIP!, VIP2 and PACAP receptor mRNA appeared to be
differentially regulated after peripheral nerve injury. Following CCI of the rat sciatic
nerve, there are visibly obvious changes in the expression of mRNA for VIP/PACAP
receptor subtypes, in the dorsal hom ipsilateral to nerve injury, as revealed by ISHH.
When compared to control and contralateral values, the number ofneurones
expressing mRNA for the VIPi receptor appeared to decrease in the ipsilateral dorsal
horn following CCI. These decreases were significantly different (p < 0.05) in the
lateral edges of laminae III/IV (Figure 7.3(a)) with a decrease in the average cell
count from 15 ± 1 to 12 ± 1 (contralateral) or 13 ± 1 (control value). The expression
of VIP i receptor mRNA, represented by silver grain deposition, also appeared to
show a decrease (25 ± 2 to 19 ± 1: contralateral versus ipsilateral values). Although
there was no significant difference between the contralateral and control values for
either cell counts or silver grain densities (two-tailed unpaired student /-test: P <
0.05), the overall expression of silver grains, including background expression, was
slightly higher in the neuropathic sections. In contrast, the ipsilateral cell count and
silver grain density values in lamina II remained not detectably changed from either
176
control or contralateral values (Figure 7.4(a)), that is a large proportion of lamina II
neurones still appeared to be expressing mRNA for the VIP] receptor.
On the other hand, the number of cells expressing mRNA for the VIP2
receptor, markedly increased in laminae III/IV, in the same lateral edges where the
expression of VIP] receptor mRNA was seen to decrease (Figure 7.3(b)). This
significant increase was highly consistent for both cell counts and absolute silver
grain counts. The average number of positively-expressing cells within the area of
analysis increased in the ipsilateral spinal cord to a value of 11 ± 1 from a
contralateral value of 7 ± 1 cells per 30 625 pm 2. Similarly, the average silver grain
density increased markedly from a contralateral value of 16 ± 2 to 25 ± 1 in the
ipsilateral dorsal horn. As with the VIP] receptor, there were no apparent changes in
the expression ofmRNA for the VIP2 receptor in lamina II of the dorsal horn
following CCI (Figure 7.4 (b)). Raw data in Table 7.1. Again, there were no
significant differences between the contralateral and control values for either mean
cell counts or silver grain densities (two-tailed unpaired student t-test: P < 0.05),
As with the control sections, the expression of silver grains, indicative of
expression of PACAP receptor mRNA, was consistently low throughout the entire
spinal cord of all sections analysed, including background expression. This made it
difficult to distinguish between expressing, and non-expressing dorsal horn neurones.
From the data obtained, the levels of mRNA expression for the PACAP receptor
appeared to be much lower than those observed for the VIP] and VIP2 receptors, in
the ipsilateral dorsal horn of neuropathic animals. No significant changes were seen
in the low number of cells expressing (approximately 7-8 per 30 625pm ), or the
density of expression of PACAP receptor mRNA in contralateral versus ipsilateral
dorsal horn, nor in contralateral versus control values, in either laminae III/IV
(Figure 7.3 (c)) or lamina II (Figure 7.4 (c)). As the PACAP hybridisation observed
here is equivalent to background levels, this suggests that there may be very little
PACAP receptor mRNA expressed in the spinal cord of normal and neuropathic
animals.
Data showing the average number ofpositively-labelled mRNA-expressing
cells (per 30 625pm 2) and the average silver grain density for these expressing cells,
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are displayed as summary histograms for all three receptor subtypes in Figures 7.5
and 7.6 respectively.
7.3.3 Controls
To verify the sensitivity of the PACAP receptor mRNA hybridisation, the
constitutive expression in untreated rat brain was assessed. Positively labelled cells
were observed in the dentate gyrus and CA1-CA3 layers of the hippocampus, as well
as throughout the thalamus (data not analysed).
Control experiments with RNase A pre-treatment prior to hybridisation, or
using hybridisation with an excess of unlabeled probe, failed to give convincing
specific hybridisation:
(a) RNase controls
No positively-labelled cells were detected in the spinal cord sections which
had been pre-treated with RNase A prior to hybridisation. This treatment produced a
low, even distribution of silver-grains equivalent to the non-specific background
observed in positive controls, when using the VIP,/VIP2/PACAP probes (See Figure
7.1).
(b) "Cold" Probe Controls
The specificity of the ISHH technique was further demonstrated by diluting
the radiolabeled probe with a 10-fold molar excess of "cold" unlabelled probe. This
resulted in a significant decrease in the density of silver grain expression in the





Tables showing the mean number ofpositively-labelled cells per 30 625pm (A) and
the average number of silver grains per positively-labelled cell (B), for each of the
three receptor subtypes, in lamina II and laminae III/IV ofnormal and neuropathic
rats, as revealed using in situ hybridisation histochemistry.
Data is expressed as the mean ± the standard deviation for each test animal.
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VIP1 41 ± 11 14 ± 1 32 ±9 15 + 6 43 + 11 15+2
41 ±5 13 ± 1 30 ± 10 12 + 1 31+7 15 + 5
27 ±6 12 ± 1 16 ± 3 10 + 6 18 + 2 14 + 6
41± 8 8 + 2 39+1 13 ± 1
VIP2 10 ± 6 9 ± 1 20 ±5 14 + 2 16 + 7 8 + 2
6 ± 4 8 ± 3 11 ± 1 10 + 1 6+1 7+1
8 ± 3 7 + 2 5 + 2 8 + 3 3 + 2 7 + 2
3 + 1 10 + 4 4+1 6+1
PACAP 15 ± 1 6 ± 1 8 + 1 9 + 2 7 + 3 7 + 3
7 ± 4 5 ±2 5 + 2 8 + 2 5 + 3 7 + 2
6 ± 1 6 ± 1 12 + 3 7+1 8 + 4 9 + 2







VIP1 10 + 2 23+4 12 + 2 18 + 2 13 + 1 20+1
10+1 22+1 9 + 3 18 + 2 11+3 24 + 4
10 + 3 20+1 12 + 1 20 + 2 13 + 2 25 + 2
14+1 19 + 6 17 + 2 29+1
VIP2 6 + 4 19 + 4 5 + 2 23 + 9 5 + 2 13 + 6
3 ± 1 12 + 2 10+1 26+1 7 + 1 21 ± 1
5 + 1 15 + 3 6 + 3 25 + 7 6 + 2 15 + 7
PACAP 6+1 9+1 8 + 3 13 + 7 8 + 1 15 + 9
10+1 20+1 7 + 2 21 ± 1 8 + 1 20 + 5
6 + 2 10 + 2 6 + 1 15+5 6+1 11+3
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Figure 7.2
Photomicrographs Showing Areas of Analysis Within the Spinal Dorsal Horn,
and RNase Treated Control Tissue
Part (A) shows a low power lightfield, black and white photomicrograph of the
dorsal horn of normal rat lumbar spinal cord (outlined in white), as revealed by ISHH
(scale bar 150pm). This photomicrograph represents tha basal expression of VIP]
receptor mRNA within the normal dorsal horn, although it is easier to see the
expression of individual silver grains at higher power (see figures 7.3/7.4). The
black boxed areas show the regions of analysis for Lamina II (upper box) and
Laminae III/IV (lower box).
Parts B, C and D represent high power, light field, black and white photomicrographs
showing the typical levels ofbackground hybridisation with probes for VIP], VIP2
and PACAP receptor mRNA respectively, in laminae III/IV of control dorsal hom,
following pre-treatment of the sections with RNaseA prior to hybridisation (scale bar
30pm). Note the absence of silver grain clustering around the cell nuclei (a
characteristic of labelled cells). The non-specific silver grain expression here is
similar to the low level of even background expression seen in control regions within





VIP!, VIP2 and PACAP Receptor mRNA Expression in Laminae III/IV of the
Rat Spinal Dorsal Horn Before and After CCI
Highpower lightfield, black and white photomicrographs showing the typical levels
of (A) VIPi, (B) VIP2 and (C) PACAP receptor mRNA expression in the lateral
edges of Laminae III/IV of rat lumbar spinal cord (scale bar 30pm). Parts (i) show
the receptor mRNA expression ipsilateral to a chronic constriction injury of the rat
sciatic nerve, while parts (ii) and (iii) show typical examples of the expression
contralateral to nerve injury and in control tissue respectively. Positively-labelled
neurones where identified by a dense accumulation of silver grains (approximately
> 5 times background expression) over and around haematoxylin stained nuclei.
Despite the higher levels ofbackground silver grain expression, a significant
decrease in the expression of VIP! receptor mRNA ipsilateral to the nerve injury
(Part A(i)) when compared to contralateral (A(ii)) tissue can clearly be seen. In
contrast, the expression of VIP2 receptor mRNA is seen to significantly increase
ipsilateral to nerve injury (B(i)) from control (B(iii)) or contralateral (B(ii)) levels.
While the ipsilateral expression ofmRNA for the PACAP receptor (C(i)) remains
relatively unchanged from contralateral (C(ii)) or control (C(iii)) levels.
There were no significant differences between contralateral and control levels of





VIPi, VIP2 and PACAP Receptor mRNA Expression in Laminae II of the Rat
Spinal Dorsal Horn Before and After CCI
Highpower lightfield, black and white photomicrographs showing the typical levels
of (A) VIPi, (B) VIP2 and (C) PACAP receptor mRNA expression in the lateral
edges of Lamina II of rat lumbar spinal cord (scale bar 30pm). Parts (i) show the
receptor mRNA expression ipsilateral to a chronic constriction injury of the rat
sciatic nerve, while parts (ii) and (iii) show typical examples of the expression
contralateral to nerve injury and in control tissue respectively. Positively-labelled
neurones where identified by a dense accumulation of silver grains (approximately
> 5 times background expression) over and around haematoxylin stained nuclei.
Note the higher number of positively-labelled cells for VIP, receptor mRNA (Parts
A), compared to VIP2 and PACAP (Parts B and C respectively). This was consistent
throughout the whole of lamina II in all the sections analysed. There were no
significant differences due to CCI between average values of the number of
positively-expressing cells, or the density of mRNA expression for either VIPi, VIP2




Mean number of Positively-Expressing Dorsal Horn Neurones for VIPi, VIP2
and PACAP Receptor mRNA
Summary histogram showing the average number of dorsal horn neurones (per 30
625pm2) positively-expressing VIPj, VIP2 or PACAP receptor mRNA in Lamina II
and Laminae III/IV of the lumbar spinal cord. Values ipsilateral to the nerve injury
( m ) are shown with respect to contralateral ( ^ ) and control ( ^ ) values.
The average number of cells expressing mRNA for any of the three receptors was
relatively unchanged in Lamina II in normal compared to neuropathic spinal cord. In
laminae TIT/TV however, the number of cells expressing VIP! receptor mRNA was
seen to markedly decrease ipsilateral to nerve injury compared to contralateral
values, while those expressing VIP2 receptor mRNA significantly increased (two-
tailed paired student t-test: * P < 0.05). There were no significant differences
between contralateral and control values for any of the three receptors (two-tailed
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Figure 7.6
Average Silver Grain Density of Positively-Expressing Dorsal Horn Neurones
for VIPj, VIP2 and PACAP Receptor mRNA
Summary histogram showing the average silver grain density for dorsal horn
neurones positively-expressing VIPi, VIP2 or PACAP receptor mRNA in lamina II
and laminae III/IV. Values ipsilateral to the nerve injury ( H ) are shown with
respect to contralateral ( ^ ) and control ( 53 ) values.
The average silver grain density per expressing cell, indicative of the expression of
receptor mRNA, was relatively unchanged for all three receptors in Lamina II, in
normal compared to neuropathic spinal cord. In laminae III/IV however, the density
of expression of VIP! receptor mRNA was seen to markedly decrease ipsilateral to
nerve injury compared to contralateral values, while that of VIP2 receptor mRNA
significantly increased (two-tailed paired student /-test: * P < 0.05). There were no
significant differences between contralateral and control values for any of the three
receptors (two-tailed unpaired student /-test: P < 0.05).
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7.4 Discussion
These results provide new insight into the distribution of the VIPi, VIP2 and
PACAP receptors within rat spinal dorsal horn, as well as revealing, for the first
time, changes in expression of these receptor subtypes following an experimental
peripheral mononeuropathy.
It has previously been shown that there is a distinct distribution of the VIP],
VIP2 and PACAP receptors in both the peripheral and central nervous systems of the
rat (Harmar and Lutz, 1994; Lutz et al. 1993; Shioda et al. 1997; Usdin et al. 1994;
Vertongen et al. 1997). ISHH studies have revealed that VIP! and VIP2 receptor
mRNA shows differential expression within the brain (Harmar and Lutz, 1994; Lutz
et al. 1993; Usdin et al. 1994), with just some areas of overlap. More recently, the
production ofhigh affinity agonists with marked selectivity for the VIP! and VIP2
receptors (Gourlet et al. 1997a; 1997b) has allowed autoradiographic mapping of the
VIP receptor proteins to be carried out, using iodinated forms of these molecules
(Vertongen et al. 1997). These studies have confirmed the differential expression of
VIPi and VIP2 receptors within the rat brain. The VIP2 receptor was shown to be
expressed in a number of areas where VIPi receptor expression was absent, or
present at very low levels, including the thalamic nuclei, suprachiasmatic nucleus and
the periventricular nucleus. In contrast, the VIPi receptor was the predominant
receptor expressed in the dentate gyrus and supraoptic nucleus (Vertongen et al.
1997). As with previous findings, expression of both receptors was found to overlap
in some areas of the brain, including the cerebral cortex, claustrum, the nucleus
accumbens and the choroid plexus (Vertongen et al. 1997).
This differential expression is also observed in the periphery, as the VIPi
receptor has been shown to be expressed in a number ofperipheral tissues including
the liver, lung, small intestine and the thymus (Harmar and Lutz, 1994; Usdin et al.
1994), while the VIP2 receptor was found in a number of areas where VIP acts but
where VIPi receptor mRNA is absent, or is present at very low levels, including the
stomach and testes (Usdin et al. 1994). The combined VIPi/VIP2 receptor mRNA
distribution, is consistent with the overall distribution of VIP-binding sites, as shown
by autoradiography (Besson et al. 1986; Staun-Olsen et al. 1985), and so it is clear
that the actions of VIP within the central and peripheral nervous systems may be
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mediated by either of these receptor subtypes, and may reflect different functional
roles for VIP within these different areas.
The expression ofmRNA for the PACAP receptor shows some degree of
overlap with that of the VIP|/VIP2 receptors. It is abundantly expressed in the brain
where it shows some similarities to the distribution of the VIP2 receptor, notably in
the olfactory bulb, thalamus, hippocampus, pituitary and the hypothalamus (Cauvin
et al. 1991; Masuo et al. 1992; 1993; Shioda et al. 1997). However, there are some
distinct differences, with the preferential expression of the PACAP receptor within
the hypothalamus, cerebellum, pons and medulla oblongata (Sheward et al. 1995). In
addition, there is very little PACAP receptor mRNA expression in the peripheral
tissues (Arimura and Shioda, 1995; Hashimoto et al. 1993), unlike VIP! and VIP2
receptor mRNA. This distinct distribution of VIP/PACAP receptors may reflect
different functions for each of the three receptor subtypes. As the distribution of
these receptors within the spinal dorsal horn has not been previously investigated in
any great detail, the aim of this study was to determine any differences in the
expression ofmRNA for the VIPi, VIP2 and PACAP receptors within normal rat
spinal cord, and to try and ascertain whether the levels of expression change
following a peripheral nerve injury.
Indeed, mRNA for VIPj, VIP2 and PACAP receptors appeared to show
differing degrees of expression within the dorsal horn ofnormal animals. Expression
of mRNA for all three receptors was found, to some degree, throughout the lumbar
segments of the spinal cord studied, particularly in the dorsal horn. The small
diameter neurones in lamina II showed a predominant expression of VIP! receptor
mRNA expression, while the number of cells expressing either VIP2 or PACAP
receptors were relatively low in this lamina. This level of receptor expression
appeared to be relatively unchanged following nerve injury.
In contrast, this study has demonstrated that CCI of the rat sciatic nerve leads
to marked changes in the expression of VIP/PACAP receptor subtypes in the deeper
ipsilateral dorsal horn. The most marked change in receptor expression was seen in
the lateral edges of laminae III/IV, where the levels of VIP! receptor mRNA
significantly decreased, ipsislateral to nerve injury, while the expression of VIP2
receptor mRNA significantly increased. As discussed previously, it has been shown
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that the mRNAs encoding the VIP! and VIP2 receptors have a complementary
distribution within the rat brain (Usdin et al. 1994; Vertongen et al. 1997), and so it
was interesting to see that the levels of VIP2 receptor expression appeared to increase
in the same areas where VIP! receptor levels dropped. If these receptors do have
different functional properties, this change-over may reflect the need for different
receptor functions following the central changes brought about by neuropathy.
The ISHH results observed here as regards the expression of PACAP receptor
mRNA were somewhat surprising. Five oligonucleotide probes were used in this
investigation to try and increase the sensitivity of the assay, as mRNA for the
PACAP receptor could not be detected in the spinal cord using one or two probes
alone. All five probes were highly specific for regions of the DNA sequence for the
PACAP receptor as produced by Hoysoya et al. (1993). Although a number of
different subtypes of the PACAP receptor can be generated by alternative splicing
(Spengler et al. 1993), the probe sequences used in the present study were common
to mRNAs for all the variants and so should have bound to any mRNA for subtypes
of the PACAP receptor present. At least 6 isoforms of the PACAP receptor have
been described (Spengler et al. 1993) which differ in the amino acid sequence within
the 3rd intracellular loop, an area which is considered to be crucial for interactions
with G-proteins (Spengler et al. 1993). Expression of these different receptor
subtypes in transfected cells, has been shown to be associated with different patterns
of stimulation of adenylate cyclase and PLC, and PCR-amplified products of
different regions of the brain, have revealed the differential prominence of these
different splice variants of the PACAP receptor (Spengler et al. 1993) This
highlights the possibility that PACAP could mediate a number of different
physiological roles via different receptor variants.
From the results observed in the agonist study (Chapter 6) it is clear that
PACAP-38 has the ability to activate approximately two-thirds of the dorsal horn
neurones tested in both normal and neuropathic animals. In contrast, the present data
suggest that the expression of mRNA for the PACAP receptor is relatively low in the
rat spinal cord, in comparison to the VIPi and VIP2 receptors. This may be due to
the fact that the ISHH conditions were not at their optimum for hybridisation of the
PACAP probes, but all of the probes used (for PACAP, VIP] and VIP2) were of
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similar base lengths (45-48mer) and had similar G/C contents (50-60%) and so the
optimum conditions for all probes should be in a similar range. In addition,
positively-labelled cells were observed in certain areas of the brain known to express
the PACAP receptor, including the hippocampus and thalamus. Thus it seems likely
that expression of the PACAP receptor within the rat spinal cord is in fact very low,
although it is possible that other unknown technical factors, including for example
low message stability, could have contributed to these findings. As PACAP can also
bind with a relatively high affinity to the VIP! and VIP2 receptors (Hashimoto et al.
1993; Shivers et al. 1991), this would suggest that any effects that PACAP may have
within the spinal cord are mediated via the VIP! and VIP2 receptors, and so may
reflect a different physiological role for PACAP within the spinal cord than in other
areas of the central nervous system (notably the brain) where the PACAP receptor
predominates.
The changes in expression of VIP] and VIP2 receptor mRNAs, but not of that
for the PACAP receptor, seen in this ISHH study, parallel those deduced from the
agonist study in Chapter 6. From these results therefore, we can speculate that VIP2
receptor protein expression is increased within the deeper laminae of the ipsilateral
dorsal horn following CCI, while that of VIPi decreases. This differential change in
receptor expression may reflect a change in function for VIP/PACAP within the
spinal cord ofneuropathic animals (consistent with evidence for elevated expression
ofVIP and PACAP peptides in DRG neurones) and highlights the potential
importance of the VIP2 receptor in particular in the development of neuropathic pain
states. These results therefore implicate the VIP2 receptor as a possible target for
analgesics in neuropathy. In addition, the relatively low expression of mRNA for the
PACAP receptor within the spinal cord, and the lack of change of expression for this
receptor after nerve injury, may suggest that any functional role PACAP has within
the dorsal horn is most likely to be mediated primarily via the VIPj receptor in
normal conditions and the VIP2 receptor following neuropathy.
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Chapter 8 Summary and Conclusions
Neuropathic pain due to nerve injury, may occur as a result of
peripheral tissue damage due to disease or trauma, or may be a direct result of nerve
transection, crushing or constriction. The chronic pain states which develop include
spontaneous pain, hyperalgesia and allodynia, and they may persist long after the
initial injury has healed (Scadding, 1984). These abnormal pain states show a
reduced sensitivity to classical opioid analgesics (Arner and Meyerson, 1988; Mao et
al. 1995), and anaesthetic nerve blocks or surgical sympathectomies often provide
only temporary relief (Loh and Nathan, 1978; Luo and Wiesenfeld-Hallin, 1995).
However, treatments using anticonvulsant drugs such as carbamazepine (Fields et al.
1997; McQuay et al. 1995; Tanelian and Brose, 1991), or tricyclic antidepressants
(McQuay et al. 1996) have shown more promising results. The mechanisms
underlying the development of neuropathic pain are poorly understood, but
inflammatory mediators released at the periphery (Tracey and Walker, 1995), central
changes within the spinal cord (Woolf, 1983), including changes in receptor and
protein expression (Hokfelt et al. 1994), and biochemical and pathological changes
within the damaged nerve itself (Coggeshall et al. 1993; Sebert and Shooter, 1993)
are all thought to contribute.
A number ofneurochemical changes within dorsal root ganglion neurones
and the spinal dorsal horn, have been well-documented following peripheral nerve
injury (Hokfelt et al. 1994) including a marked up-regulation of the expression of
VIP and PACAP. Previous evidence has suggested that these peptides may have
neurotransmitter and/or neuromodulatory functions within the CNS (Jeftinija et al.
1982; Phillis et al. 1978; Narita et al. 1996; Salt and Hill, 1981; Xu and Weisenfeld-
Hallin, 1996) and so this project combined electrophysiological and molecular
biological techniques to gain further insight into these proposed roles.
Although many different conditions can lead to the development of
neuropathic pain, including diabetes and the herpes zoster virus (Scadding 1984), the
most commonly used models of neuropathy usually involve peripheral nerve injury.
In this study we utilised the Bennett and Xie chronic constriction injury model
(1988), in which four chromic cat gut ligatures were tied loosely around the rat
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sciatic nerve so as to barely constrict it. Consistent with previous studies (Attal et al.
1990; Bennett and Xie, 1988), the animals subsequently developed mechanical and
thermal allodynia, as well as mechanical hyperalgesia, in their affected hind limb.
These lowered thresholds to sensory stimuli showed maximal changes approximately
2 weeks after the initial nerve injury. At this time point, those animals showing
strong signs of neuropathic pain (that is, a significantly reduced threshold to von Frey
filaments, a prolonged paw elevation time when placed in a shallow cold water bath,
and an exaggerated response to noxious pin-prick) were then used to investigate
whether VIP/PACAP receptors are important regulators of the amplified sensory
responses which had developed.
Selective agonists and antagonists were used to address the role of VIP and
PACAP within the spinal dorsal horn, as mediated via the VIPj, VIP2 and PACAP
receptors. Firstly, an electrophysiological study was carried out using novel selective
antagonists for the three receptor subtypes. The effects of these receptor antagonists
were investigated on the sustained neuronal activity of individual dorsal hom
neurones, induced by sensory stimuli. These experiments were performed in normal,
as well as neuropathic rats at approximately 2 weeks PO, and the results compared.
Subsequently, the effects of ionophoretic application of novel selective agonists for
the VIP], VIP2 and PACAP receptors were examined on multireceptive dorsal horn
neurones, in both normal and neuropathic animals. Finally, a complementary ISHH
study was carried out to investigate the distribution of mRNA for the three receptor
subtypes within the spinal dorsal horn, and to ascertain whether the expression of
these receptors was altered in any way following an experimental peripheral
mononeuropathy.
8.1 VIPj/VnyPACAP Receptor Involvement in the Transmission of Sensory
Information
VIP1; VIP2 and PACAP receptors appear to play an important role in the
transmission of sensory information within the spinal cord of both normal and
neuropathic rats.
Despite the fact that VIP and PACAP are present in relatively low abundance
in the spinal cord and DRG under normal circumstances (Noguchi et al. 1993;
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Mulder et al. 1994), the present data provided clear evidence for the presence of
functional V1P/PACAP receptors on multireceptive dorsal horn neurones in normal
animals. The sustained sensory-induced activity ofmultireceptive dorsal hom
neurones, was clearly mediated or promoted, at least in part, by the VIPi, VIP2 and
PACAP receptors. Selective antagonists for the VIP! and PACAP receptors
appeared to exert a generalised modulation of dorsal horn neurone responses,
inhibiting both brush- and mustard oil-induced activity to similar extents. In contrast,
the novel VIP2 receptor antagonist was selectively antinociceptive (markedly
inhibiting only the sustained C-fibre activity induced by topical application of the
chemical irritant mustard oil) and thus suggesting a more restricted influence in the
normal state.
In neuropathic animals a modulatory role for the three receptor subtypes was
still evident, but the effects were clearly different from those seen in normal animals.
The most obvious difference was the lack of effect of all three receptor antagonists
on the brush-induced activity of dorsal horn neurones. The reduced threshold to von
Frey filaments in CCI animals, indicative of mechanical allodynia, would imply that
this stimulus would now be noxious in conscious animals. The development of
mechanical allodynia therefore clearly has different contributing influences than
those of thermal allodynia and mechanical hyperalgesia, which appear to be
modulated, at least in part, by the VIP/PACAP receptors. In normal animals, VIP!
and PACAP receptors appear to contribute to the brush responses, but this influence
is apparently suppressed or outweighed in neuropathy. How this might be achieved
is quite unknown, but the lack of Ap fibre involvement in neuropathy is a likely
candidate, as the CCI model of neuropathy causes a marked degeneration of these
fibres within the sciatic nerve (Basbaum et al. 1991; Coggeshall et al. 1993). The
neuropathy-induced increase in the expression of VIP and PACAP is predominantly
in small to medium diameter DRG neurones corresponding to the small diameter A5
and C fibres (Noguchi et al. 1989; Zhang Q et al.1995) which would also suggest that
VIP/PACAP are not likely candidates for direct mediators of the brush response in
neuropathic animals unless new fibre types become involved. A gradual recovery of
fibre composition within the sciatic nerve does occur, including both regeneration
and sprouting (Coggeshall et al. 1993; Koerber et al. 1994; Ramer et al. 1997; Woolf
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et al. 1995) and so it might be of interest to determine whether the inhibitory roles of
the VIP! and PACAP receptors return in animals one or two months after the initial
nerve injury, which would further implicate Ap fibre involvement.
Whatever mechanisms underlie the changes that occur following nerve injury,
an alteration in VIP/PACAP receptor function is clearly evident, as all three receptor
subtypes showed selective antinociceptive actions in CCI animals. VIP! and PACAP
receptor antagonists showed inhibitory effects on the cold-induced firing of dorsal
horn neurones, implicating them in the development and/or maintenance of cold
allodynia following nerve injury. On the other hand, exaggerated responses to
noxious stimuli, indicative of hyperalgesia, may be mediated by all three receptor
subtypes as antagonists for VIPi, PACAP, and in particular, VIP2 receptors all
inhibited mustard oil-induced nociceptive activity in neuropathic animals. The clear
differences in the effects ofVIPi/PACAP from VIP2 receptor selective antagonists on
the cold-induced neuronal activity, highlights the possibility of differential roles for
each of the receptor subtypes in the regulation of different aspects of neuropathic
pain.
These functional effects in neuropathy may be mediated by VIP and/or
PACAP, as both peptides show a high affinity ofbinding to both VIPj and VIP2
receptors (Christophe, 1993). Following peripheral axotomy or nerve ligation, the
levels of both peptides increase dramatically in small diameter DRG neurones and
nerve terminals within the superficial dorsal horn (Knyihar-Csillik et al. 1993;
Noguchi et al. 1989; Shehab and Atkinson, 1986a; Zhang Q et al. 1995; Zhang et al.
1995), but with different time courses. There is a rapid upregulation ofPACAP
(within 1-2 days) which slowly reverses after 1-2 weeks (Zhang Q et al. 1995), while
the levels ofVIP are markedly increased within the first two weeks after nerve
injury, and remain elevated for long periods of time (Nahin et al. 1994). This would
be consistent with the possibility that PACAP may be an important regulator of the
onset ofneuropathy, while VIP may be more important in maintaining the prolonged
pain states which subsequently develop.
Functional studies have already provided strong evidence of a regulatory role
for VIP and PACAP at the spinal cord level, with both peptides showing facilitatory
effects on the flexor reflex (Cridland and Henry, 1988; Narita et al. 1996;
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Wiesenfeld-Hallin, 1987; Xu and Weisenfeld-Hallin, 1996), when applied
intrathecally. This regulatory action appears to be particularly important in
neuropathic animals, especially for VIP. It has been suggested that VIP takes over
the role of SP as one of the main central neurotransmitters ofnociceptive afferents
following peripheral nerve section, as a VIP antagonist was shown to be highly
effective in attenuating the electrically-induced flexor reflex in axotomised rats
(Wiesenfeld-Hallin et al. 1990; Xu and Wiesenfeld-Hallin, 1991) while the SP
antagonist Spantide II had no such effect, a complete reversal of the effects seen in
normal animals.
So, VIP and PACAP both appear to play important regulatory roles in the
transmission of sensory information at the spinal cord level. The fact that the VIP1;
VIP2 and PACAP receptors are functionally active in normal animals, suggests that
their roles may not simply be restricted to episodes of chronic pain. However, the
selective antinociceptive nature of VIP], VIP2 and PACAP receptors in neuropathic
animals, makes them important new targets for the development of drugs to control
currently intractable neuropathic pain states.
8.2 Altered Expression of VIPi/VIP2/PACAP Receptors Following Peripheral
Nerve Injury and their Possible Function within the Rat Spinal Cord
The differential expression of the VIPl5 VIP2 and PACAP receptors has been
demonstrated on numerous occasions within the CNS (Harmar and Lutz, 1994; Lutz
et al. 1993; Shioda et al. 1997; Usdin et al. 1994; Vertongen et al. 1997), and this was
further confirmed here in both the agonist and in situ hybridisation studies performed
within rat spinal cord.
Changes in the responsiveness ofmultireceptive dorsal horn neurones in
normal and neuropathic animals, suggested that the expression of the VIP2 receptor
was increased following CCI of the rat sciatic nerve, while VIP! receptor expression
appeared to decrease. Oligonucleotides complementary to specific areas in the
mRNA of these two receptor subtypes also confirmed this. This dramatic increase in
the expression of mRNA for the VIP2 receptor may indicate a relatively greater role
for this receptor in neuropathy compared to the normal state. Indeed, combined with
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the antagonist results in the previous electrophysiological study, these data implicate
the VIP2 receptor as a prime target for the development of new analgesic agents.
In contrast with VIP! and VIP2, the expression ofPACAP receptor mRNA
(and the appropriate agonist responses) appeared to be unaltered following
neuropathy. It must be remembered however, that PACAP has the ability to act
through all three receptor subtypes, as the VIPi and VIP2 receptors show a high
binding affinity for both VIP and PACAP (Christophe, 1993). So although these
data suggest that there is no significant change in the expression of PACAP
receptors, PACAP may still play an important role in the development of neuropathy
via the VIP! and VIP2 receptors.
Indeed, PACAP may even mediate its effect indirectly via NMDA receptor-
mediated events, in addition to actions via the VIPi and VIP2 receptors, as recent
whole-cell patch-clamp recordings have revealed that PACAP-38 has the ability to
exert modulatory effects on both cultured chick cortical neurones (Liu and Madsen,
1997) as well as sympathetic postganglionic neurones (SPN) (Wu and Dun, 1997).
This potentiation ofNMDA-receptor-mediated responses in SPN recordings is
thought to be carried out via a cAMP-dependant mechanism (i.e. probably a VIP or
PACAP receptor) (Wu and Dun, 1997), as prior incubation of the spinal cord slices
with an adenylate cyclase inhibitor attenuated the facilitatory effects. With the
cultured chick cortical neurones however, PACAP-38 appeared to have a direct
modulatory effect on the NMDA receptor, which was independent of intracellular
second messengers (such as cAMP, calcium and inositol phosphate), and is thought
to be mediated instead, through the glycine coagonist site(s) (Liu and Madsen, 1997).
Such a direct modulation of the NMDA receptor has previously been suggested for
other peptides, including the opioids (Chen et al. 1995; Rusin and Randic, 1991) and
the tachykinins, substance P and NKA (Rusin et al. 1992; 1993). So there could
potentially be two ways in which PACAP could contribute to the development of
neuropathic pain states via its facilitatory effects at the NMDA receptor. The first is
by direct chemical gating of the NMDA receptor to stimulate an influx of calcium
ions, resulting in an increased responsiveness of the dorsal horn neurones to sensory
inputs, and ultimately leading to the development of hyperalgesia and allodynia. The
second is by triggering alterations in membrane excitability through interactions with
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second messenger systems and protein kinases, which phosphorylate membrane-
bound proteins (Nestler and Greengard, 1983). However, intracellular recording
techniques are currently not advanced enough to distinguish between these two
posiibilities. A large amount of evidence implicates NMDA receptor involvement in
the development and maintenance of neuropathic pain states. Pre- and/or post-injury
treatment with intrathecal MK-801 (a selective NMDA receptor antagonist) has been
shown to significantly attenuate the development and/or onset ofboth mechanical
and thermal hyperalgesia resulting from nerve injury (Kawamata and Omote, 1996;
Mao et al. 1992a; 1992b; Smith et al. 1994). In addition, intrathecal MK-801, given
just prior to axotomy, significantly suppresses autotomy in rats (Seltzer et al. 1991),
suggesting that NMDA receptors may also be involved in the development of
spontaneous pain following neuropathy. From these reports then, the long-lasting
excitatory effects of PACAP-38 seen in the present studies, following ionophoretic
application of the peptide on to multireceptive dorsal horn neurones, may in fact be
NMDA receptor-mediated. This highlights a potential role for PACAP in the altered
responsiveness of dorsal horn neurones to sensory stimuli and ultimately in the
development and maintenance of the abnormal pain states which ensue neuropathy.
VIP on the other hand, only appears to have one mode of action, via the VIP,
and VIP2 receptors, which are both coupled only to adenylate cyclase (Ishihara et al.
1992). As mentioned previously, activation of these G-protein linked receptors
triggers alterations in the cell membrane excitability through the activation of the
cAMP pathway, which subsequently result in the phosphorylation of membrane-
bound proteins (Nestler and Greengard, 1983). This increased metabolic activity can
result in other intracellular changes however, including alterations in gene expression
which may favour cell growth and differentiation, and/or cell survival.
Indeed, although the present study has concentrated on the potential
neurotransmitter role of VIP and PACAP, activation of the VIPl5 VIP2 and PACAP
receptors can ultimately result in a number of biological and physiological changes
both centrally and in the periphery. There is considerable data regarding the
neurotrophic actions of VIP and PACAP. Both peptides have been shown to exhibit
a number of distinct actions on the cell proliferation, survival and differentiation of
well-characterised cell culture systems (Brenneman and Eiden, 1986; Gonzalez et al.
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1997; Klimaschewski et al. 1995; Lioudyno et al. 1998; Pellegri et al. 1998; White
and Mansfield, 1996). Some of these actions appear to be directly mediated by VIP
and PACAP (Gonzalez et al. 1997; Klimaschewski et al. 1995; Lioudyno et al.
1998). However they also, and possibly more commonly, act indirectly by
stimulating the release of trophic factors (including various cytokines and growth
factors) from cells such as glial cells and lymphocytes (Pellegri et al. 1998; Tatsuno
et al. 1996; Waschek, 1996; White and Mansfield, 1996). So it is clear then that VIP
and PACAP have a multitude ofbiological actions which may directly contribute to
the development of neuropathic pain states, or may even ultimately counteract them.
These properties include neuronal protection (cell survival), enhancement of cell
differentiation and proliferation, repair of damaged neurones through the indirect
release of growth factors, as well as having the potential to enhance nerve fibre
growth and regeneration (Brenneman and Eiden, 1986; Gonzalez et al. 1997;
Klimaschewski et al. 1995; Lioudyno et al. 1998; Pellegri et al. 1998; Tatsuno et al.
1996; White and Mansfield, 1996).
In conclusion then, VIP and PACAP are extremely important mediators of
neuropathy. The altered expression of the VIP/PACAP receptors, and the increased
expression of the peptides themselves, may compensate functionally for the lack of
classical neurotransmitters ofnociceptive afferents (e.g. substance P) which are
decreased in response to nerve injury, thus enabling VIP and PACAP to have direct
regulatory roles in the transmission of sensory information within the spinal cord,
and subsequently in the altered pain states which develop following nerve injury. In
addition, they may also promote neuronal survival and fibre growth within the
damaged nerve, as well as influencing spinal cord plasticity over the long-term,
thereby contributing to the maintenance of chronic pain states.
8.3 Potential Therapeutic Value
This project provides new insight into the roles of VIPl5 VIP2 and PACAP
receptors within the central nervous system, and underlines the potential importance
ofVnyvnyPACAP receptor antagonists as new analgesic agents for use in
currently intractable neuropathic pain states.
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The profile of influence of these VIP/PACAP receptors is clearly very
different from that of other modulators of sensory processing, such as the opioid and
tachykinin peptides (Fleetwood-Walker et al. 1988;1993) as certain aspects of
neuropathic pain appear to be less responsive to classical opioid analgesics (Arner
and Meyerson, 1988; Mao et al. 1995). VIPj, VIP2 and PACAP receptors appear to
play an important role in the regulation ofnociceptive inputs of both normal and
neuropathic rats. This may be a direct result of the cellular influences of VIP and/or
PACAP acting at their receptors, or it could be that activation of these receptors may
help to maintain a state which promotes responsiveness to nociceptive inputs. How
this state of 'sensitisation' might be achieved is still unknown, and future
pharmacological studies into the functions of VIP!, VIP2 and PACAP receptors may
prove to be crucial in our understanding of the pain states which ensue nerve injury.
Overall, these results predict that VIP2 receptor antagonists should serve as
selective analgesics, strongly reducing polymodal C-fibre-mediated pain both in
normal and neuropathic pain states. On the other hand, although the VIPi and
PACAP receptor antagonists are rather non-selective inhibitors of sensory inputs in
the normal state, they appear to have the useful property of attenuating cold allodynia
as well as polymodal C-fibre responses in neuropathic animals, while preserving the
low threshold mechanical responses.
In conclusion then, this study has highlighted potential regulatory roles for
VIP and PACAP, via their selective VIP], VIP2 and PACAP receptors, within the
spinal cord of normal and neuropathic animals. This suggests that antagonists
selective for these receptors, may be important new drugs for use in neuropathic pain.
Further investigations to provide a better understanding of the function of VIPi, VIP2
and PACAP receptors, may therefore result in the development of new strategies for
the treatment of chronic pain conditions.
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Summary—The excitatory responses of individual dorsal horn neurons to cutaneous brush, repeated application
of the C-fibre-selective chemical algogen, mustard oil, or to ionophoretic (1S\3R)-ACPD [a metabotropic
glutamate receptor (mGluR) agonist] were monitored by extracellular recording. We have previously shown
that the responses ofdorsal horn neurons to mustard oil are inhibited by several selective antagonists of mGluRs.
Effects of ionophoresis of the mGluR antagonists (R.S)-CHPG and L-AP3 and a range of selective inhibitors
of intracellular signalling pathways were examined on evoked responses here. The results suggest that protein
kinase C, phospholipase A2 and perhaps Ca2+/calmodulin kinase 11 play a role in mediating the sustained
elevated activity of dorsal horn neurons that is incrementally elicited by repeated application of mustard oil,
but probably make little contribution to sustained brush-evoked activity. Concurrence in the sensitivity of
mustard oil- and (lSARFACPD-evoked activity to (R,S)-CHPG, L-AP3 and to inhibitors of intracellular
signalling pathways, suggests that mGluRs are an important origin of these intracellular signals required for
sustained nociception.
Keywords—Metabotropic glutamate receptors, nociception, spinal cord, intracellular signalling, protein kinase
C, phospholipase A2.
he possible role of metabotropic glutamate receptors
nGluRs) in spinal sensory processing has been
ivestigated relatively little. Their potential importance is
ighlighted by evidence for their role in gating NMDA
^ceptor-dependent and -independent forms of the
nsitization phenomenon in the hippocampus known as
ng-term potentiation (LTP) (Bortolotto and
ollingridge, 1993; Bortolotto et a/., 1994) and by the
cilitation by mGluR agonist [(l,S,3/?)-ACPD] of
MPA and NMDA responses in dorsal horn neurons
lleakmaneta!., 1992;Cerneand Randic, 1992). Wehave
•eviously provided evidence for a mediatory role of
—GluRs in the sustained activation of dorsal horn
urons elicited by repeated cutaneous application of the
fibre selective chemical algogen, mustard oil (Young
al., 1994), which is known to bring about central
nsitization of dorsal horn neurons to afferent inputs,
le repeated cutaneous application of mustard oil elicits
increasingly powerful and sustained activation of
o whom all correspondence should be addressed.
dorsal horn neurons (analogous to "wind-up") until a
state of persistent elevated activity is reached (Munro
et al., 1993). This persistent mustard oil-evoked activity
was inhibited by ionophoretic application of the
selective mGluR antagonists L-(but not D-)-l-amino-3-
phosphonopropanoic acid (L-AP3), (R,5)-4-carboxy-3-
hydroxyphenylglycine (R,N-CHPG) and, more variably,
by (R,5')-a-methyl-4-carboxyphenylglycine (R.S-cc-
MeCPG) (Young et al., 1994). In behavioural analgesia
experiments, intrathecally-applied (5)-CHPG, which is
the enantiomer with activity at mGluRs, produces
antinociceptive effects in thermal and mechanical paw
withdrawal tests (Young et al., 1995). In animals treated
by unilateral intraplantar injection of carrageenan, these
effects are amplified and an antinociceptive influence of
L-AP3, but not D-AP3, is also apparent (Young et al.,
1995). Co-administration ofAMPA and mGluR agonists
is reported to bring about behavioural hyperalgesia in
acute mechanical nociceptive tests (Meller et al., 1993).
The sensitization of dorsal horn neurons brought about
by intra-articular inflammation is also inhibited by the
mGluR antagonist I.-AP3 (Neugebaucr et al., 1994).
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While these data provide compelling evidence that
mGluRs play some role in spinal processing of
nociceptive inputs (most likely in the sensitization of
dorsal horn neurons to sustained high intensity C-fibre
input), any evidence is lacking as to their intracellular
mechanism of action. We have previously reported that
neuronal activity evoked by repeated mustard oil
application is profoundly inhibited by antagonists of
protein kinase C (PKC) (Munro et al., 1994a). This
corresponds to the attenuation of behavioural nociceptive
responses to subcutaneous formalin injection (and of
their facilitation by glutamate) seen with PKC inhibitors
(Coderre, 1992; Coderre and Yashpal, 1994). Since the
intracellular signals leading to PKC activation are likely
to also involve elevation of Ca2+ levels, it is possible that
the Ca2+-activated enzyme, Ca2+/calmodulin-dependent
protein kinase II [which has been implicated in LTP (Silva
et al., 1992)], may also play a role here. Additionally,
evidence for the involvement of prostanoids in the
nociceptive responses to formalin (Malmberg and Yaksh,
1992a.b; Chapman and Dickenson, 1992) and the
facilitation of such behavioural responses by the
prostanoid precursor arachidonic acid (Coderre and
Yashpal. 1994), suggests that the arachidonic acid-gener¬
ating enzyme, phospholipase A2 (PLA2) may play a role
in sensitization. Further transduction mechanisms which
could potentially play a role are cAMP-dependent protein
kinase (PKA), since PKA activation can potentiate
NMDA responses of dorsal horn neurons (Cerne et al.,
1993), and non-receptor tyrosine kinases, which can be
activated by a number of phosphoinositide-hydrolysing,
G protein-coupled receptors (Zachary et al., 1991).
The present experiments utilized a range of selective
inhibitors applied by ionophoresis, to assess the role of
these various signal transduction pathways in neuronal
responses to repeated application of mustard oil, to
activation by the mGluR agonist (lS,3R)-l-aminocy-
clopentane-l,2-dicarboxylic acid [(1S,3J?)-ACPD] and to
light innocuous brushing of the cutaneous receptive field.
Whilst these reagents were all chosen for their reported
high degree of selectivity, it is not possible to say with
certainty that their expected effects represent the actual
mechanism of action in the present experiments. For this
reason, pairs of reagents (with quite different structures,
but with the common property of selectively blocking
particular signal transduction pathways) were tested in
each case.
METHODS
Experiments were carried out on 43 male Wistar rats
(240-420 g). Following an initial halothane anaesthesia,
animals were given intravenous a-chloralose (60 mg
kg" ') and urethane (1.2 g kg '). Supplementary doses of
a-chloralose were given when required. Core body
temperature was maintained at 37-38°C by means of a
thermostatically controlled heat blanket. A light flow of
0; (0.1 1 min ') was passed over the end of a tracheal
cannula to enrich the inspired air. Once the thoracolum¬
bar spinal column was supported, using 3 pairs of
swan-necked clamps, a laminectomy (L|-L4) was carried
out. To provide stability, agar was injected under the most
rostrally clamped vertebra, then over the whole area of
the laminectomy. An agar core was removed to expose the
recording region. The dura was then cut and a pool of
37"C liquid paraffin applied to the region.
Extracellular recordings were made from neurons in
the deeper dorsal horn of spinal segments L|-L4, using the
central barrel of 7-barrelled glass micioelectrodcs. The
remaining barrels contained I M NaCl for automatic
current balancing (Neurophore Ionophoresis System),
2% Pontamine Sky Blue in 0.5 M sodium acetate for
histological marking of recording sites and combinations
of the following drugs for ionophoresis: (lS,3/?)-ACPD
(Irving et al., 1990), 10 mM aqueous, pH 8.0—8.5;
(/?,S)-and (S)-CHPG (Watkins and Collingridge, 1994),
10 mM aqueous, pH 8.0-8.5; L-AP3 (Schoepp et al.,
1990), 10 mM aqueous, pH 8.0-8.5; calmidazolium
(Silver et al., 1986), 50 /(M in 0.5% dimethylformamide,
pH 4.0-4.5; KN62 (Tokumitsu et al., 1990), 50 //M in
0.5% dimethylformamide, pH 4.0-4.5; GF109203X
(Toullec et al., 1991), 100 /<M in 0.5% dimethylfor¬
mamide, pH 4.0-4.5; chelerythrine (Herbert et al., 1990)
1 mM aqueous, pH 4.0-4.5; ONO-RS-082 (Banga et al.
1986), 100 /iM in 0.5% dimethylformamide, pH 4.0^1.5
benzenesulphonamide 4 (BS4; Oinuma et al., 1991), 5(
/iM in 0.5% dimethylformamide, pH 4.0-4.5; KT572(
(Kase et al., 1987), 50 ;iM in 0.5% dimethylformamide
pH 4.0-4.5; H89 (Chijiwa et al.. 1990). 100 /<M in 0.5°/
dimethylformamide, pH 4.0-4.5; lavendustin A (Hsi
et al., 1991), 200 /<M in 0.2% dimethylformamide, pf
4.0-4.5; and piceatannol (Geahlen and McLaughlin
1989), 300 /(M in 0.3% dimethylformamide, pH 4.0-4.5
(1S.3/0-ACPD, (R,S)-, (S)-CHPG and L-AP3 were fron
Tocris Neuramin, calmidazolium was from Sigma
piceatannol was from Boehringer Mannheim and a)
other compounds were from Calbiochem, except BS4—
which was a gift from Mike Clark (Schering-Ploug
Research, Kenilworth, NJ. U.S.A.), and ONO-RS-081
which was a gift from Dr Tsuboshima (ON(
Pharmaceuticals, Osaka, Japan). The signal transductio
reagents were dissolved at the maximum concentratio
that could be achieved in an acceptable vehicle (0.5°/
dimethylformamide) that did not affect neuronal activit
(see below). With certain reagents it was possible to u;
lower concentrations of the solvent in ionophoret
solutions.
Neuronal receptive fields were initially located t
brushing of the ipsilateral hindlimb and then furthi
examined with noxious heat (48 "C, 10 sec). All neuroi
tested displayed a low basal firing rate of 0-1 Hz. T1
mustard oil experiments were carried out on a total of i
multireceptive cells which responded to both brush ar
noxious heat. Repeated applications of mustard oil (All—
isothiocyanate, Aldrich Chemical Company, 7.5%
paraffin oil) were made to an area of about 3 cm2 coverii
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the receptive field, and after 2-5 applications separated by
5 min intervals, a steady elevated firing rate (4-37 Hz) was
maintained. The inhibitory effects of antagonists were
calculated as the mean evoked activity through the 20 or
30 sec period encompassing greatest inhibition, compared
to the mean evoked activity in the 20 or 30 sec period
immediately prior to antagonist administration. Analysis
was routinely over 20 sec, but was occasionally for the
longer period of 30 sec if spurious variations occurred in
the control sampling period, so that more truly
representative values were obtained. The effects of
antagonists, over a similar current range to that used on
mustard oil-evoked activity, were also tested on responses
of cells to a motorized brush applied continuously to the
cutaneous receptive field and to ionophoretically-applied
(1S,37?)-ACPD. The ionophoretic current ranges used
were the lowest found to cause > 50% reduction of
mustard oil-evoked activity without any detectable spike
distortion; equivalent currents were then tested on brush-
and (lS,3R)-ACPD-evoked responses. The statistical
significance of drug-induced changes from control
responses was assessed by the Wilcoxon test on the mean
evoked raw firing rate in the sampling periods before and
during drug administration. All analysed activity data are
quoted as mean + SEM values.
RESULTS
The majority of the neurons examined were multirecep-
tive (i.e. responded to both innocuous brushing and
noxious pinch or noxious heating to 48 C, of the
cutaneous receptive field). As described previously
(Munro et al., 1993; Young et al., 1994), the majority of
these were vigorously excited by cutaneous adminis¬
tration ofmustard oil, with several successive applications
resulting in sustained elevated activity. The majority of
—Pontamine Sky Blue spots recovered from neuronal
recording sites were within laminae 11I V of the dorsal
horn. Of the population of neurons recorded in the
present study, approximately one-fifth (47 out of 244)
were overtly excited by ionophoresis of (15,3/?)-ACPD
(0-60 nA). Ionophoresis of 0.5% dimethylformamide-
:ontaining vehicle or saline at up to 80 nA, had no
detectable or consistent effect on basal, mustard oil-,
lY,3/?)-ACPD- or brush-evoked responses (/; = 5). For
;ach mGluR antagonist or signal transduction reagent,
vhenever recovery of responses was examined, full
'ecovery was seen in most cases by 10 sec-15 min after
onophoresis was stopped.
Figure 1 extends the previously reported observations
Young et al., 1994; Munro et al., 1994b) that mGluR
intagonists inhibit mustard oil-evoked neuronal acti-
'ation, by demonstrating that the potent mGluR
ntagonists (R,S)-CHPG and L-AP3 act selectively to
nhibit mustard oil-evoked activity without affecting that
voked by innocuous brush. Mustard oil-evoked activity
/as significantly inhibited by (/?,S)-CHPG [(—) 15 to
— )55 nA] and I.-AP3 [(—) 15 to (— )50 nA] in 7 out of 8
cells (56 + 9% inhibition, P < 0.05) and 11 out of 16 cells
(68 + 7% inhibition, P < 0.05), respectively (Wilcoxon
test on raw data) (Fig. 1; Young et a!., 1994; Munro et al.,
1994b). In contrast, brush-evoked activity was never
altered by more than 15% in 5 out of 5 cells by
(f?,S)-CHPG and 9 out of 9 cells tested with L-AP3
(not statistically significant). Furthermore, 12 out of
12 cells tested with (X)-CHPG [(—) 15 to ( —)55 nA] also
showed negligible effects (<15% inhibition on brush-
evoked activity (not statistically significant). Similar to
their effect on mustard oil-evoked activity, (R,Y)-CHPG
and L-AP3 inhibited (15,37?)-ACPD-driven activity in
5 out of 5 and 4 out of 6 cells, respectively (Fig. 1;
Young et al., 1994). The effect of (R.5)-CHPG on
(lS^/G-ACPD-evoked activity was a mean inhibition of
64 + 6% (5/5 neurons) at currents of ( — )15 to ( — )40 nA
(P<0.05). When the percentage inhibition values of
brush-, mustard oil- and (l£,3/?)-ACPD-evoked activity
caused by (/?,S)-CHPG were compared by the
non-parametric Mann-Whitney T/-test, effects on each of
the other responses were significantly greater than those
on brush (P < 0.05). As a consequence of the lasting
nature of activation caused by mustard oil, it was not
possible to test drug effects in a side-by-side comparison
of brush-, mustard oil- and (l£,3.ft)-ACPD-evoked
responses on individual cells. Comparisons of a drug
effect on brush/mustard oil, brush/(15",3/?)-ACPD or
(15',37?)-ACPD/mustard oil were however made in a
number of cases. In individual examples of each
combination, both (R,S)-CHPG and L-AP3 caused
similar inhibition (by > 50%) of mustard oil/(15,3R)-
ACPD responses, but in examples of sequential
brush/mustard oil and brush/( 15,3/?)-ACPD tests the
antagonists inhibited brush responses by < 15%, if at all,
despite causing > 50% reduction in mustard oil and
(1Y,3R)-ACPD responses.
When a range of selective inhibitors of signal
transduction pathways was tested on activity evoked by
brush, mustard oil or (1 Y,37?)-ACPD, there was general
concurrence in the effects of each inhibitor on mustard
oil- and (15,3/?)-ACPD-evoked responses. These re¬
sponses were significantly inhibited by ionophoresis of
each of the agents tested (P < 0.05, by Wilcoxon test, in
each case; Table 1). However, in the case of certain
inhibitors of Ca2+/calmodulin kinase II, PKC and PLA ,
but not the other agents, there appeared to be a lesser
effect on brush-evoked activity than on the other
responses. The Ca2+/calmodulin kinase II inhibitor,
calmidazolium, the PKC inhibitor GF 109203X, and the
PLA: inhibitor ONO-RS-082 had no significant effect on
brush-evoked activity. The mean percentage inhibition of
mustard oil- and (lS,3R)-ACPD-evoked responses by
calmidazolium, ONO-RS-082 and a further PLA:
inhibitor, BS4, was consistently at least 2-fold greater
than their effect on brush responses (and in the case of
GF109203X, many fold more). In the case of
GF109203X, the percentage inhibition of mustard oil and
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than that of brush responses (P < 0.05, Mann-Whitney
t/-test). The effect of ONO-RS-082 on (15,3/?)-ACPD-
evoked activity was also significantly greater than that on
brush (P < 0.05), but no other such "between-response"
comparisons revealed differences that were significant
with the present samples. Figure 2 shows examples of the
effect of the Ca2+/calmodulin kinase II inhibitor KN62
and of the PLA: inhibitor BS4, illustrating concurrent
inhibition of mustard oil- and (lSJRFACPD-evoked
activity with little or no effect on brush responses. In the
overall populations, however, both K.N62 and BS4
caused a relatively small, but significant, inhibition of
brush as well as the other responses, with each drug
showing no marked effect ( ^ 20% change) in approxi¬
mately 50% of the cells (as in the examples illustrated)
(Fig. 2; Table 1). In the case of the PKA inhibitors,
KT5720 and H89, and the tyrosine kinase inhibitors,
lavendustin A and piceatannol, each reagent tested
caused a significant inhibition of all types of evoked
activity (Table 1). It was not possible to make direct
sequential comparisons of a drug's effects on brush,
mustard oil and (1S,3R)-ACPD responses of the same
cell. Flowever, comparisons between two types of evoked
response were possible in a number ofcases. For example,
in the case of a single neuron tested with BS4, direct
comparison of effects on brush/( 1SJTO-ACPD responses
revealed selective inhibition of the latter, in accordance
with the overall population of neurons investigated.
Similarly, piceatannol caused inhibition of both brush
and mustard oil responses when directly compared on a
single cell, again typical of the overall population
(Table 1). A total of 17 cells were tested sequentially with
several drugs on either responses to brush (6 cells),
mustard oil (6 cells) and (1S',37?)-ACPD (5 cells). In order
to avoid any possible cumulative drug effects, this
involved drugs considered to act on independent signal
transduction pathways. Time for full recovery was always
allowed between sequential tests on the same neuron (up
to 15 min) and the results from these multiple tests were
always typical of the overall population described in
Table 1.
DISCUSSION
The present experiments extend the evidence for a role
of mGluRs in mediating the prolonged firing of dorsal
horn neurons evoked by repeated application of mustard
oil. Furthermore, they demonstrate modality specificity,
in that neuronal activation caused by mustard oil, but not
that due to continuous innocuous brushing, was inhibited
by the mGluR antagonists (R,,S)-CHPG and L-AP3
(Fig. 1). Administration of the single enantiomers
Table 1. Effects of ionophoretically-applied inhibitors of intracellular signalling pathways on the activity of dorsal horn neurons evoked by brush,
mustard oil or (lS,3/t)-ACPD
Inhibition of evoked activity (% inhibition compared to
mean pre-drug controls)
Principal target Drug Brush Mustard oil (1S,3R)-ACPD (0-10 nA)




16 + 10 NS
n = 8 (25%)
42 + 13*
n = 12 (50%)
42 ± 14*
n = 7 (71%)
51 + 19*
n = 5 (80%)
68 + 16*
n = 5 (80%)
83 + 9*





3 + 3 NS
n = 5 (20%)
53 + 10*
n = 9 (89%)
70 ± 10*
n = 8 (100%)
86 + 12*
n = 5 (100%)
84 + 11 *





28 + 13 NS
n = 9 (44%)
37 + 12*
n = 9 (56%)
70 + 11 *
n = 5 (100%)
74+11*
n = 5 (100%)
75 ± 9*
n = 8 (100%)
86 + 6*






n = 10 (70%)
45 ± 15*
n = 10 (50%)
73 + 13*
n = 7 (86%)
66 ± 10*




n = 6 (100%)





n = 11 (82%)
48 ± 15*
n = 13 (61%)
58 ± 10*
n = 8 (88%)
87 ± 7*
n = 6 (83%)
69 ± 12*
n = 7 (100%)
84 ± 9*
n = 6 (100%)
the ranges of ionophoretic currents required for the effects reported, are indicated in parentheses below each drug. In the case of (1S,3R)-ACPD,
higher currents ( < 60 nA) were sometimes briefly used to initiate firing but, after the first few seconds, the elevated activity could always be
maintained by sj 10 nA.
The effects of the drugs on evoked responses are indicated as the mean ± SEM percentage inhibition compared to pre-drug control acitvity. In
each case, the number of neurons contributing to the data is shown below and in parentheses, the proportion (percentage) of those neurons
which individually gave a clear response of > 20% inhibition. The statistical significance of drug-induced changes in firing rate was assessed
using the Wilcoxon test on mean raw firing rate data in action potentials per second (R/sec); comparing the 20 or 30 sec period immediately
prior to drug administration with the 20 or 30 sec period centred on the greatest inhibitory effect of drug ^represents P < 0.05; NS represents
not significantly different, P > 0.05).
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(S>CHPG and L-AP3, which display the greater activity
as mGluR antagonists, failed to modify brush responses
of the neurons. Interestingly, Eaton et al. (1993) have
previously shown that (S)-CHPG affected nociceptive,
but not non-nociceptive, responses of thalamic neurons.
Neuronal activity evoked by the mGluR agonist
(lS,3/?)-ACPD was also significantly inhibited by
(R.Sd-CHPG or by L-AP3 (Fig. 1; Young et al., 1994).
a-MeCPG was not investigated in the present exper¬
iments due to the rather variable effects it exerts on dorsal
horn neuron responses to mustard oil (Young et al., 1994)
and to dorsal root stimulation (Cao et al., 1995).
Although the mGluR antagonists inhibited mustard
oil-evoked activity in 75% of the neurons tested here,
(l.S,3R)-ACPD only elicited neuronal firing in approxi¬
mately 25% of cases. This apparent anomaly may be a
consequence of the mustard oil-evoked synaptic input
involving a number of other mediators beyond mGluRs;
for example AMPA, neurokinin and perhaps NMDA
receptors. Agonist stimulation of mGluRs alone, in the
absence of other components, may be insufficient to
regularly elicit overt neuronal firing in the recorded cell.
Other explanations are of course possible.
The mGluR antagonist used here, (R,S)-CHPG, is a
potent inhibitor of intracellular signalling responses
elicited by the phosphoinositide-hydrolysing mGlui
receptor, but not by mGlu2 or mGlu4 receptors (Watkins
tnd Collingridge. 1994). It is likely that the properties of
nGlus receptors correspond broadly to those of mGlui,
md further subtypes to mGlu24 receptors, which suggests
hat the receptor subtype involved in the mGlu antagonist
•ffects may well be mGlui or mGlu,. Although the
R)-enantiomer ofCHPG displays some NMDA receptor
tntagonism (Watkins and Collingridge, 1994) it can be
nferred that the inhibitory effects of (R,5')-CHPG on
nustard oil responses here are mainly due to luGluR
ilockade, since they are mimicked stereoselectively by
-AP3, but not D-AP3 (effective at mGluR and NMDA
eceptors respectively; Young et al., 1994).
This evidence for mGluR involvement in a sensitized
ociceptive response is consistent with evidence from
ther studies on the amplification of neuronal responses
y intra-articular inflammation or carrageenan-induced
Meugebauer et al., 1994; Young eta!., 1995). It is clear,
owever, that mGluRs are not the sole mediator of
:nsitization, since both NK2 and NK, neurokinin
■ceptors in the dorsal horn can also contribute to the
istained nociceptive activation and increased neuronal
:sponsiveness (Xu et al., 1991; Munro et al., 1993;
hompson et al., 1994). Interestingly, the ntGlu, and
Glu, subtypes of mGluR. together with NK, and NK2
ceptors have the common property of signal
ansduction by means of phosphoinositide hydrolysis
•lakajima et al., 1992; Watkins and Collingridge, 1994).
orrespondingly, neuronal responses to mustard oil, but
>t brush, were significantly reduced by inhibitors of
CC and by calmidazolium, an antagonist of the Ca2+
nding protein calmodulin (thence Ca2+/calmodulin
kinase II) both classical mediators of phosphoinositide-
hydrolysing receptors (Table 1). Responses to the mGluR
agonist (lS,3/?)-ACPD were also significantly inhibited
by these reagents, consistent with the hypothesis that a
phosphoinositide-hydrolysing mGluR may participate in
mediating responses to mustard oil. Both Ca2+/calmod-
ulin kinase II and the Ca2 + /calmodulin-activated
phosphatase calcineurin, have been implicated in long
term changes in responsiveness in hippocampal neurons
(Silva etal., 1992; Lisman, 1989). It is not possible to draw
any conclusion from the experiments here with KN62,
since it significantly inhibited all types of activity tested in
the overall population of cells and there is thus no
assurance that its effects are other than non-specific.
The prominent blockade of mustard oil-evoked activity
by PKC inhibitors (Table 1; Munro et al., 1994a) is
consistent with the translocation/activation of dorsal
horn PKC observed in both inflammatory and
loose-ligation neuropathy models of sustained nocicep¬
tion (Mao et a!., 1993; Munro et a!., 1994a). The
sensitivity of hippocampal LTP to inhibition of PKC
(Bliss and Collingridge, 1993) maintains the analogy
between that phenomenon and the sensitization of dorsal
horn neurons by sustained nociceptive input. Further¬
more, PKC inhibitors attenuate the behavioural
nociceptive responses elicited by subcutaneous formalin
injection (Coderre, 1992; Coderre and Yashpal, 1994) and
also attenuate the enhancement of such responses
brought about by glutamate or substance P. Metabo¬
tropic glutamate, NK, and NK2 receptor agonists can
facilitate neuronal responses to NMDA (Cerne and
Randic, 1992; Bleakman et a!., 1992; Rusin et a!., 1992)
and, where tested (on the NK, agonist, substance P), these
effects were reversed by a protein kinase inhibitor (Rusin
etal., 1992).
Not only PKC-activating phorbol esters (Gerber et a!.,
1989) but also the PKA activator forskolin (Cerne et al.,
1993) can facilitate neuronal responsiveness in the dorsal
horn, but the inhibitory effects of the PKA inhibitors
KT5720 and H89 here are equivocal because all types of
activity were inhibited and the possibility of non-specific
actions cannot be excluded. No evidence was found in
support of the hypothesis that the mGluR subtype here
might be one acting by adenylate cyclase inhibition, in
which case PKA inhibitors might have been expected to
mimic rather than inhibit (1 S,3R)-ACPD responses.
The two PLAj inhibitors tested, ONO-RS-082 and
BS4, significantly inhibited both mustard oil and
(1Y,3R)-ACPD responses, whereas ONO-RS-082 had no
significant effect on brush-evoked activity and BS4
showed at least twice the magnitude of effect on the other
responses than on brush. These agents- are reported to
block low and high molecular weight species of PLA2
respectively, and in each case both Ca2+ and PKC have
been implicated in their activation cascades (Banga et al.,
1986; Oinuma et al., 1991; Mayer and Marshall, 1993).
The present results are consistent with observations in
behavioural models implicating PKC and prostanoids in
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the development of hyperalgesic states (Coderre, 1992;
Malmberg and Yaksh, 1992a,b; Coderre and Yashpal,
1994).
Two selective inhibitors of tyrosine kinases (which
could potentially disrupt the effects of either growth
factor receptor tyrosine kinases or of receptor-indepen¬
dent tyrosine kinases operated downstream of phospho-
inositide hydrolysis responses) were also tested. These
agents caused generalized inhibition of all types of evoked
activity and so no clear conclusions can be drawn about
their actions in the context of the present experiments.
In summary, the present results suggest that PKC,
PLA2 and perhaps a calmodulin-dependent mechanism,
such as Ca2+/calmodulin kinase II, play a role in the
mustard oil model of sustained and sensitized nociception
in the dorsal horn and that an mGlu, or mGlu- receptor
may be one of the synaptic mediators involved in
triggering these signal transduction pathways.
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80 THE EFFECTS OF VIP AND PACAP RECEPTOR AN¬
TAGONISTS ON SUSTAINED NOCICEPTIVE AND NON-
NOCICEPTIVE INPUTS TO RAT DORSAL HORN NEURONES
T. Dickinson and S.M. Fleetwood-Walker. Dept of Preclinical Veteri-
narv Sciences, Umv of Edinburgh, Summerhall. Edinburgh, EH9 IQH,
UK*
Aim of Investigation: To investigate the role of Vasoactive Intestinal
Polypeptide (VIP) and Pituitary Adenylate Cyclase Activating Peptide
(PACAP) in the normal somatosensory processing of dorsal hom neu¬
rones.
Methods: Antagonists selective for VTP or PACAP receptors were
ionophoresed locally onto functionally characterised dorsal horn neu¬
rones in the intact spinal cord of anaesthetised rats. Neurones were
classified as bemg non-nociceptive if they responded to light brushing
of the hairs of the cutaneous receptive field only, and multireceptive if
they responded to brush, noxious pinch and/or noxious heat inputs. The
activation of single dorsal horn neurones was induced by innocuous
brushing of the hind limb or by peripheral application of the C-fibre-
selective algogen, mustard oil.
Results: When applied near non-nociceptive neurones both VIP and
PACAP antagonists showed negligible effects on sustained neuronal
firing to a brush stimulus. However, upon lonophoresis near multire¬
ceptive neurones, [p-Chloro-D-Phe0, Leu^j-VIP showed 53 ± 6% in¬
hibition (n=19) of responses induced by innocuous brush and 59 ± 8%
inhibition (n=ll) of mustard oil responses. Similarly PACAP (6-38)
inhibited brush-evoked activity by 60 ± 9% (n=16) and mustard oil
induced activity by 66± 9%, (n=9).
Conclusion: These results provide the first evidence that VIP and/or
PACAP receptors expressed on dorsal horn neurones in normal condi¬
tions, may play an important role in mediating somatosensory process¬
ing in the spinal cord. Furthermore, they also suggest that VIP and/or
PACAP act solely on cells which receive small diameter C and A5
fibres.
Neuropeptides (1997) 31 (2), 175-185
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Evidence for roles of vasoactive
intestinal polypeptide (VIP) and
pituitary adenylate cyclase activating
polypeptide (PACAP) receptors in
modulating the responses of rat
dorsal horn neurons to sensory inputs
T. Dickinson,* S. M. Fleetwood-Walker,* R. Mitchell,fE. M. Lutz+
'Department of Preclinical Veterinary Sciences, Royal (Dick) School of Veterinary Studies, University of Edinburgh, Summerhall, Edinburgh EH9 1QH
fMRC Brain Metabolism Unit, 1 George Square, Edinburgh EH8 9JZ, UK
Summary The extracellularly recorded electrophysiological activity of single multireceptive dorsal horn neurons was
markedly increased by ionophoretic administration of vasoactive intestinal polypeptide (VIP) or pituitary adenylate
cyclase activating polypeptide (PACAP)-38. Some cells responded selectively to PACAP-38 (suggesting mediation by
a PACAP receptor), whereas others responded to both VIP and PACAP-38 (suggesting a VIP, and/or VIP2 receptor).
Most non-nociceptive cells were unaffected by PACAP-38 and all were unaffected by VIP. The selectivity of VIP/PACAP
receptor antagonists was established on cloned rat VIP,, VIP2 and PACAP receptors in vitro before their utilization to
indicate the likely involvement of VIP,, and possibly PACAP receptors, in VIP- and PACAP-38-mediated responses of
dorsal horn neurons. The VIP/PACAP receptor antagonists inhibited responses of multireceptive cells to sustained
innocuous (brush) and noxious (mustard oil) stimuli, with a selectivity suggesting the involvement of VIP, and PACAP
receptors, although the participation by VIP2 receptors cannot be excluded. These data implicate both VIP and PACAP
in regulating the basal responsiveness of multireceptive dorsal horn neurons to sensory stimuli.
INTRODUCTION
The 28-amino acid peptide, vasoactive intestinal
polypeptide (VIP)1 is expressed widely in both the
peripheral and central nervous systems (CNS) of a vari¬
ety of species.2 More recently, a related peptide pituitary
adenylate cyclase-activating polypeptide (PACAP) was
discovered3 which shows 68% homology with VIP at its
N-terminal.4 PACAP is also widely expressed in many
central and peripheral neurons.5 VIP and the two alter¬
native processing forms of PACAP (PACAP-38 and
PACAP-27) are recognized by a family of three receptors:
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the PACAP receptor which displays a much greater affin¬
ity for the two forms of PACAP than for VIP, and the VIP,
and VIP2 receptors which display no marked selectivity
for any one of the peptide ligands.6-8 Immuno-
histochemical studies have revealed the presence of VIP-
immunoreactive fibres in the superficial dorsal horn
(especially at lower lumbar to sacral levels) which are
depleted by dorsal rhizotomy and correspond to the
presence of a modest number of small VlP-immunoreac-
tive cell bodies in dorsal root ganglia.9-14 Some VIP-
immunoreactive cell bodies have also been observed in
dorsal horn at all levels.12'13'15'16 Similarly, PACAP-
immunoreactive perikarya are present in dorsal root
ganglia at all levels, and fibres are densely present in
superficial dorsal horn.17'18 Capsaicin treatment markedly
depletes the number of PACAP-immunoreactive fibres in
these tissues.17 Messenger RNA for VIP is present at only
low levels in lumbar dorsal root ganglia under normal
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conditions19 whereas PACAP mRNA is normally present
in about 10% of dorsal root ganglion cells.20 PACAP
mRNA is also present in spinal cord extracts.5
Furthermore, release of VIP-like immunoreactivity
occurs into spinal perfusates in response to sciatic nerve
stimulation at A8- and C-fibre intensity.21 Binding sites
for VIP and PACAP ligands are correspondingly present
in spinal cord,22-25 and the mRNA for VIP!,6 VIP226 and
PACAP receptors27 is also expressed in spinal cord, espe¬
cially in dorsal horn.
Functional studies have reported that ionophoretically
applied VIP excites dorsal horn neurons and facilitates
their sensory responses and similarly excites neurons of
the trigeminal nucleus caudalis.28'29 In addition, intra-
thecally applied VIP and PACAP-38 facilitate nociceptive
flexor reflexes,30-32 while intrathecal VIP decreases reac¬
tion latency in the thermal tail flick test.33 In contrast,
one study reported an attenuation of a nociceptive reflex
with both VIP and PACAP-38,34 while intrathecal admin¬
istration of either PACAP-27 or -38 has been shown to
reduce the instances of formalin-induced flinching
behaviour.35'36
These data suggest that VIP, PACAP and their recep¬
tors may play an important regulatory role in the trans¬
mission of nociceptive information in the spinal cord of
the rat. The present experiments were therefore carried
out with several agonists and antagonists for VIP and
PACAP receptors (having defined the specificity of these
agents on receptors heterologously expressed from their
cDNAs). Responses of functionally characterized classes
of dorsal horn neurons to sustained innocuous and
noxious stimuli were investigated in order to assess the
specificity of VIP/PACAP influences with respect to
neuronal cell type and sensory input.
MATERIALS AND METHODS
Electrophysiological techniques
Experiments were carried out on 45 male Wistar rats
(296-394 g), anaesthetized with intravenous a-chlo-
ralose (60 mg/kg) and urethane (1.2 g/kg) following
induction with halothane. Supplementary doses of a-
chloralose were given as required and the core tempera¬
ture was maintained at 37-38°C by means of a
thermostatically controlled heated blanket. The trachea
was then cannulated and oxygen (0.1 L/min) was passed
over the end of the cannula to enrich the inspired air.
The thoraco-lumbar spinal column was supported using
three pairs of swan-necked clamps on alternate seg¬
ments, and a laminectomy performed to expose seg¬
ments L1-L4. Agar was injected under the most rostrally
clamped vertebra and then over the whole area of the
laminectomy to provide stability. A core of agar was then
removed to expose the recording region, the dura care¬
fully cut and a pool of 37°C liquid paraffin applied to the
exposed area.
Extracellular recordings were made from single
neurons located in dorsal horn laminae III-V, using the
central barrel (4 M NaCl, pH 4.0-4.5) of 7-barrelled glass
microelectrodes, with tip sizes 4.0-5.0 pm. One side
barrel contained 1 M NaCl (pH 4.0-4.5) for automatic
current balancing (Neurophore Ionophoresis System). A
second side barrel contained 2% Pontamine Sky Blue
(PSB) in 0.5 M sodium acetate for histological marking
of recording sites. The remaining barrels contained the
following compounds: VIP37 (Sigma, UK) (0.25 rnM
aqueous, pH 4.5), PACAP-3838 (0.25 mM aqueous, pH
4.5), [^-Cl-D-Phe6,Leu17]-VIP39 (0.25 mM aqueous, pH
4.5), VIP(6-28)40 (0.25 mM aqueous, pH 4.5),
PACAP(6-38)41 (0.25 mM aqueous, pH 4.5) or the vehi¬
cle control pH 4.5 H20. All peptides were from Bachem
UK, unless otherwise stated. The peptides were ejected
using positive currents of 30-70 nA and a retention cur¬
rent of -12 nA was applied to each barrel when not in
use. The resistance of the side barrels was monitored
regularly and electrodes with resistance values exceed¬
ing 45 Mil were rejected.
Neuronal receptive fields were initially located by
widespread manual brushing of the ipsilateral hind limb
and then further examined with noxious pinch and heat
(48°C, 10 s). The neurons were classified according to
their sensory input with non-nociceptive neurons being
those which responded only to light brushing of the
hairs of the cutaneous receptive field, while those which
responded to brush, noxious pinch, and/or noxious heat
inputs were classed as being multireceptive. No noci-
specific neurons were investigated in this experiment.
Prior to ionophoresis of the solutions, or stimulation of
the neuron by a sensory input, recording was started to
determine the basal firing level. All neurons tested dis¬
played a low basal firing rate of 0-1 Hz.
To demonstrate the presence of VIP-related receptors
on dorsal horn neurons, either VIP or PACAP agonists
were ionophoresed at increasing currents over a set
period of time, initially starting at 30 nA and increasing
to 45 and 60 nA, if necessary, after 90 s, until activation
was achieved. To further investigate the receptor sub¬
type involved, a number of neurons activated by both
VIP and PACAP-38 were selected, and where possible,
the firing was stabilized by decreasing the peptide cur¬
rent accordingly and then either the [^Cl-D-Phe6,Leu17]-
VIP or PACAP(6-38) antagonist was applied at 60 nA, for
up to
3 min, to assess inhibition of the agonist-induced activ¬
ity. If inhibition was present, ionophoresis of the peptide
was stopped to look for recovery. The inhibitory effect of
the antagonists was assessed as the mean evoked activ-
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ity in the 30 s period encompassing the greatest inhibi¬
tion, compared to the mean evoked activity in the 30 s
period immediately prior to antagonist administration.
The change in activity was expressed as a percentage of
mean control activity ± the standard error of the mean
(SEM). VIP was generally tested first, followed by a recov¬
ery period of at least 10 min to allow the firing to return
to basal firing levels before PACAP-38 was tested.
To demonstrate the contribution of VIP-related recep¬
tors to sensory inputs, the effects of the VIP and PACAP
antagonists were examined on sustained sensory inputs.
Sustained innocuous inputs were set up by means of a
rotating, motorized brush, producing a steady firing rate
of 5-33 Hz, while a sustained noxious sensory input was
produced by application of the C-fibre selective chemical
algogen mustard oil (8% allyl isothiocyanate in paraffin
oil). The mustard oil experiments were carried out on 26
multireceptive cells which responded to both brush and
noxious heat. Repeated applications of mustard oil were
made to an area of approximately 2 cm2 covering the
receptive field, and after 2-7 applications, separated by 5-
min intervals, a steady elevated firing rate (6-45 Hz) was
maintained. The antagonists were then applied during
these sustained sensory inputs, initially starting at 30 nA
and increasing to 45 or 60 nA, until clear effects were
seen. The antagonists were usually ejected for 1.5-2 min
in order to assess any maintained inhibition. If inhibition
was present, ionophoresis of the peptide was stopped to
look for recovery. In addition, current and vehicle con¬
trols were also applied to the brush- and mustard oil-
induced activity. The data was analysed using the
Mann-Whitney U-test and inhibitory values of P < 0.05
were considered as being significant.
In vitro characterization of antagonists
COS 7 cells were transfected (using DEAE dextran) with
constructs in pcDNAl encoding the rat VIP,, VIP2 and
short-form PACAP receptors as previously described.6^42
The cells were then plated into 24-well plates and used
72 h after transfection. After washing three times in MEM
with 0.25% bovine serum albumin at 37°C, a further
0.5 mL aliquot of this medium was added with 0.5 mM
isobutylmethybcanthine to block phosphodiesterase
action. Following 15 min preincubation, the antagonists [p-
Cl-D-Phe6,LeuI7]-VIP,39 VIP(6-28)40 or PACAP(6-38)43 were
added at concentrations through the range 10-10 000 nM.
The agonist, VIP was then added, at a range of concentra¬
tions from 0.1 to 1000 nM and incubation continued for
20 min before the addition of an equal volume of ice-cold
0.2 M HCl and rapid freezing on solid carbon dioxide. After
thawing, well contents were homogenized and 50 pL sam¬
ples of the supernatant were assayed for cAMP using a
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double antibody immunoprecipitation radioimmunoassay
based on rabbit primary antiserum RIB7.44
RESULTS
The effects of VIP and PACAP receptor agonists
These results were obtained from 22 neurons, 8 of which
were classed as being non-nociceptive (excited by
innocuous brush only) while the remaining 14 were
multireceptive (activated by brush, pinch and/or noxious
heat). All neurons displayed a low basal firing rate of 0-
I Hz, and current control tests had no detectable effect
on any of the neurons tested. In all cases, the cells were
tested separately with both VIP and PACAP-38, with cur¬
rents ranging from 30 to 65 nA. The majority of cells
were found to be within laminae III-V as determined by
histological marking with Pontamine Sky Blue.
Both VIP and PACAP-38, when applied ionophoreti-
cally, were found to cause a marked excitation of
multireceptive dorsal horn neurons. Only 3 of the 14
multireceptive cells tested were not activated by either
VIP or PACAP-38. The remaining neurons showed vari¬
able effects, which may reflect a difference in receptor
expression between dorsal horn neurons. Five out of the
II cells activated responded to PACAP-38 alone (50-60
nA), while another five were activated by both VIP
(40-60 nA) and PACAP-38 (30-65 nA). Figure 1(A) shows
a typical example of the activation of an isolated dorsal
horn neuron by VIP and PACAP-38. Only one neuron
appeared to be activated by VIP alone. Excitation was
observed as the initiation of firing of a previously quies¬
cent cell or as an increase in basal firing, and had a
latency of onset ranging from several seconds to 4 or 5
min following application of the agonist. Of the six neu¬
rons excited by VIP, two produced a marked and sus¬
tained increase in firing, two were seen to produce a
sharp burst of high activity which then declined, while
the remaining two displayed a modest increase in basal
firing which declined to control levels when application
of the peptide was terminated.
PACAP-38 appeared to be much more effective, demon¬
strating a much greater activation of the neurons tested.
Only one out of the 10 cells excited showed a modest
increase in basal firing, five of the remaining cells showed
a sharp, sudden burst of firing which could not be main¬
tained, while the remaining four neurons displayed a large
increase in activity which often continued for several min¬
utes after the application of PACAP-38 was terminated.
Of the eight non-nociceptive neurons tested here,
none of them showed any apparent activation in
response to VIP (30-60 nA), suggesting that VIP respon¬
siveness may be restricted to neurons with nociceptive
inputs. PACAP-38, however, demonstrated a marked acti-
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Fig. 1 Effects of ionophoretically applied VIP and PACAP-38 on multireceptive dorsal horn neurons. Individual recordings of ongoing firing
frequency are displayed as the action potentials per second (rate, integrated over 1000 ms bins) plotted against time. (A) The excitation of a
previously silent dorsal horn neuron by VIP, 45 nA (* indicates brief control challenges with innocuous brush), and the subsequent excitation
of the same neuron by PACAP-38, 30 nA, 10 min after the termination of VIP. Note the sustained level of firing following application of
PACAP-38, even after ionophoresis of this peptide was terminated; a phenomenon seen for a number of the neurones tested. (B) This trace
shows the negligible effects of PACAP(6-38) (60 nA) and marked inhibitory effect of [p-CI-D-Phe6,Leu17]-VIP (60 nA) antagonists
respectively, on the sustained activity evoked by application of VIP (60 nA) in a neuron responding to both VIP and PACAP-38. (C) The
effects of PACAP(6-38) (60 nA) on PACAP-38-evoked activity (60 nA), in a typical neuron activated by both PACAP-38 and VIP.
vation of three of the eight neurons. Only one of the
responsive cells showed a sustained level of activity, the
other two neurons showed a sudden burst of activity
which could not be maintained. So it seems possible that
some non-nociceptive dorsal horn neurons may express
a receptor type enabling responsiveness to PACAP but
not to VIP, i.e. a PACAP receptor.
Effects of VIP/PACAP receptor antagonists on
sustained agonist-driven activity
In this study, a further six multireceptive neurons were
selected for their ability to be clearly activated by both
VIP and PACAP-38, in order to try and further ascertain
the receptor subtypes expressed on dorsal horn neurons
under normal conditions. VIP (45-60 nA) produced an
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Fig. 2 Effects of ionophoretically applied VIP and PACAP receptor antagonists on sustained brush-evoked responses of non-nociceptive
dorsal horn neurons. Individual records of sustained firing are displayed as the action potentials per second (rate, integrated over 1000 ms
bins), plotted against time. (A), (B) and (C) show the generally observed lack of effect on the sustained firing of non-nociceptive dorsal horn
neurons when [p-CI-D-Phe6,Leul7]-VIP, VIP(6—28) and PACAP(6-38) respectively, were applied to innocuous brush-evoked activity. Each
trace is from a different neuron and is entirely typical of the results obtained in the overall population sampled here.
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Fig. 3 Effects of the ionophoreticaliy applied VIP and PACAP receptor antagonists on sustained evoked responses of multireceptive dorsal
horn neurons. Individual records of sustained firing are displayed as the action potentials per second (rate, integrated over 1000 ms bins),
plotted against time. (A) The marked inhibitory effects of [p-CI-D-Phe6,Leu17]-VIP when applied to the sustained neuronal activity evoked by
innocuous brush or noxious mustard oil application. Similarly (B) and (C) show clear antagonist effects of VIP(6-28) and PACAP(6-38)
respectively on brush- and mustard oil-evoked activity. All examples show a marked inhibition of neuronal firing following application of the
antagonist, with almost immediate recovery following termination of peptide application. In all three cases both the brush- and mustard oil-
induced activities are evoked from the same multireceptive dorsal horn neurons, and the results are typical of those obtained in the
population sampled.
average 9-fold increase in activity (4.2-22.3 Hz) when
applied to multireceptive neurons (n = 6). [/>C1-d-
Phe6,Leu17]-VIP significantly inhibited this agonist driven
activity (P < 0.05) showing a mean percentage inhibition
of 42 ± 14%, while PACAP(6-38) exhibited little effect,
12 ± 9% inhibition (Fig. 1(B)).
Five of the six neurons tested produced agonist-driven
activity which was sustained following application of
PACAP-38 (30-60 nA), thereby allowing us to test the
effects of antagonist application. The sustained levels
of firing (10.3-31.8 Hz) were an approximate 17-fold
increase from basal levels (n = 5). This time [^-C1-d-
Phe6,Leu17]-VIP showed negligible effects on activation
by PACAP-38 with a mean percentage inhibition of 6 +
4%. In contrast, PACAP(6-38) significantly inhibited
neuronal activity by 29 + 9% (Fig. 1(C)). Recovery was
observed in all cases of inhibition, with the majority of
neurons taking approximately 60 s to return to control
firing levels.
Effects of VIP/PACAP receptor antagonists on
sustained neuronal firing evoked by sensory inputs
The majority of neurons examined were within laminae
III-V of the dorsal horn, as determined by histological
marking with Pontamine Sky Blue. Eleven were classed
as non-nociceptive neurons while 27 were classed as
multireceptive. Only neurons with receptive fields on
hairy skin were used, to facilitate classification and
mustard oil application. Ionophoresis of vehicle (pH 4.5
H20) or NaCl current controls had no detectable effect
Neuropeptides (1997) 31(2), 175-185 © Pearson Professional Ltd 1997
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Fig. 4 Summary histogram showing the inhibition of stimulus-
evoked neuronal firing rate of dorsal horn neurons caused by
VIP/PACAP receptor antagonists in comparison with control vehicle
application (pH 4.5 H20). Responses in the presence of □ vehicle
control,B[p-CI-D-Phe6,Leu17]-VIP,BVIP(6-28) and ilPACAP(6-38)
are shown. All three antagonists showed negligible effects when
applied to sustained neuronal activity of non-nociceptive neurons
(A), while both innocuous brush- and noxious mustard oil-induced
activity of multireceptive neurons were markedly decreased (* = P
< 0.05) by application of any of the three antagonists (B).
on the brush or mustard oil-induced activity of those
neurons tested.
In non-nociceptive neurons, all three antagonists
showed negligible effects when applied to sustained
neuronal firing induced by innocuous brush, with ejec¬
tion currents of 30-60 nA. [^-Cl-D-Phe6,Leu17]-VIP
showed a mean percentage inhibition of 8 ± 2% (n = 14),
VIP(6-28) exhibited 10 ± 4% inhibition (n = 7), while
PACAP(6-38) had a mean percentage inhibition of
11 + 7% (n = 6) (Fig. 2). In multireceptive neurons, how¬
ever, the VIP and PACAP antagonists significantly inhib¬
ited both brush- and mustard oil-induced responses
(Fig. 3). [/?-Cl-D-Phe6,Leu17]-VIP showed 53 ± 6% inhibi¬
tion (n = 19) of sensory responses induced by innocu¬
ous brush and 59 ± 8% inhibition (n = 11) of those
induced by mustard oil. The latency of inhibition varied
slightly from cell to cell, but recovery was observed in
all cases, with the activity of the majority of cells return¬
ing to control levels within about 90 s. Similarly,
VIP(6-28) inhibited brush-evoked activity by 67 ± 6%
(n = 13) and mustard oil-induced activity was inhibited
by 71 ± 13% (n= 7). Again recovery was observed in all
cases, from 2-3 s to 2 min. PACAP(6-38) also showed a
marked effect on both types of response with 60 ± 9%
inhibition (n = 16) of innocuous brush and 66 ± 9%
inhibition (n = 9) of noxious mustard oil-induced activ¬
ity. The activity of approximately half the cells tested
with PACAP(6-38) returned to control firing levels
within 5 s of terminating ionophoresis of the peptide,
while the remaining neurons took anything from 1.5 to
8 min to recover. Figure 4 shows a summary histogram
of the antagonist effects.
In vitro characterization of antagonists
VIP (0.1-1000 nM) caused concentration-dependent
increases in cAMP generation by COS 7 cells expressing
VIP,, VIP2 or PACAP receptors, with EC50 values
of 3.3 ± 0.7, 0.9 ± 0.2 and 29 ± 6 nM respectively
(means ± SEM from 8-12 separate determinations). Cells
transfected with vector alone showed no response to VIP.
Since the agents were not in all cases simple competitive
antagonists, Schild analysis could not be completed and
inhibition curves were constructed at a fixed submaximal
agonist concentration of 5 nM. This concentration of VIP
elicited cAMP generation of 12.2 + 0.9-, 14.3 ± 1.3- and 8.5
± 1.4-fold over basal levels at VIP,, VIP2 and PACAP recep¬
tors, respectively. Table 1 illustrates that f/r-Cl-D-
Phe6,Leu17]-VIP was a more potent inhibitor of cAMP
generation at VIP, receptors (IC50 approximately 3 pM)
than at either PACAP or VIP2 receptors, with a margin of
selectivity (estimated from inhibition curves) of 7- and 8-
fold respectively. The potency of [^-Cl-D-Phe6,Leu17]-VIP
was however quite low, even at VIP, receptors, and fur¬
thermore this compound alone acted as a weak partial
agonist at VIP, and VIP2, but not PACAP, receptors (to less
than 20% of the VIP maximum at 10 pM). Additionally,
VIP, receptor antagonism by this analogue was not purely
competitive, with a clear reduction of maximal responses
to VIP. Its greater effectiveness at VIP, than at VIP2 recep¬
tors has been described previously.45 VIP(6-28) was a
moderately potent antagonist at PACAP receptors (IC50
approximately 2 pM), a weak antagonist at VIP2 receptors
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Table 1 Antagonist potencies on heterologously expressed VIP,, VIP2 and PACAP receptors
IC50 value (pM) on cAMP generation elicited by 5 nM VIP






(24 ± 4% inhibition at 10 pM)
»3
(16 + 6% inhibition at 3 pM)
> 10




(36 ± 8% inhibition at 10 pM)
1.67 ±0.38
0.014 ±0.002
Each value is the mean ± SEM from 8-12 separate determinations.
(IC50 approximately 9 pM) and showed very little affinity
for VIP, receptors. PACAP(6-38) was an extremely potent
antagonist of PACAP receptors (IC50 of 14 nM) and unex¬
pectedly also showed high potency at VIP2 receptors (IC50
of 170 nM). In contrast, PACAP(6-38) demonstrated little
or no interaction with VIP, receptors throughout the con¬
centration range tested and thus displayed a selectivity
sequence of PACAP > VIP2, » VIP, with selectivity ratios
of approximately 12- and »30-fold respectively.
DISCUSSION
These results further support previous evidence that VIP
and its related peptides may play important physiological
roles as neurotransmitters within the central nervous
system, as well as providing us with new insights into the
type of VIP/PACAP receptors functionally important in
rat dorsal horn neurons, under normal conditions.
Despite the fact that VIP and PACAP are normally pre¬
sent in relatively low abundance,19'20 the present results
provide clear evidence for the presence of VIP/PACAP
receptor subtypes on dorsal horn neurons under normal
conditions. The agonist study carried out has provided
the first direct evidence that PACAP is an effective exci¬
tant of spinal dorsal horn neurons, while reinforcing pre¬
vious evidence of an excitatory role for VIP within the
spinal cord. Although the two agonists used produced
similar results, three main differences are apparent.
The first is that PACAP-38 appears to be more potent
than VIP in terms of neuronal excitation, as it seems to
have a much more marked excitatory effect, despite
being used at the same concentration and similar
ionophoretic currents. Approximately two-thirds of the
neurons tested (10 out of 14) were activated by PACAP-
38 compared to only 6 out of 14 with VIP. In the majority
of cases PACAP-38 was also found to have a longer dura¬
tion of action than VIP, lasting for at least 20 min in some
cases. This long-term activation of a small proportion of
some of the neurons, even after application of PACAP-38
had been terminated, would be consistent with the possi¬
bility that PACAP-38 may have induced some form of
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sensitization at the spinal cord level. The source of
endogenous PACAP-38 which may be able to achieve
this is likely to include afferent C-fibres, since it has been
previously shown that the levels of PACAP in dorsal horn
are markedly decreased by capsaicin treatment.17 The rel¬
atively prolonged action of VIP and more especially
PACAP-38, suggests a longer term regulatory role for
these peptides, and the disparities between the two ago¬
nists could be due to a more prolonged effect of PACAP
at the site of action, but may simply be due to differences
in the enzymatic degradation processes for the two pep¬
tides.
The fact that some cells were activated by PACAP-38
and not by VIP (the second difference) suggests that a
sub-population of cells may express PACAP receptors
either instead of, or in addition to, VIP, or VIP2 receptors
under normal conditions. However, a number of other
cells responded to both PACAP and VIP, suggesting a
response mediated by either VIP, and/or VIP2 receptor
subtypes, where VIP and PACAP show similar potency. It
is not clear whether PACAP and VIP receptors mediate
dual regulation of individual cells. The efficiency of elec-
trophoretic transport out of the electrodes may not nec¬
essarily be identical for VIP and PACAP-38, and so may
bias our results. In the majority of cells tested, there was
a relatively slow onset of effect and activation was often
observed at fairly high currents (up to 60 nA), suggesting
either quite low transport efficiency or diffusion to the
site of action, so it is not possible to make a direct com¬
parison. On balance, however, these results would sug¬
gest that PACAP may have a more widespread effect
within the spinal cord than VIP.
The third difference involved the type of dorsal horn
neuron activated. Responsiveness to VIP appeared to be
highly selective for multireceptive neurons only, while
PACAP-38 also excited a sub-population of the non-noci-
ceptive neurons tested. Previous investigators have
reported VIP to be equally effective in exciting both noci¬
ceptive and non-nociceptive trigeminal neurons,29 but in
the present study we found VIP to have no significant
effect on any of the non-nociceptive dorsal horn neurons
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tested. These results also correspond to the antagonist
experiments carried out where none of the VIP/PACAP
receptor antagonists used produced any significant effect
on the brush-induced activity of non-nociceptive dorsal
horn neurons. The agonist results suggest that whilst
both VIP and PACAP cause a marked excitation of neu¬
rons within the spinal dorsal horn, there may be some
differences in the distribution of their receptors and that
they may each play a role (perhaps independently) in reg¬
ulating sensory transmission at the spinal cord level.
The importance of VIP/PACAP-mediated transmission
under normal conditions is highlighted in the antagonist
study, where the sustained activity of multireceptive
spinal cord neurons brought about by topical application
of the C-fibre selective irritant mustard oil, innocuous
brushing of the hindlimb or ionophoretic application of
the agonists VIP or PACAP-38, is clearly regulated (or
mediated), at least in part, by VIP/PACAP receptors.
Blockade of these sensory responses shows a remarkable
similarity between the effects of VIP and PACAP receptor
antagonists. All three antagonists used showed a marked
inhibition of the firing induced by either innocuous
brush or noxious mustard oil application to the receptive
fields of multireceptive neurons, while having no signifi¬
cant effect on the brush-induced activity of non-
nociceptive dorsal horn neurons. This highlights the pos¬
sibility that these peptides are largely restricted to neu¬
ronal pathways concerned with the regulation of
C-fibre-mediated transmission, and the pharmacological
profile suggests that both VIP and PACAP receptors may
play a role. While a small population of non-nociceptive
neurons may express PACAP receptors, the lack of effect
of the PACAP receptor antagonist on the brush-induced
responses of non-nociceptive neurons indicates that
these receptors do not exert a significant functional influ¬
ence under normal conditions.
Nociceptive afferents, including C-fibres, terminate in
the superficial layers of the dorsal horn, and previous evi¬
dence has already demonstrated the fact that both VIP
and PACAP are found in small diameter fibres,18'22'46
inferred to be the A5- and C-fibres associated with poly-
modal and mechanical nociceptors. The majority of VIP-
and PACAP-immunoreactive fibres are also present in
laminae I and II of the rat spinal dorsal horn17'18-21 with
additional fibres being found around the central canal
and in lamina VII. These histological findings initially
provided the grounds for suggesting a role for these pep¬
tides in the control of normal sensory transmission, and
the present antagonist data has now provided the first
physiological evidence. The firing rate of the majority of
cells tested was restored almost immediately the antago¬
nist application was terminated. This suggests the possi¬
bility that the VIP/PACAP receptors are found on the
recording neurons themselves and that VIP and PACAP
are acting directly on the dorsal horn neurons. However,
slow onset agonist responses could also be consistent
with actions on cells which indirectly (but non-selec-
tively with respect to input modality) regulate the
recorded neurons. It has been shown previously that pro¬
tein kinase A inhibitors such as H89 inhibit both brush
and mustard oil responses of neurons47 so it is possible
that the VIP and PACAP receptors are acting here via
cyclic AMP pathways. This is consistent with evidence
for facilitation of dorsal horn neuron responses to excita¬
tory amino acids following pre-incubation with the
adenylate cyclase activator forskolin.48
Although totally specific agonists and antagonists are
not yet available for VIP,, VIP2 and PACAP receptors, it
is possible to use the relative selectivity of a number of
compounds to make inferences about the type of recep¬
tor^) which may be involved in physiological responses.
PACAP receptors are activated with much greater
potency by PACAP-38 than by VIP,8'42 suggesting that a
response elicited by PACAP-38 but not by VIP is likely
to be mediated by a PACAP receptor. In contrast, VIP,
and VIP2 receptors are activated by VIP with a potency
similar to or greater than that for PACAP-38,6-745 sug¬
gesting that a response elicited by either VIP or PACAP-
38 with similar ionophoretic currents is likely to be
mediated by VIP, or VIP, receptors. Thus it appears that
most multireceptive neurons are regulated by some
form of VIP/PACAP receptor - with the predominant (or
sole) effective form in about half of the population
being VIP, or VIP2 - while that in the remaining half
appears to be the PACAP receptor. PACAP receptors may
also be present on a minor subpopulation of non-noci¬
ceptive cells.
The receptor selectivity of the antagonists used allows
further analysis of the subtypes of VIP/PACAP receptor
likely to be involved in regulating sensory inputs. The
cAMP production assay on individual receptor types
expressed from their cDNAs characterizes the specificity
of the antagonists used. The [^-Cl-D-Phe6,Leu17]-VIP
antagonist appears to be selective for the VIP, receptor
whilst showing only very low affinity for the VIP2 or
PACAP receptors. This is in agreement with a previous
study which also provided evidence for selectivity of [p-
Cl-D-Phe6,Leu17]-VIP for VIP, relative to VIP2 receptors.45
VIP(6-28), however, appeared to be moderately selective
for PACAP receptors, with more than 4-fold lower affinity
for VIP2 receptors, and very little affinity for VIP, recep¬
tors. Although PACAP(6-38) is very highly selective for
PACAP receptors, it also has a sufficiently high affinity
for VIP2 receptors to raise the possibility that it could be
acting in the electrophysiological studies by VIP2 rather
than PACAP receptor blockade. PACAP(6-38) appeared
to be essentially inactive at VIP, receptors through the
concentration range tested.
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Whilst agonist selectivity alone points strongly to the
presence of PACAP receptors in cells responding to
PACAP-38, but not VIP, the type of VIP receptor present
in VIP-responsive cells can only be inferred from antago¬
nist experiments. The blockade of VIP-evoked responses
in such cells by [^-Cl-D-Phe6,Leu17]-VIP, but not by
PACAP (6-38), suggests VIP, rather than VIP, receptor
mediation because of their relative selectivity for VIP,
and VIP2 receptors, respectively. The blockade of PACAP-
evoked activity by PACAP (6-38), but not [p-Cl-D-
Phe6,Leul7]-VIP, is consistent with the additional pres¬
ence of PACAP receptors, given that PACAP-38 will
activate PACAP receptors at much lower concentrations
than VIP, and VIP2 receptors.
The issue of which of these receptors are functionally
important in normal dorsal horn was addressed by
applying antagonists during recordings of sensory
responses. [/?-Cl-D-Phe6,Leu17]-VIP, VIP(6-28) and
PACAP(6-38) all inhibited both brush- and mustard oil-
evoked responses of multireceptive cells, suggesting that
VIP,, PACAP (and possibly also VIP2) receptors are
involved normally in the regulation of dorsal horn neu¬
ron responsiveness. The origin of the endogenously
released VIP/PACAP is not clear, with either local or
afferent neurons being candidates. In summary, this is
the first demonstration of an active role of VIP/PACAP
receptor subtypes in regulating acute sensory inputs to
dorsal horn neurons under normal conditions.
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.bstract
A combined study of behavioural and electrophysiological tests was carried out in order to assess the role of metabotropic glutamate
jceptors (mGluRs) in mediating sensory inputs to the spinal cord of the rat. In the behavioural study the responses of conscious animals,
'ith or without carrageenan-induced inflammation, to noxious mechanical and thermal stimuli were observed both before and after the
ltrathecal administration of mGluR antagonists l( + )-2-amino-3-phosphonopropionic acid (l-AP3) and (5)-4-carboxy-3-hydroxyphenyl-
lycine (CHPG). It was found that the mGluR antagonist (Sl-CHPG was capable of increasing both mechanical threshold and thermal
itency in both groups of animals, and l-AP3 did so in those with inflammation induced in their hindpaw. Following this study, the
■-sponses of single lamina III-V dorsal horn neurons to an innocuous A /3 fibre brush stimulus and a noxious C fibre (mustard oil)
imulus were extracellularly recorded and the effect of ionophoretically applied drugs was examined. Cyclothiazide (CTZ), a selective
itagonist at mGluR,, markedly reduced the activity evoked by mustard oil, but not that elicited by brushing of the receptive field,
ctivity induced in dorsal horn neurons by ionophoresing various mGluR subgroup agonists was examined. CTZ successfully inhibited
le activity evoked by group I mGluR agonist 3,5-dihydroxyphenylglycine (DHPG). In comparison to the neurons which responded to the
nophoresis of DHPG, less were activated by the selective mGluR5 agonist trans-azetidine dicarboxylic acid (t-ADA). Together these
suits indicate that group I mGlu receptors, in particular mGluRj, play a crucial role in mediating nociception, particularly following a
istained noxious input. © 1997 Elsevier Science B.V.
tywords: Pain; Metabotropic glutamate receptors; Spinal cord; Analgesia; Nociception
Introduction
There is a large body of evidence supporting a role for
e excitatory amino acid glutamate in mediating sensory
-formation and there are a number of receptors which
ay contribute to this role. These receptors have been
vided into (i) the ionotropic group, non-A'-methyl-d-
-partate (NMDA) and NMDA receptors, which contain
trinsic ion channels, and (ii) the metabotropic group,
tich are coupled to G proteins and several signal trans¬
action pathways.
Corresponding author. Tel.: +44 (131) 650-6091; Fax: +44 (131)
1-6576; E-mail: sfw@labO.vet.ed.ac.uk
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lite Lion Road. Buckinghamshire HP7 9LL, UK.
Despite the recent interest in the role of metabotropic
glutamate receptors (mGluRs) in the central nervous sys¬
tem, their contribution to nociceptive processing in the
spinal cord is still unclear. There are eight cloned mGluRs
known at present [1,14,33,36,44], and these have been
further divided into three subgroups, according to their
pharmacological and signal transduction profiles: group I
(mGluRs,/5), group II (mGluRs2/3) and group III
(mGluRs4/6/7/8) [1,34,37], Until recently the pharmaco¬
logical tools available could not distinguish adequately
between the different receptors, however with the advent
of newer, more specific drugs at the receptor subtypes it
has been possible to begin to investigate the separate roles
of these three mGluR subgroups. A number of studies have
provided evidence that mGluRs are involved in selectively
mediating noxious inputs to the spinal cord [35,51,52] as
)6-8993/97/$17.00 © 1997 Elsevier Science B.V. All rights reserved.
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well as the thalamus [15,16], although the particular recep¬
tors) involved could not be fully elucidated from the
compounds used. In a previous study we demonstrated
how mustard oil-evoked responses could be blocked by
mGluR I antagonists (R.Sj-CHPG and l-AP3, while
brush-induced activity remained unchanged [51,52],
The effect of mGluR compounds on activity at the
NMDA receptor channel is of particular interest, as this
receptor is important in nociceptive mechanisms. Several
studies have demonstrated an interaction between the
NMDA receptor and mGluRs. In electrophysiological ex¬
periments, both in vitro [5,8] and in vivo [6], NMDA-
evoked responses are enhanced when mGluR agonists are
co-applied. Also, in behavioural studies using the formalin
model, the co-administration of NMDA with mGluR ago¬
nist (( + )-l-aminocyclopentane-trani-l,3-dicarboxylic acid
(trans-ACPD) results in a much greater increase in noci¬
ceptive behaviours than seen with either agonist given
alone [11]. A more recent study utilising this model has
confirmed that an increase in nociceptive behaviour is
induced by intrathecally-administered mGluR agonists
(R.SO-dihydroxyphenylglycine (DHPG; group I) or
(1 S,3s)-ACPD (non-selective mGluR), but not
(2s,rr,2'r,3'r)-2-(2',3'-dicarboxy-cyclopropyl)-glycine
(DCG-IV; group II) and that this can be reversed by the
administration of NMDA antagonist d-2-amino-5-phospho-
nopentanoic acid (d-AP5) prior to testing [17]. It was in
light of this evidence that we chose to investigate more
closely the role of group I mGluRs.
We evaluated the role of these receptors in mediating
noxious inputs in two ways: The first was a behavioural
study in which we assessed the effect of intrathecally-de-
livered mGluR antagonists (which act preferentially at
group I mGluRs) on the responses of conscious animals to
noxious mechanical and thermal stimuli, both in normal
and carrageenan-treated animals. The second was an elec¬
trophysiological study in which we observed the effect of
ionophoresing mGluR, antagonist cyclothiazide (CTZ)
during the activity elicited by (i) repeated topical applica¬
tions of the C-fibre irritant mustard oil, and (ii) innocuous
brushing of the receptive field. We also tested several
mGluR agonists to assess their ability to induce excitation
of dorsal hom neurons. In this way we aimed to determine
the extent to which mGluRs are involved in mediating
noxious inputs, particularly mGluRs1/5.
2. Materials and methods
2.1. Behavioural testing
Animals were Glaxo-bred male and female Lister-
hooded rats (30-70 g). All drugs, i.e. l( + )-2-amino-3-
phosphonopropionic acid (l-AP3), d-AP3 ([38] 60 nmol)
and (S)-carboxyhydroxyphenylglycine (CHPG) ([19] 48
nmol), were administered as a 10-p.l injection in saline.
The pH of each solution was adjusted to 7.2-7.4.
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Animals received a single intrathecal (i.t.) injection b;
means of a 10 p.1 Hamilton microsyringe, as described b;
Hylden and Wilcox [23], Young animals were used for thi
procedure since access to the intrathecal space was fount
to be much easier than in large adults. Baseline measure
ments of paw withdrawal threshold/latency to noxiou
mechanical/thermal stimulation were taken prior to druj
administration. Following the i.t. injection of drug o
vehicle, paw withdrawal reactions were tested at 1, 3 and '.
min. Paw withdrawal threshold to a noxious mechanica
stimulus was measured using a Ugo Basile Analgesy-Me
ter and measurement of paw withdrawal latency to noxiou
heat (to the nearest 0.1 s) was measured with a Ugo Basili
Tail Flick Unit. One group of animals had no treatment t<
their paws, whereas a second group were used to assess th<
effects of drugs in the inflamed state. In these animals
inflammation was induced in one hindpaw by the adminis
tration of A-carrageenan. Prior to the induction of thi;
peripheral inflammation, baseline responses were recordei
for each animal. A 100-p.l unilateral injection of 2°/
A-carrageenan was administered subcutaneously into thi
dorsal (hairy) surface of the right (ipsilateral) hindpav
under a brief halothane anaesthesia. After 3 h, paws wer
seen to be swollen and local oedema was apparent. Furthe
reflex testing showed these animals to display decrease'
threshold responses, thus indicating hyperalgesia of th
paw.
All withdrawal responses were calculated as a percent
age of those determined before the administration of vehi
cle or drug. The data shown are mean + S.E.M. values fc
groups of subjects; however, each individual animal had il
own percentage change calculated. In separate groups c
animals in which inflammation was induced a second s<
of baseline measurements were recorded 3 h after cai
rageenan administration, but prior to drug delivery. Dim
induced effects were compared to those evoked by vehicl
administration and statistical analysis was carried out usin
the Mann-Whitney U-test.
2.2. Electrophysiology
Experiments were carried out on 34 adult male Wist
rats (240-420 g). Under an initial halothane anaesthes
the jugular vein and trachea were cannulated. Anima
were then given intravenous a-chloralose (60 mg kg"
and urethane (1.2 g kg-1) with supplementary doses -
a-chloralose (10 mg ml-1) given throughout the expei
ment. Core body temperature was maintained at 37-38c
by means of a thermostatically-controlled heat blank
linked to a rectal probe. Animals breathed freely with
light flow of oxygen (0.1 1 min-1) passed over the trache
cannula to enrich the inspired air. The animal was plao
in a stereotaxic frame and the thoraco-lumbar spinal cc
umn was supported using three pairs of swan-neck'
clamps. A laminectomy (L1-L4) was performed and
provide stability agar was injected under the most rosti
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'ertebra and then over the exposed spinal cord. A small
rea of this agar was removed to uncover the recording
egion. Finally the dura was removed and liquid paraffin,
>7°C, was then poured over the exposed spinal cord.
Extracellular recordings were made from single neurons
n laminae III—V via the central barrel of a 7-barrelled
;lass microelectrode filled with 4 M NaCl (pH 4.0-4.5).
lie tip diameter ranged from 4-5 p,m with DC resistances
1 5-8 Mil. The bandwidth of the recording amplifier was
Hz-7 kHz. The following drugs were ionophoresed from
le side barrels of the electrode: non-selective mGluR
.gonist (1 5,3 R)-1 -aminocyclopentane-1,3-dicarboxylic
cid (ACPD; [24]), mGluR5 agonist frans-azetidine-2,4-di-
arboxylic acid (t-ADA; [28]), group II agonist
25,35,45)-CCG/(25,l'5,2'5)-2-(carboxycyclopropyl)gly-
ine; L-CCG-i; [22]), group III agonist l( + )-2-amino-4-
hosphonobutyric acid (l-AP4; [34]), a-amino-3-hydroxy-
-methyl-4-isoxazolepropionic acid (AMPA) and antago-
sts l( + )-2-amino-3-phosphonopropionic acid (l-AP3;
[38]), (R,5)-4-carboxy-3-hydroxyphenylglycine (CHPG;
[47]), (5)-CHPG [4] and the selective group II antagonist
(25, r5,2'5)-2-(2-carboxycyclopropyl)alanine (MCCG;
[40]) were all 10 mM in distilled water, pH adjusted to
8.0-8.5 with sodium hydroxide; mGluR, antagonist cyclo-
thiazide (CTZ; [41]), 0.1 mM in 0.5% dimethylformamide,
pH 4.5; group I agonist 3,5-dihydroxyphenylglycine
(DHPG; [39]), 10 mM aqueous, pH 4.5. All compounds
were obtained from Tocris Neuramin. Retention currents
of +10 nA were employed to minimise drug leakage
between tests. One of the remaining barrels contained 1 M
NaCl (pH 4.0-4.5) for automatic current balancing, using
a Neurophore BH2 Ionophoresis system, and current con¬
trols. A second side barrel contained Pontamine sky blue
(PSB; 2% in 0.5 M sodium acetate) which was used to
mark recording sites by ejecting for 12-14 min at 10 p,A.
The resistance of the side barrels was standardly measured
and ranged from 25-30 MO.

























I. The effects of intratherally-applied L-AP3 on paw withdrawal responses in nunnal and inflamed paws. Paw withdrawal responses ( + S.E.M.) are
Am as a percentage of the response immediately prior to drug administration (100%; that is the threshold and latency, respectively, in mechanical and
mal stimulation experiments). In A, open symbols show the data from saline-treated rats, whereas filled symbols represent L-AP3-treatment; triangles
responses to noxious mechanical stimulation and squares responses to noxious thermal stimulation. The data highlight the marked analgesic effect of
P3 administration seen following the induction of inflammation by A-carrageenan, but not in untreated animals. Although values in naive rats tended to
ligher with L-AP3 administration than in saline controls, this did not reach statistical significance in the present study. * * P<0.01; * P < 0.05,
ificant differences with respect to saline (Mann-Whitney C/-test). B shows a comparison of the effects of intrathecally-applied L-AP3 and its
'.oisomer D-AP3 in animals which had been previously treated with carrageenan. The histogram demonstrates the analgesic effect of L-AP3 (lightly
—led columns) in both mechanical and thermal tests, and how it was significantly different from the near-baseline effect observed with D-AP3 (heavily
led columns), thus implicating an mGluR-mediated effect. Data are shown as a percentage of pre-drug responses; P < 0.05 with respect to D-AP3
nn-Whitney U-test). C shows a comparison of the effect of L-AP3 on non-inflamed versus inflamed paws. There was a significant difference between
lal animals (lightly hatched columns) and carrageenan-treated animals (heavily hatched columns) following the intrathecal administration of L-AP3 (60
1). In both mechanical and thermal tests, L-AP3 was significantly analgesic only following inflammation, suggesting a more prominent role for
uRs under these conditions. * * P < 0.01; * P < 0.05 with respect to the untreated paw (Mann-Whitney U-test).
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using a widespread manual brushing of the cutaneous
surface of the hindlimb. Further characterisation was car¬
ried out using a noxious radiant heat stimulus (48°C, 10 s).
All neurons exhibited low basal firing rates between 0 and
1 Hz. In the experiments using mustard oil (allyl isothio-
cyanate, Aldrich Chemical Co., 7.5% in paraffin oil); this
irritant was repeatedly applied over an area of about 3 cnr
and after 2-5 applications, separated by 5 min, steady
elevated firing rates were observed (4-60 Hz). The in¬
hibitory effects of antagonists were calculated as the mean
evoked activity through a 20- or 30-s period encompassing
the maximum observed inhibition, compared to the mean
evoked activity in the 20-30-s period immediately preced¬
ing drug ionophoresis. The effects of the antagonists on
motorised brush-, topically applied mustard oil- and ago¬
nist-evoked activity were compared over similar current
ranges. Statistical analysis was carried out on raw data
using the Wilcoxon test.
3. Results
3.1. Behavioural study
A total of 91 rats was used in this study, with each
animal being randomly assigned to a test group. Nocicep¬
tive reflexes were assessed in these rats by their with¬
drawal reaction to a noxious (mechanical or thermal)
stimulus applied to one hindpaw prior to and following
intrathecal drug administration. The effects of mGluR
antagonists were compared in normal rats and in those
where a subcutaneous injection of A-carrageenan had been
given 3 h earlier, resulting in an inflammation of the paw.
The mean changes in paw withdrawal responses per group
of rats are given (8 < n < 14; mean percentage change +
S.E.M.) with statistical significance as determined using
the Mann-Whitney U-test (see Fig. 1A,C and Fig. 2). All
drug-induced effects were compared to those of saline
vehicle. In a separate set of experiments, the effects of
l-AP3 were directly compared with those brought about by
its stereoisomer d-AP3, which is without effect at mGluRs,
though it is a weak antagonist at the NMDA receptor [38]
(see Fig. IB).
In normal animals an intrathecal injection of L-AP3 (60
nmol) resulted in only minor changes in paw withdrawal
responses to either mechanical or thermal stimulation (n =
14 and 8, respectively), which did not reach statistical
significance in this study (see Fig. 1). However, when
(S)-CHPG was applied (48 nmol; n= 14), both thermal
latency and mechanical threshold were increased from
pre-drug levels in control (as well as inflamed) animals
and this was statistically significant at the 3-min time point
from the effects observed using vehicle (P < 0.05; see Fig.
2). The difference between the effect of these compounds
may well be due to the fact that (.S'+CHPG is a far more
potent antagonist at mGluRs than L-AP3 [37].
TIME (mins)
Fig. 2. Effect of intrathecally applied (S)-CHPG on paw withdrav
responses in normal and inflamed paws. Paw withdrawal respon:
( +S.E.M.) are shown as a percentage of the response immediately pr
to drug administration. Open symbols show the data from saline-trea;
rats, whereas filled symbols represent (S)-CHPG treatment; triangles
responses to noxious mechanical stimulation and squares are to noxii
thermal stimulation. In comparison to saline controls, this compoi
significantly raised responses in both tests, not only in carrageenan-trea
animals but also in normal rats. (* * P < 0.01; * P < 0.05; Mann-Wl
ney I/-test).
The results obtained from the animals which had
inflammation induced using carrageenan were differ
from those observed in the normal animals. (Sj-CH)
(n = 13) now induced more profound effects with
creases in thermal latency at the 1-min time point
+ 74+10% (P<0.05) and mechanical threshold
+ 130 + 31% (P < 0.01; see Fig. 2). Interestingly, l-A
was now also found to significantly increase the wi
drawal responses (see Fig. 1A and C). The withdra1
threshold to noxious mechanical stimulation was increa
by this compound (n = 14) to + 156 + 58% (P< 0.
and thermal latency was increased by +97 + 6% (/
0.01). Neither of these analgesic effects were mimicked
d-AP3 in inflamed animals (see Fig. IB). (R)-CHPG 1
not tested as it has antagonist properties at the NM—
M.R. Young et al. /Brain Research 777 (1997) 161-169 165
eceptor [4], This effect of L-AP3 in the inflamed group
vas significantly different from that observed in the nor-
nal group (,P< 0.05 in mechanical testing and PC 0.01
>n thermal tests; see Fig. 1C).
'.2. Electrophysiology
Most neurons tested were multireceptive, responding to
>oth innocuous brushing of the receptive field as well as
loxious heating to 48°C. Microdrive readings indicated
hat the neurons recorded from were in the deeper dorsal
torn (laminae III-V), and this was confirmed with histo¬
rical examination of PSB spots post-experimentally,
onophoresis of Na+ or CP up to 80 nA had no detectable
ffects on any of the evoked activities discussed here.
.2.7. Agonist study
In a previous study we ionophoresed the non-selective
iGluR agonist 1,5,3 77-ACPD and found that approxi-
lately one-fifth (47/244; 19%) of cells could be excited
y this compound [52]. In the present experiments, we
lvestigated a range of different mGluR agonists and
■bserved their ability to evoke activity in single dorsal
3rn neurons. As well as the group I agonist 3,5-DHPG,
e also used the mGluR5-selective compound t-ADA,
oup II agonist L-CCG-I and group III agonist L-AP4.
Interestingly in the present experiments we found that
ection of the mGluR,-selective agonist 3,5-DHPG (4-45
nA) could activate over 40% (55/137) of the neurons
tested. Although this population was not identical to the
one previously reported on using (1 S,3 7?)-ACPD [52], it is
likely that they shared broadly similar characteristics as the
same search stratagem and depth range were used in both
cases. These results therefore indicate that perhaps
(15,3/0-ACPD was activating some additional inhibitory
systems, and the overall effect observed was one of lesser
excitation. The activation of group II and III mGluRs by
this compound would explain this, as they are negatively
coupled to cAMP production. The other three agonists
tested also activated a lower proportion of neurons; t-ADA
induced activity in 6 of 31 cells (19%), L-CCG-I in 4 of 20
(20%) and L-AP4 only 1 of 19 units tested (5%). In the
case of the latter two compounds, the lower proportion of
responses may be due to the fact that they are linked to
inhibitory cascades and the occasions on which we did see
activation may indicate a polysynaptic event. In the case of
t-ADA it is interesting that only a relatively small number
of cells were activated, since it is clear from immunocyto-
chemical experiments that mGluR5 are present in the
dorsal horn [46,47]. The clearly greater proportion of cells
activated by 3,5-DHPG may result from its additional
ability to activate mGluR,.
3.2.2. CTZ study
Twelve of the 51 units which responded to ionophoresis




3. Ionophoresis of mGluR, antagonist cyclothiazide (CTZ) during evoked activity in single dorsal horn neurons. Traces show raw data as responses
second, collected in 700-ms bins. The ejection of CTZ during co-ionophoresis of mGluR agonist 3,5-DHPG resulted in a marked reduction of
rity (A). Similarly, mustard oil-evoked C-fibre activity could be reduced when CTZ was ionophoresed (C), though the activity which resulted from
icuous brushing of the hindlimb receptive field was unaffected (B).
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When 3,5-DHPG was ejected (4-25 nA), the mean in¬
crease in background firing rate was 13 + 2 Hz. This
agonist-evoked activity was markedly reduced by the co-
application of mGluR |-selective antagonist CTZ (30-60
nA) in 12 out of f2 cases, with a mean inhibition of
72 + 7% (see Fig. 3A). A further five cells were tested
with repeated brief (10-20 s) applications of AMPA (20-
30 nA). In all five cases, the brief afterdischarge, limited to
2-3 s, was more than doubled in the presence of CTZ
(50-60 nA), as would be expected from its known attenua¬
tion of AMPA receptor desensitisation [7], The results
obtained when ionophoresing CTZ during evoked sensory
inputs were very similar to those already published using
L-AP3 and (R.Sj-CHPG [51], in that in 9 out of 11 cases
the noxious input elicited using the topical application of
the C-fibre irritant mustard oil was markedly inhibited by
CTZ (mean percent decrease for these 9 was 40 + 4%;
P < 0.05 compared to pre-drug firing levels; see Fig. 3C).
The lack of any noticeable inhibitory effect of L-AP3 and
(R,S)-CHPG on innocuous brush-evoked activity [51] was
also mirrored by ionophoretic application of CTZ (n = 18;
see Fig. 3B). Therefore this mGluR, antagonist appears to
be selectively blocking the transmission of nociceptive
inputs evoked by the C-fibre irritant mustard oil, but not
the low threshold brush-evoked activity.
In three out of three experiments, the 40-60% inhibi¬
tion of mustard oil-evoked activity caused by (S)-CHPG
(45-60 nA) was unaltered by co-application of MCCG
(45-60 nA), thus providing no strong evidence to suggest
a major role of group II rnGlu receptors in the effects of
(S)-CHPG here.
4. Discussion
The current study has demonstrated how antagonists
which act preferentially at group I mGlu receptors are both
analgesic in behavioural tests and selectively antinocicep¬
tive in electrophysiological recording experiments. Having
found in a previous electrophysiological study that mGluR
antagonists L-AP3 and (R,.S')-CHPG attenuated the re¬
sponses of single dorsal horn neurons to a sustained nox¬
ious input [51], we decided to assess the effect of adminis¬
tering these drugs intrathecally in conscious animals. The
S isomer of CHPG had since become available and was
used in the present experiments as it is the isomer with
activity at mGluRs [4],
We evaluated the effect of applying these compounds in
two models: firstly in normal animals and secondly in
those which had inflammation induced peripherally with a
subcutaneous injection of A-carrageenan into one hindpaw.
In the normal group we found that (S)-CHPG administra¬
tion resulted in a decreased response to both noxious
mechanical and thermal stimuli, thus implying that relative
analgesia was obtained. This compound has been shown to
act preferentially at group I mGluRs [37], so it would
appear from our data that mGluR 1/5 are participating in
the nociceptive reflexes under examination. The second1
antagonist used, L-AP3, is a weak antagonist at mGluRs-
[38]. This compound failed to significantly elevate me¬
chanical threshold or thermal latency in the naive animals.
Since (50-CHPG was successful in causing analgesia, anc
both of these compounds are likely to act at the same
receptors [37], the low potency of L-AP3 at mGluRs [37] it
likely to be the reason for this lack of effect. Interestingly
when we assessed the effects of the two antagonists in the
carrageenan-treated animals we found the outcome wa:
different to that in the normal group. Following inflamma
tion L-AP3 was analgesic, in both mechanical and therma
tests, and (S')-CHPG was even more effective in elevatin;
the responses than it had been in naive animals. Then
were no motor defects observed as a result of the adminis
tration of either mGluR antagonist. It therefore appear
that mGluR,/5 play a more profound role in an inflame*
state. This is in agreement with the results of Neugebaue
et al. [35], who found that L-AP3 inhibited the activit
evoked in dorsal horn neurons following intra-articulf
inflammation, but not before and those of Fisher an
Coderre [17] who showed attenuation of second phase, bt
not first phase formalin-induced nociceptive behaviour b
(•SO-CHPG. The increased mechanical threshold/therm;
latency induced by L-AP3 in the inflamed state is highl
likely to be due to mGluR blockade, as its stereoisomi
D-AP3 did not elicit any effects discernible from salir
controls. We chose not to assess the effects of the
isomer of CHPG as this compound is an NMDA antagi
nist [4] and many studies have implicated NMDA recepti
involvement in sustained rather than brief sensory input
so effects of this reagent would be difficult to interprt
Although we cannot fully exclude the possibility that son
of the effects of (S)-CHPG may be due to its agoni
properties at group II mGluRs [20,49], pilot electrophysi
logical experiments provided no evidence that the selecti'
group II antagonist MCCG could attenuate the reduction
mustard oil responses caused by (S)-CHPG. Clearly tl—
current investigation provides evidence that the analge;
effects of L-AP3 and (SO-CHPG are very short-acti)
under the present conditions at least. This may be som
what discouraging when considering the possibility
novel analgesic compounds. However, if a role for t
receptors at which these drugs act can be elucidated, th
identification of the target itself is a valuable tool for t
further development of more longer-lasting analgesic co
pounds.
It would therefore appear that the role of mGlu
(likely to be group I) in the spinal cord is far mi
profound following the induction of inflammation in I
hindpaw. This reflects the somewhat similar observatic
made in our earlier electrophysiological experime
whereby mGluR antagonists markedly reduced the e
vated C-fibre activity evoked when mustard oil was repe
edly applied to the cutaneous receptive field [51]. 1
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lerefore returned to the electrophysiology paradigm in
rder to further evaluate the specific mGluRs involved in
lis mediation of nociception.
Since our initial experiments, the compounds used (l-
tP3, (R,S)~ and (S)-CHPG) have been shown to act
referentially at group I mGluRs [37]. In agreement with
lis profile we have shown that the excitatory effects of a
elective group I mGluR agonist (3,5-DHPG) were much
reater than those of non-selective group II or group III
gonists. This is entirely consistent with the results of
isher and Coderre [18], who showed that intrathecal
ljections of group I mGluR agonists elicited much greater
lontaneous nociceptive behaviour than group II agonists
nd that a group III agonist was without effect. In order to
y and discern the role of mGlu, or mGlu, receptors, we
lerefore tested both a selective mGluR5 agonist, t-ADA
id an agent described to selectively inhibit mGluR, com-
ired to mGluR 5, CTZ. The proportion of cells activated
/ t-ADA was much less than that responding to 3,5-
HPG, indicating that mGluR, and perhaps also mGluR5
tes play a role in the activation of dorsal horn neurons,
lis is in agreement with a study in which it was reported
at intrathecally administered 3,5-DHPG, but not t-ADA,
icits spontaneous nociceptive behaviour [18]. These re-
Its were also consistent with our observations using
-fZ. Although CTZ has been shown to have some facilita-
ry effects at the AMPA receptor [7], we did not observe
y increase in ongoing sensory responses to brush or
ustard oil, despite evidence that AMPA receptors, partic-
ite in both non-nociceptive and nociceptive pathways
-?]. We were able, however, to demonstrate that CTZ
used a marked prolongation of afterdischarges in five
t of five cells challenged with brief ionophoretic pulses
AMPA. This suggests that effects of CTZ on AMPA
:eptor-mediated responses may be more apparent in brief
ponses rather than the maintained stimuli used here to
;ess sensory inputs. When we ionophoresed CTZ during
• activity evoked in single dorsal horn neurons by a
—ht, innocuous brushing of the cutaneous receptive field
re was no significant change, thus implying no major
—luence from facilitation of the AMPA receptor, as well
no apparent involvement of mGluR,. Conversely, if this
npound was ejected whilst a cell was activated by
eated topical application of mustard oil, a marked re¬
gion was observed. Although results with compounds
ch as CTZ) that are active at multiple sites always
uire interpretation with caution, these data provide evi-
ice to suggest that mGluR, is selectively involved in
—diating a sustained C fibre input to dorsal horn neurons,
not an innocuous A/3 fibre input. In further studies
igned to address this hypothesis, it may be of interest to
—form similar studies in rats which have been neonatally
ted with capsaicin. The mechanism by which mGlu
:ptors may contribute to sustained nociceptive inputs
ains unresolved, although numerous downstream cellu-
changes have been described [2,9,37,42,43]. Enhance¬
ment of NMDA receptor channel activity by mGluRs has
been demonstrated, both in electrophysiological experi¬
ments in vitro [5,8] and in vivo [6], and more recently in
behavioural studies [17]. Activity at group I mGluRs may
result in initiation of a number of downstream signal
transduction steps, including PKC activation [29], and we
have previously demonstrated how inhibitors of PKC (as
well as Ca2+/calmodulin-dependent kinase II and phos-
pholipase A2) can block mGluR agonist-evoked activation
of dorsal horn neurons [52], PKC inhibitors can block LTP
in the hippocampus [25-27], as well as the sustained
activity in dorsal horn neurons elicited by the cutaneous
application of C-fibre activator mustard oil, but not in¬
nocuous brushing of the recepuvc fieiu lJ-J. Eurtneriuoic,
[3H]phorbol-12,13-dibutyrate ([3H]PDBu) binding assays
have shown how sustained noxious inputs result in the
translocation of PKC to the membrane compartment in the
spinal cord in this mustard-oil model [32], as well as in
chronic constrictive injury (CCI, [30,31]) and in formalin-
evoked hyperalgesia [50]. Such PKC activation has been
demonstrated to correlate with behavioural hyperalgesia
[30,31], Also, the behavioural hyperalgesia brought about
by CCI [21] or subcutaneous formalin, [12,50] is reduced if
PKC activation is prevented. PKC-mediated enhancement
of the voltage activation of NMDA receptors has been
reported by several groups [3,10,45], Furthermore, the
spontaneous nociceptive behaviour and facilitation of for¬
malin responses elicited by intrathecally-applied mGluR,
agonist were inhibited by an NMDA antagonist [17,18].
Thus it seems possible that mGluR1/5-elicited PKC activa¬
tion may play a role in noxious, though not innocuous,
inputs to the dorsal horn of the spinal cord by means of
NMDA receptor phosphorylation and enhancement. We
have also shown in the current investigation that 3,5-
DHPG, which activates mGluR 1/5 is a relatively potent
excitant of dorsal horn neurons, compared to agonists at
group II and III mGluRs and that the selective mGluR,
agonist t-ADA was much less effective. Since 3,5-DHPG-
evoked activity (and mustard oil-evoked activity) could be
reduced consistently by the co-ejection of CTZ, it appears
that mGluR, may be activated in most of these cases of
excitation.
In summary, our present data provide further evidence
that mGluRs are crucial in processing high threshold sen¬
sory information, particularly following a sustained noci¬
ceptive input to the spinal cord. Furthermore, the evidence
indicates that group I mGluRs, in particular mGluR,, may
be of particular importance in these events.
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ABSTRACT
19th Annual Winter Neuropeptide Conference 1998
Breckenridge, Colorado.
February 6-10, 1998
THE ROLE OF VTP/PACAP RECEPTOR SUBTYPES IN SPINAL
SOMATOSENSORY PROCESSING AFTER CHRONIC CONSTRICTION
INJURY TO THE SCIATIC NERVE.
Tracey Dickinson: Patrick Robberecht* and Susan M Fleetwood-Walker
Department of Preclinical Veterinary Sciences, Royal (Dick) School of
Veterinary Studies, Summerhall, Edinburgh EH13 1QH, Scotland, UK and
*Department of Biochemistry and Nutrition, Medical School, Universite Libre
de Bruxelles, Brussels, Belgium.
Peripheral nerve damage leads to a state of hyperalgesia and allodynia which
involves important changes at the level of the spinal cord and is intractable to
classical opioid analgesics. Since VIP and PACAP expression is increased in dorsal
root ganglion cells following peripheral nerve injury, we have investigated the
expression and influence of VTPi, VTP: and PACAP receptors in dorsal hom in the
chronic constriction injury (CCI) model of neuropathic pain. Selective antagonists of
VIP2 and, to a lesser extent VIPi and PACAP receptors, inhibited the sensitised
responses of dorsal horn neurones to mustard oil, but not to brush. Neuropathy-
induced responses to cold were attenuated by VTPi and PACAP, but not VIP2,
receptor antagonists. In CCI animals compared to controls, a selective VIP2 receptor
agonist excited twice as many cells to more than 5 fold greater extent. The number
of cells excited by a selective VIPi receptor agonist decreased, whereas responses to
PACAP-38 were unaltered.
In situ hybridisation histochemistry correspondingly showed that in particular
laminae of the dorsal horn the expression of VTPi receptor mRNA was reduced,
VIP2 receptor mRNA was markedly increased and PACAP receptor mRNA was
essentially unaltered as a result of CCI.
These data indicate that VIP/PACAP receptors may contribute importantly to
neuropathic sensitisation and may represent novel targets for analgesics designed
against the hyperalgesia and allodynia of neuropathic pain states.
ABSTRACT




THE ROLE OF MP/PACAP RECEPTOR SUBTYPES IN SPINAL SENSORY
PROCESSING FOLLOWING EXPERIMENTAL MONONEl RAPTHY
Tracev Dickinson. Patrick Robberecht+ and Susan Fleetwood-Walker
Department of Preclinical Veterinary Sciences, Royal (Dick) School of Veterinary
Studies. University of Edinburgh, Summerhall, Edinburgh EH9 1QH. Scotland
UK. f Department of Biochemistry and Nutrition. Medical School. Universite
Libre de Bruxelles. Brussels. Belgium.
Peripheral nerve damage often results in the development of chronic pain states,
resistant to classical opioid analgesics. The expression of Vasoactive Intestinal
Polypeptide (VIP) and Pituitary Adenylate Cyclase-Activatmg Polypeptide (PACAP)
is markedly up-regulated in small dorsal root ganglion neurones following a chronic
constriction injury (CCI). We investigated the expression and influence of VIP..
VIP: and PACAP receptor subtypes in the rat dorsal horn following CCI.
Electrophysiological studies revealed that selective antagonists of VIP,, VIP: and
PACAP receptors inhibit mustard oil-induced activity, but not brush-induced
activity, of dorsal horn neurones in CCI animals. Cold-induced neuronal activity-
was attenuated by VIP, and PACAP. but not VTP: receptor antagonists. Selective
agonists for the three receptor subtypes revealed that the VIP; receptor agonist
excited twice as many cells (to a 5 fold greater extent ) in CCI compared to normal
animals. The number of cells excited by the VIP, receptor agonist decreased
whereas responses to PACAP-38 were unchanged. In situ hybridisation
histochemistry revealed that CCI of the rat sciatic nerve resulted in a significant
increase in the expression of VIP: receptor mRNA in laminae IITIV of the dorsal
horn. In contrast, the expression of mRNA for VIP, receptors was seen to decrease
while that for PACAP receptors was essentially unaltered. Therefore, VIP/PACAP
receptors may be important factors in neuropathic pain states. The VIP2 receptor
appears to be particularly important in the transmission of nociceptive information,
while VIP, and PACAP receptors may also be involved in certain aspects of
allodvnia.
